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Friedreich’s ataxia (FRDA) is a progressive spinocerebellar ataxia (SCA) 
inherited as an autosomal recessive trait. The neurodegeneration, cardiomyopathy, 
diabetes mellitus and skeletal deformities characteristic to FRDA result from a deficiency 
in the mitochondrial protein frataxin. Frataxin chaperones iron to heme and iron-sulfur 
clusters and its deficiency causes mitochondrial iron accumulation and oxidative stress. 
To address the effect of frataxin deficiency on mitochondrial iron chemistry, 
mitochondria were isolated from FRDA and control fibroblasts. X-ray absorption 
spectroscopy showed that ferrihydrite was the predominant form of iron in both. Near 
edge analysis showed that the ferrihydrite in the FRDA mitochondria resembled the 
highly organized ferrihydrite of ferritin. Western blotting confirmed that FRDA 
mitochondria had 3-fold more holoferritin containing stainable iron. I conclude that 
mitochondria from FRDA fibroblasts mineralize excess iron as ferrihydrite within 
mitochondrial ferritin.  
To address how cellular iron dysregulation affected metal distribution in brain and 
spinal cord, a new synchrotron imaging technique, rapid-scanning x-ray fluorescence 
(RS-XRF) was employed and validated. Brain structures were readily identified by their 
unique metal content and distribution. This showed that RS-XRF could be used to reveal 
metal pathologies associated with diseases of metal metabolism such as FRDA. Since 
human FRDA tissues were not available for a detailed study, RS-XRF was employed to 
study the distribution of metals in normal cerebellum, a major site of FRDA-associated 
neurodegeneration, and to localize and quantify metals in the brain and spinal cord from a 
patient with a SCA of unknown aetiology. The motivation for this work is the prospect of 
future systematic studies on metal pathology in neurodegenerative diseases with direct 
application to FRDA. Novel findings arising from this work were the metal segmentation 
of the dentate nucleus, the high copper content of the olivary region and the different 
metal content of lesions at different stages of neurodegeneration. My results suggest that 
not only iron, but also copper and zinc may play a role in the physiopathology of 
neurodegeneration. Therefore, all three metals should be investigated in FRDA and other 
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In 1863, Nikolaus Friedreich, a German doctor, described a nonsyphilitic 
hereditary type of locomotor ataxia occurring as a familial disease in young patients. 
Locomotor ataxias had already been described by Duchenne as the prominent feature of 
tabes dorsalis (degeneration of the posterior columns of the spinal cord associated with 
neurosyphilis). Thus, the separation of Friedreich’s ataxia from the general group of 
locomotor ataxias was first greeted with skepticism. While Charcot considered that 
Friedreich’s patients suffered from multiple sclerosis, Gowers was the first neurologist to 
accept the new disease entity (Greenfield 1954; Berciano et al. 2000; Pearce 2004). Two 
years after Friedreich’s death, Charcot himself demonstrated that a young man suffering 
from ataxia did not have syphilis and recognized hereditary ataxia. Following that, 
Duchenne affirmed the existence of the new disease and in 1882, Brousse attached 
Friedreich’s name to the new entity (Greenfield 1954; Berciano et al. 2000; Pearce 2004). 
 
1.2 Clinical and Pathological Features 
Friedreich’s ataxia (FRDA) is a progressive neurodegenerative disease inherited 
as an autosomal recessive trait that affects 1:50,000 Caucasians (Campuzano et al. 1996). 
This is a typical example of a progressive spinocerebellar ataxia and is characterized by 
neurodegeneration, cardiomyopathy, diabetes mellitus and skeletal deformities. 
 
1.2.1 Neuroanatomy Overview 
Before reviewing the clinical and pathological features characteristic to FRDA, a 
short overview of the neuroanatomy and especially of the major structures and pathways 
affected in FRDA is appropriate.  
The somatosensory information (bodily sensations of pain, temperature, touch, 
vibration and limb and joint position sense, also called proprioception) travels from 
peripheral receptors to the spinal cord and brain through sensory nerves. The cell bodies 
of sensory neurons are located in the dorsal root ganglion and have one process that 
brings sensory information from the periphery and a second process that conveys this 
information to the central nervous system through the dorsal nerve roots. The 
proprioception, vibration and fine, discriminative touch sensory modalities are carried 
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through large diameter, myelinated axons. They enter the dorsal columns of the white 
matter of the spinal cord and ascend towards the medulla forming the dorsal column – 
medial lemniscal pathway. The somatosensation from the lower limbs and lower half of 
the body travels medially in the posterior columns forming the gracile fascicle. The 
somatic sensation from the upper limbs and upper half of the body travels laterally in the 
dorsal columns and form the cuneate fasciculus. The neurons in the dorsal root ganglia 
that send axons in the gracile and cuneate fasciculi (also named first order neurons) 
synapse onto second order neurons in the nucleus gracilis and nucleus cuneatus, 
respectively. Both these nuclei are located in the medulla. The axons of the second order 
neurons decussate (cross-over from one side of the medulla to the other side) and form 
the medial lemniscus that carries the information to the third order neurons located in the 
thalamus. The thalamic neurons then project to neurons of the primary somatosensory 
cortex for the conscious perception of the proprioception, vibration and touch sensations 
(Blumenfeld 2002). 
Rather than continuing their ascend, some fibers of the posterior columns enter 
the gray matter of the spinal cord and synapse onto neurons located in the dorsal nucleus 
of Clarke. Fibers arising from this nucleus ascend in the lateral columns of the spinal cord 
white matter where they form the spinocerebellar tracts. These pathways travel through 
the brainstem and end in the cerebellar cortex. Thus, the spinocerebellar tracts carry the 
proprioception, vibration and touch sensations to the cerebellum for their unconscious 
perception important in coordination of muscular activity, facilitation of movement, 
motor planning and motor learning (Blumenfeld 2002).  
Outputs from the cerebellum are carried by the Purkinje cells of the cerebellar 
cortex to the deep cerebellar nuclei (including the dentate nucleus) and vestibular nuclei 
(located in the brainstem). Through its wide spread projections not only to the deep 
cerebellar nuclei and vestibular nuclei, but also to the red nucleus, thalamus and primary 
motor cortex, the cerebellum is involved in motor coordination, planning and learning, 
balance and eye movements (Blumenfeld 2002). 
The somatic motor pathways carry motor commands issued by the brain to 
muscles. This results in the execution of voluntary movements. The primary motor cortex 
of the cerebrum issues these motor commands. Thus, it is responsible for the execution of 
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movements, direction of movements and force of muscle contraction. Axons of cortical 
neurons that carry the motor information descend through the subcortical white matter 
and internal capsule, midbrain, pons and arrive in the medullary pyramids. The majority 
of the fibers decussates and continues the descent in the contralateral lateral columns of 
the white matter forming the lateral corticospinal tract. The rest of the fibers descend in 
the ipsilateral anterior columns of the spinal cord without decussating and form the 
anterior corticospinal tract. Both the lateral and the anterior corticospinal tracts synapse 
onto motor neurons located in the anterior horns of the gray matter of the spinal cord. 
Axons of these neurons exit the spinal cord through the ventral roots, form the motor 
nerves and deliver the somatic motor commands to muscles. The lateral corticospinal 
tract controls the muscles of the contralateral limb, while the anterior corticospinal tract 
controls the bilateral axial and girdle muscles (Blumenfeld 2002).  
Thus, the primary motor cortex is responsible for the voluntary execution of 
movements, the cerebellum coordinates complex motor patterns and stores memory of 
learned movement patterns and the basal ganglia (caudate, putamen, globus pallidus, 
substantia nigra) modulate and adjust motor patterns at the subconscious level. 
 
1.2.2 Clinical and Pathological Features of FRDA 
FRDA typically presents before 25 years of age with progressive ataxia of gait 
and limbs, dysarthria, loss of deep tendon reflexes, extensor plantar responses, muscle 
wasting and loss of sensation, especially of vibration and joint position sense (Greenfield 
1954; Geoffroy et al. 1976; Harding 1981; Durr et al. 1996). As the disease progresses, 
there may be horizontal nystagmus (involunatry rhythmic oscillations of the eyeballs, 
characterized by a smooth pursuit in one direction and a fast movement in the opposite 
direction), saccadic-pursuit eye movements (rapid correction eye movements to redirect 
the line of site during smooth pursuit of an object), difficulty with swallowing and 
breathing as well as cardiomyopathy, diabetes mellitus and skeletal deformities 
(Greenfield 1954; Geoffroy et al. 1976; Harding 1981; Durr et al. 1996). Some patients 
can develop optic nerve atrophy and hearing loss (Greenfield 1954; Geoffroy et al. 1976; 
Harding 1981; Durr et al. 1996). In contrast to the typical early onset form, late onset 
FRDA progresses more slowly and tendon reflexes are often retained (De Michele et al. 
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1994; Durr et al. 1996; Coppola et al. 1999). Magnetic resonance imaging in patients 
with typical and late onset FRDA reveals spinal cord atrophy that is sometimes 
associated with atrophy of the brainstem and cerebellum (Wessel et al. 1989; Klockgether 
et al. 1991; Wullner et al. 1993; Mascalchi et al. 1994; De Michele et al. 1995; 
Bhidayasiri et al. 2005). 
The neurological features of FRDA are explained by the neuropathological 
findings characteristic to this disease. The peripheral sensory nerves are severely affected 
with loss of large myelinated axons and loss of neurons in the dorsal root ganglia 
(Greenfield 1954; Hughes et al. 1968; Oppenheimer 1979; Lamarche et al. 1984). The 
spinal cord shows neuronal loss in the nucleus dorsalis of Clark and loss of myelinated 
fibers in the posterior columns with the gracile fasciculus almost always more affected 
than the cuneate fasciculus (Greenfield 1954; Oppenheimer 1979; Lamarche et al. 1984). 
There is also degeneration of the corticospinal lateral and spinocerebellar tracts and, less 
frequently, of the corticospinal anterior tracts (Greenfield 1954; Oppenheimer 1979; 
Lamarche et al. 1984). Neurodegenerative changes seen in the dorsal columns and 
pyramidal tracts of the spinal cord can be traced through the medulla: neuronal loss in the 
gracile and cuneate nuclei and axonal degeneration in the pyramids (Greenfield 1954; 
Oppenheimer 1979; Lamarche et al. 1984). The loss of large, myelinated axons in the 
spinocerebellar pathways can also be traced through the inferior and superior cerebellar 
peduncles to the cerebellar Purkinje cells. In FRDA, these neurons degenerate, especially 
in the vermis of the cerebellum (Greenfield 1954; Oppenheimer 1979; Lamarche et al. 
1984). Severe neuronal loss is also seen in the dentate nucleus (Oppenheimer 1979; 
Lamarche et al. 1984; Koeppen et al. 2007). Some cases also present with neuronal loss 
in the optic nerves and tracts, subthalamic nuclei, thalamus and globus pallidus 
(Oppenheimer 1979; Lamarche et al. 1984). 
  Hypertrophic cardiomyopathy (thickening of the ventricular septum and walls of 
the left ventricle) leads to arrhythmias and heart failure, which are the most common 
cause of death for these patients (Greenfield 1954; Hewer 1968; Sanchez-Casis et al. 
1976; Lamarche et al. 1980; Harding 1981; Durr et al. 1996). The pathology of the 
cardiac degeneration consists of interstitial fibrosis, hypertrophy and degeneration of 
cardiac cells, muscle necrosis and intracellular accumulation of lipofuscin, iron and 
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calcium deposits (Greenfield 1954; Hewer 1968; Sanchez-Casis et al. 1976; Lamarche et 
al. 1980). Diabetes mellitus is seen in 10% of the patients and is associated with a 
decrease in the number of pancreatic β cells (Hewer 1968; Hewer and Robinson 1968; 
Harding 1981; Durr et al. 1996). Skeletal deformities include pes cavus (hammer toes) 
and kyphoscoliosis (abnormal lateral and posterior curvature of the vertebral column) 
(Harding 1981; Durr et al. 1996). 
 
1.3 Human Frataxin 
The frataxin gene (FRDA gene) has been localized on chromosome 9q13 
(Chamberlain et al. 1988; Fujita et al. 1989; Campuzano et al. 1996). It is composed of 7 
exons (1, 2, 3, 4, 5a, 5b, and 6). The major transcript (exons 1 to 5a) is a 1.3 kb mRNA 
that encodes a 210 amino acid protein called frataxin (Campuzano et al. 1996).  
Frataxin mRNA expression is very high in heart, intermediate in liver, skeletal 
muscle and pancreas, and low in other tissues, including whole brain. In different parts of 
the Central Nervous System (CNS), frataxin mRNA expression is the highest in the 
spinal cord, with less expression in cerebellum and very little in cerebral cortex 
(Campuzano et al. 1996). 
The amino acid sequence of frataxin predicts a small protein, without any 
transmembrane domain and with a cleavable signal peptide formed by the 22 N-terminal 
amino acids (Campuzano et al. 1996). Segmentation analysis has shown that the N-
terminal amino acids form a non-globular domain with the typical features of a 
mitochondrial targeting peptide: α-helicity, abundant Arg, Ser and Leu residues, rare Glu 
and Asp residues (Gibson et al. 1996). Co-localization of frataxin with cytochrome-c 
oxidase (Campuzano et al. 1997; Koutnikova et al. 1997), the intracellular localization of 
frataxin-GFP fusion protein (Babcock et al. 1997; Priller et al. 1997), 
immunocytofluorescence and immunoelectron microscopy (Campuzano et al. 1997) have 
shown that frataxin is, indeed, a mitochondrial protein. Furthermore, the first 20 amino 
acids are sufficient to target frataxin N-terminal portion-GFP fusion protein to the 
mitochondria and mutation of the two Arg residues in the consensus of the mitochondrial 
signal peptide results in a diffuse cytoplasmic and nuclear localization of frataxin 
(Campuzano et al. 1997). 
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The N-terminal mitochondrial targeting sequence is proteolytically removed in 
two sequential steps by a zinc metallopeptidase called Mitochondrial Processing 
Peptidase (MPP). In the first step, MPP cleaves the 21 kDa frataxin precursor (p-fxn) 
between residues 41-42 yielding an 18.8 kDa intermediate (i-fxn). The second cleavage 
occurs between residues 55-56 and produces the 17 kDa mature frataxin (m-fxn). M-fxn 
corresponds to the endogenous frataxin found in human tissues (Branda et al. 1999; 
Cavadini et al. 2000). 
It has been suggested that m-fxn is not only confined to the mitochondria but that 
an extramitochondrial pool of frataxin exists (Acquaviva et al. 2005; Condo et al. 2006). 
This cytosolic m-fxn has been demonstrated in several cell lines: human embryonic 
kidney HEK-293, cervical carcinoma HeLa, T-cell leukemia Jurkat, bone marrow 
neuroblastoma SH-SY5Y (Condo et al. 2006) and human colon carcinoma Caco-2 
(Acquaviva et al. 2005). It appears that the extramitochondrial frataxin is able to 
functionally substitute for the mitochondrial frataxin in promoting cell survival, 
protection against reactive oxygen species (ROS) and apoptosis (Condo et al. 2006) and 
is involved in extramitochondrial ISC biosynthesis (Acquaviva et al. 2005). However 
studies in normal adult mouse tissues have shown that frataxin is strictly localized to 
mitochondria and have excluded the presence of a cytosolic pool of frataxin (Martelli et 
al. 2007). 
 
1.4 Human Frataxin and FRDA 
FRDA is the consequence of frataxin deficiency. FRDA patients have extremely 
low, sometimes even undetectable frataxin mRNA levels (Campuzano et al. 1996; Cossee 
et al. 1997) and show a severe reduction in frataxin expression ranging from 4 to 29% of 
normal levels (Campuzano et al. 1997). Frataxin deficiency is the result of a GAA 
trinucleotide repeat in the first intron of the gene (Campuzano et al. 1996; Durr et al. 
1996; Pandolfo 1998). Repeats in normal genes contain between 7 and 40 triplets, while 
FRDA genes have over 66 triplets and they can go as high as 1700 GAA repeats. Smaller 
expansions allow for a higher level of residual gene expression (Campuzano et al. 1997). 
Most patients (95-98%) are homozygous for the expanded alleles (Campuzano et al. 
1996; Durr et al. 1996) and the GAA repeats adopt a triple helical structure 
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(GAA·GAA·TTC) under physiological conditions. When the triplet sequence is long 
enough, two purine·purine·pyrimidine (R·R·Y) triplexes associate and form a novel stable 
non-B DNA structure called “sticky DNA”. This structure inhibits transcription of the 
FRDA gene by sequestration of the RNA polymerases (Bidichandani et al. 1998; 
Ohshima et al. 1998; Sakamoto et al. 1999; Sakamoto et al. 2001), formation of a 
persistent RNA·DNA hybrid (Grabczyk et al. 2007) and/or aberrant pre-mRNA 
processing (Baralle et al. 2008). These properties are specific to GAA repeats since GGA 
interruptions inserted into long GAA repeats abolish sticky DNA formation and alleviate 
transcription repression possibly by introducing base mismatches into the R·R·Y triplex 
(Sakamoto et al. 2001).  
Another model suggests that GAA·TTC repeats induce formation of 
heterochromatin through hypermethylation of DNA and reduced histone acetylation that 
could disrupt the binding of transcription factors and reduce the frataxin message (El-
Osta and Wolffe 2000; Elgin and Grewal 2003; Saveliev et al. 2003; Herman et al. 2006; 
Gottesfeld 2007; Greene et al. 2007; Al-Mahdawi et al. 2008; Castaldo et al. 2008). 
Histone deacetylase inhibitors (HDACI) increase both frataxin mRNA and protein 
expression (Herman et al. 2006). Erythropoietin increases frataxin expression in FRDA 
lymphoblasts (Sturm et al. 2005), fibroblasts (Acquaviva et al. 2008) and patients 
(Boesch et al. 2007) acting on the frataxin protein at the post-translational level, but the 
exact mechanism is not known (Acquaviva et al. 2008). 
There is a direct correlation between the number of GAA repeats, more precisely 
the number of repeats on the small allele, and age of onset, rate of disease progression 
and other disease manifestations. Earlier onset FRDA is associated with large repeats on 
the small allele. The frequency of some clinical signs (cardiomyopathy, skeletal 
deformities and extensor plantar response) increases with the size of GAA expansion, 
while cerebellar ataxia is associated with both the number of GAA repeats and the 
duration of the disease (Durr et al. 1996; Filla et al. 1996; Montermini et al. 1997). The 
relationship between the number of GAA repeats and the level of frataxin expression, and 
ultimately the severity of the disease, is sustained by the finding that there are no 
biologically relevant sequence differences in the promoter or 3′UTR (responsible for 
increasing mRNA stability) between the milder and classic forms of FRDA (Greene et al. 
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2005). There is also a direct correlation between the methylation of particular CpG sites 
on the FRDA gene and GAA expansion size and an inverse correlation between the 
degree of methylation and age of onset (Castaldo et al. 2008). 
The remaining 2-5% of FRDA patients are compound heterozygotes for a GAA 
expansion on one allele and a point mutation on the other (Durr et al. 1996; Pandolfo 
1998). Patients with truncated or missense mutations in the C-terminal half of mature 
frataxin have a phenotype similar to that of patients homozygous for the GAA expansion, 
while missense mutations located in the N-terminal half of the protein cause an atypical 
and milder clinical presentation (mild or no cerebellar ataxia, slow disease progression, 
retained or brisk tendon reflexes, absence of dysarthria) (Campuzano et al. 1996; Cossee 
et al. 1999). 
Molecular and biochemical analyses of tissues from patients with FRDA have 
shown a deficient activity of the iron-sulfur cluster (ISC) containing subunits of 
mitochondrial respiratory complexes I, II and III, deficient activity of mitochondrial and 
cytosolic aconitase (also ISC), reduced levels of mitochondrial DNA (mtDNA) and 
increased iron regulatory protein 1 (IRP1) activity (Rotig et al. 1997; Bradley et al. 2000; 
Lobmayr et al. 2005). The levels of ATP synthesized in mitochondria are below normal 
and inversely proportional to the number of GAA repeats (Lodi et al. 1999). Despite 
normal ferrochelatase activity, free erythrocyte protoporphyrin is elevated (Morgan et al. 
1979; Schoenfeld et al. 2005) and levels of mitochondrial heme a and heme c are reduced 
(Schoenfeld et al. 2005) suggesting a defect between protoporphyrin IX and heme a 
(Schoenfeld et al. 2005). Activity of cytochrome oxidase and cytochrome c are decreased 
presumably because a defect in the insertion of heme a and heme c into cytochrome 
oxidase and cytochrome c, respectively (Schoenfeld et al. 2005). Iron deposits have been 
noted in myocardial cells (Sanchez-Casis et al. 1976; Lamarche et al. 1980; Bradley et al. 
2000; Michael et al. 2006) and in the dentate nucleus (Waldvogel et al. 1999; Boddaert et 
al. 2007) in FRDA patients, FRDA fibroblast cultures (Delatycki et al. 1999), spleen and 
liver (Bradley et al. 2000), although some of these findings have been challenged lately 
(Koeppen et al. 2007). High levels of circulating transferrin receptor (TfR) (Wilson et al. 
2000) result from a redistribution of iron from the cytosol to the mitochondrial 
compartment. Finally, several markers of oxidative stress have been observed including 
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increased plasma levels of malondialdehyde (a lipid peroxidation product) (Emond et al. 
2000), reduced blood glutathione (Piemonte et al. 2001; Tozzi et al. 2002) and increased 
urinary levels of 8-hydroxy-2′-deoxyguanosine (a marker of oxidative DNA damage) 
(Schulz et al. 2000). These complete the panel of biochemical changes.   
Increased expression of TfR (Wilson et al. 2000), increased levels of IRP1 
(Lobmayr et al. 2005), iron regulatory protein 2 (IRP2) (Li et al. 2008) and increased iron 
responsive element (IRE)-binding activity of IRP1 and IRP2 (Li et al. 2008) found in 
FRDA fibroblasts and lymphoblasts are evidence of cytosolic iron depletion and show 
that the intramitochondrial iron accumulation occurs at the expense of cytosolic iron (Li 
et al. 2008). The following model of how cytosolic iron deficiency decreases expression 
of frataxin in FRDA has been proposed: frataxin deficiency impairs the mitochondrial 
ISC assembly leading to mitochondrial iron overload. Excess mitochondrial uptake and 
sequestration causes depletion of cytosolic iron which can further lower the expression of 
frataxin by decreasing its transcription (Li et al. 2008). 
 
1.5 Roles of Frataxin 
All these findings suggest that frataxin acts both as an iron chaperone for heme 
synthesis and biosynthesis of ISC containing proteins and protects against oxidative 
damage.  
It is still a debate if intramitochondrial iron accumulation is a primary event 
leading to ROS production and cellular damage (Babcock et al. 1997; Wong et al. 1999), 
or if it is a secondary event due to a deficit of ISC synthesis (Lill and Muhlenhoff 2008). 
Increased expression of TfR (Wilson et al. 2000) and increased levels of IRP1 (Lobmayr 
et al. 2005), IRP2 (Li et al. 2008) and increased IRE-binding activity of IRP1 and IRP2 
(Li et al. 2008) found in FRDA fibroblasts and lymphoblasts are evidence of cytosolic 
iron depletion and show that the intramitochondrial iron accumulation occurs at the 
expense of cytosolic iron (Li et al. 2008). It has been proposed that high levels of ferrous 
iron (Fe2+) in mitochondria could promote ROS formation through the Fenton reaction 
and, subsequently, protein degradation, lipid peroxidation and mtDNA damage (Emond 
et al. 2000; Schulz et al. 2000; Piemonte et al. 2001) and reduce frataxin expression (Li et 
al. 2008). This could explain the oxidative damage markers found in FRDA patients and 
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deficiencies of aconitase and respiratory complexes I, II and III leading to decreased 
mitochondrial respiration and oxidative phosphorylation (Rotig et al. 1997; Bradley et al. 
2000). My work has elucidated the chemical forms of iron found in mitochondria 
(Popescu et al. 2007a) and the implications of this work are dealt with in Chapter II. 
 
1.5.1 ISC and Heme Synthesis  
IscU scaffold protein provides a platform for assembly of [2Fe-2S] or [4Fe-4S] 
centers prior to delivery to an apo target protein (Yabe et al. 2004; Johnson et al. 2005; 
Chandramouli et al. 2007; Rouault and Tong 2008). The intermediate [2Fe-2S] or [4Fe-
4S] IscU-bound cluster is formed by delivery of iron and sulfur to the apo IscU. The 
sulfur donor is IscS (cysteine desulfurase) that catalyses the desulfuration of cysteine 
producing sulfide (Rouault and Tong 2008). The identity of the iron donor has not yet 
been fully established, but there is good evidence that frataxin accomplishes this function 
(Bencze et al. 2006; Rouault and Tong 2008). In vitro experiments have shown that 
frataxin forms a complex with IscU and iron is required to cross-link the two proteins 
and/or stabilize the structure of frataxin that is recognized by IscU (Yoon and Cowan 
2003). In human heart, the monomeric and oligomeric forms of frataxin bind in a stable 
manner to IscU and IscU/IscS with an IscU: frataxin stoichiometry of 1:3 (O'Neill et al. 
2005). 
 
1.5.1.1 The Role of Iron Regulatory Proteins 
Cellular iron uptake and storage are exquisitely regulated through the action of the 
two iron regulatory proteins, IRP1 and IRP2.  Although both IRP1 and IRP2 can bind to a 
canonical mRNA element called IRE found on the mRNAs of several iron-regulated 
proteins (i.e TfR, ferritin, mitochondrial aconitase, ferroportin), they act by slightly 
different mechanisms. IRP1 is a bifunctional protein. The incorporation of a new iron 
into and the formation of a [4Fe-4S] cluster transform the IRP1 from an mRNA binding 
protein into cytosolic aconitase and enable it to catalyze the conversion of citrate to 
isocitrate. Thus, cytosolic aconitase and IRP1 are actually the same protein that cycles 
between a [4Fe-4S] form that predominates under high iron conditions and a [3Fe-4S] 
form that predominates when iron is low. In FRDA increased expression of IRP1 and 
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IRP2 leads to increased iron uptake due to increased expression of TfR and to reduced 
synthesis of the iron storage protein, ferritin.  Normally in iron replete states, IRP1 
assembles an ISC and loses the ability to bind to the IRE while IRP2 degrades. Reduced 
binding of IRPs to IREs decreases the stability of the mRNA encoding TfR leading to 
reduced expression of TfR at the cell membrane and also increases translation of ferritin 
for iron storage (Klausner and Rouault 1993; O'Halloran 1993; Ponka 1999). 
 
1.5.1.2 Cytosolic ISC Proteins  
The findings (Rotig et al. 1997; Bradley et al. 2000; Lobmayr et al. 2005) that in 
FRDA, cytosolic aconitase activity is deficient, but its IRE binding activity is increased 
indicate that aconitase/IRP1 is not damaged due to oxidative stress but rather the 
deficiency of cytosolic aconitase activity could be due to an inability to incorporate iron 
into the ISC. There is strong evidence that frataxin is an iron chaperone to the Fe-S 
cluster pathway and that mitochondrial ISC assembly machinery is essential for cytosolic 
ISC biogenesis (Seznec et al. 2005).  
 
1.5.1.3 Mitochondrial ISC Proteins 
Mitochondrial ISC proteins fulfill a variety of functions from metabolic reactions 
and enzyme catalysis to electron transfer and regulatory processes. Several of these ISC 
proteins are important for FRDA: mitochondrial aconitase (citric acid cycle), ferredoxin 
(maturation of ISC proteins and biosynthesis of heme), ferrochelatase (biosynthesis of 
heme), NADH ubiquinone oxidoreductase of complex I, succinate dehydrogenase of 
complex II and ubiquinone cytochrome c oxidoreductase of complex III (the last three 
involved in electron transport chain) reviewed in (Lill and Muhlenhoff 2005). Among 
these, mitochondrial aconitase (Rotig et al. 1997; Bradley et al. 2000; Lobmayr et al. 
2005) and ferrochelatase (Morgan et al. 1979; Schoenfeld et al. 2005) have been found 
consistently downregulated in FRDA. 
Mitochondrial aconitase is a [4Fe-4S] cluster containing protein whose main 
function is to catalyze the conversion of citrate to isocitrate in the Krebs cycle. It has 
been recently shown that mitochondrial aconitase has a dual function. The oxidized form 
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of this ISC associates with mtDNA to provide stability during oxidative stress reviewed 
in (Shadel 2005). 
Frataxin has also been shown to be a high affinity partner for ferrochelatase, 
capable of both iron delivery to ferrochelatase and mediating the final step in 
mitochondrial heme biosynthesis (Yoon and Cowan 2004). Human frataxin and 
ferrochelatase seem to interact only in the presence of iron (Bencze et al. 2007). 
 
1.5.2 Assembly and Functions of Frataxin 
1.5.2.1 Iron Storage Protein 
When expressed in Escherichia Coli and Saccharomyces cerevisiae, m-fxn 
(residues 56-210) assembles into a stable homopolymer (600kDa-1MDa) that can bind 
approximately 5-10 Fe atoms/frataxin subunit (Cavadini et al. 2002). Human heart 
contains frataxin species of increasing molecular mass, ranging from monomers to 
polymers >1 MDa. Such large aggregates can sequester iron cations in a non-toxic, but 
bioavailable form and may function as iron storage proteins similar to ferritin (Cavadini 
et al. 2002). This data is supported by the fact that, while both the frataxin trimer and 
homopolymer can deliver iron to ISC and heme pathways, only the frataxin 
homopolymer has ferroxidase activity and is able to detoxify redox-active iron by 
sequestering it in a protein-protected compartment (O'Neill et al. 2005).  
Expression of a truncated form of frataxin (d-fxn) (residues 78-210) does not 
yield any assembly. Since the two forms (m-fxn and d-fxn) are produced with the same 
efficiency and exhibit similar folds, it was concluded that assembly of human frataxin is 
done by stable subunit-subunit interactions involving the non-conserved N-terminal 
region (O'Neill et al. 2005). Unlike prokaryotic and yeast frataxin homologues, iron is not 
required for assembly of human frataxin subunits (O'Neill et al. 2005). 
Frataxin homopolymers consist of ordered rod-shape polymers of globular 
particles that have small electron dense cores resembling the iron cores of ferritin 
(Cavadini et al. 2002). X-ray Absorption Spectroscopic (XAS) studies of human frataxin 
polymers assembled in vitro showed that the iron cores of frataxin contain ferrihydrite, a 
biomineral composed of ferric oxide/hydroxide octahedra. Ferrihydrite crystallites in the 
frataxin core are similar, but less ordered than iron cores of ferritin (Nichol et al. 2003).   
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1.5.2.2 Iron Chaperone 
The crystal structure of human frataxin showed the existence of a conserved 
anionic surface patch that could be a part of an iron binding site. Frataxin monomer 
doesn’t bind iron, but it could do so by assembling with itself or other proteins through its 
acidic patch. It was also shown that 15 conserved uncharged residues form a flat, neutral 
surface on the β sheet that could be able to mediate protein-protein interactions (Dhe-
Paganon et al. 2000).  
Since frataxin has been proven to form complexes with IscU, IscU/IscS, aconitase 
and ferrochelatase (Yoon and Cowan 2003; Yoon and Cowan 2004; O'Neill et al. 2005), 
it is postulated that frataxin is the iron donor for ISC assembly and heme synthesis. Both 
trimeric and assembled forms of frataxin can donate iron to IscU, aconitase and 
ferrochelatase in vitro (O'Neill et al. 2005) and iron is required for these interactions 
(Yoon and Cowan 2003; Yoon and Cowan 2004; Bencze et al. 2007). 
Both frataxin trimers and polymers enhance Fe(II) availability to ferrochelatase, 
whereas only assembled frataxin has ferroxidase activity, sequesters redox-active iron 
and limits oxidative damage to DNA. Ferroxidase activity is predominant at 
Fe(II)/subunit ratio of <1. At higher ratios, autoxidation overrides the ferroxidation. The 
ferroxidase activity at <1Fe(II)/subunit is consistent with the presence of less than one 
ferroxidation site/subunit. This implies that assembly is required for the ferroxidase 
activity of human frataxin (O'Neill et al. 2005).  
Frataxin deficiency causes a defect in heme synthesis between protoporphyrin IX 
and heme. Activity of coproporphyrinogen oxidase and cytochrome oxidase are 
decreased. Levels of mitochondrial heme and cytochrome c are also decreased. 
Deficiency of cytochrome oxidase activity and decreased levels of cytochrome c are due 
not only to deficiency of heme, but also to a decreased loading of heme onto these 
proteins (Schoenfeld et al. 2005). Ferrochelatase activity is similar in control and FRDA 
cells, but zinc-chelatase activity is increased in FRDA showing an altered metal-
specificity of ferrochelatase (Schoenfeld et al. 2005). Increased levels of zinc 
protoporphyrin IX have been found in yeast totally lacking frataxin (Lesuisse et al. 2003) 
and the same may be true of human FRDA. 
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1.5.3 Protection from Oxidative Stress 
Direct evidence exists that assembled frataxin has ferroxidase activity and is able 
to sequester redox-active iron limiting iron-induced oxidative damage to DNA (O'Neill et 
al. 2005). FRDA fibroblasts and lymphoblasts are more sensitive to oxidative stress than 
unaffected cells (Wong et al. 1999; Sturm et al. 2005) and the antioxidant glutathione is 
decreased in FRDA, possibly as a result of an excess consumption required to eliminate 
H2O2 (Piemonte et al. 2001; Tozzi et al. 2002).  
No increase in chelatable (redox-active) mitochondrial iron has been found  
(Sturm et al. 2005) and I have shown that mitochondrial iron is largely mineralized 
(Popescu et al. 2007a). It has also been shown that the activity and expression of 
superoxide dismutases (SOD) is not induced in FRDA fibroblasts, supporting the idea 
that little redox-active iron is present in FRDA cells and an alternative source of free 
radicals contributes to the disease pathology (Chantrel-Groussard et al. 2001; 
Jiralerspong et al. 2001). The effects of oxidative stress in FRDA fibroblasts can be 
partially reversed by mitochondria-targeted antioxidants (Jauslin et al. 2003) and by 
transduction of affected fibroblasts with adeno-associated virus and lentivirus vector 
constructs that encode frataxin (Fleming et al. 2005). It is clear that oxidative stress has a 
role in FRDA pathology but it is still to be established whether this is generated by 
increased ferrous iron inside mitochondria, alternative sources of free radicals, impaired 
defense mechanisms due to frataxin deficiency or a combination of these.  
 
1.5.4 Electron Donor to Respiratory Complex 
Physical interaction between frataxin and components of mitochondrial 
respiratory complex II - FAD-binding domain of succinate dehydrogenase A flavoprotein 
and succinate dehydrogenase B ISC-containing protein - suggests that frataxin may play a 
role in the entrance of electrons into the electron transport chain. In this scenario, frataxin 
deficiency is associated with inappropriate incorporation of electrons to the respiratory 
chain and incomplete reduction of ubiquinone (Q) to ubiquinol (QH2). The formation of 
the pro-oxidant semiquinone (Q·⎯) leads to ROS formation and mitochondrial oxidative 
stress (Gonzalez-Cabo et al. 2005). In this case ROS are derived independently of excess 
ferrous iron and Fenton chemistry.   
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Frataxin increases triglyceride synthesis, maximizes Krebs cycle activity, 
increases mitochondrial calcium uptake, activates mitochondrial respiration and activates 
the oxidative phosphorylation (Ristow et al. 2000; Pomplun et al. 2007).  
 
1.5.5 Conclusion 
The mitochondrion is known as an essential and dynamic component of cellular 
biochemistry that is heavily involved in iron metabolism. Since the mitochondrion is the 
only site of heme synthesis and a major site of ISC synthesis, most of the iron 
sequestered by the cell is targeted to mitochondria where the excess iron can be stored in 
mitochondrial ferritin (MtFt) in a non-toxic, but bioavailable form (Napier et al. 2005). 
The mitochondrion uses some of the heme and ISC generated for its own metabolism (i.e. 
Krebs cycle, respiratory chain) and exports the rest to the cytosol (Napier et al. 2005). 
Frataxin appears to play numerous roles in mitochondria. It regulates the flux of 
iron through the ISC and heme biosynthetic pathways. The distinct binding affinities of 
frataxin for ferrochelatase (heme synthesis) and IscU (ISC synthesis) control how much 
iron passes from frataxin to each of these two major iron dependent pathways. Frataxin 
has a protective role against oxidative stress, by mineralizing excess iron and/or 
influencing activity of the SODs. Frataxin is directly involved as an inducer of oxidative 
phosphorylation and mitochondrial respiration as well as indirectly through frataxin’s 
role in ISC and heme synthesis and protection of the proteins against oxidative damage. 
Iron binding and assembly properties of frataxin strongly support the idea that this 











1.6 Mouse Models of FRDA 
 The mouse frataxin gene (Frda gene) is localized on chromosome 19 and encodes 
a 207 amino acid protein with 73% amino acid identity to human frataxin. The N-
terminal region of mouse frataxin also contains a mitochondrial targeting signal 
(Koutnikova et al. 1997).  
In the adult mouse, frataxin mRNA expression is detected in heart, liver, skeletal 
muscle, kidney, spleen, thymus, brown adipose tissue, axial skeleton, teeth and skin, and 
more weakly in whole brain and lungs. In the nervous system, maximum expression is 
detected in spinal cord and dorsal root ganglia (Jiralerspong et al. 1997; Koutnikova et al. 
1997). These data show that mouse frataxin mRNA distribution is similar to that 
observed in humans, and these tissues are the ones most affected by frataxin deficiency. 
During embryonic development, mRNA expression is first detected in embryonic day 
(ED) 10.5, reaching maximum expression in ED 14.5 and persisting into postnatal period 
(Jiralerspong et al. 1997).  
Concerning the assembly properties of mouse frataxin, a high molecular weight 
pool of frataxin is present in mouse heart indicating that frataxin can assemble under 
physiological conditions (Cavadini et al. 2002). 
Disruption of mouse frataxin by deletion of exon 4 of the frataxin gene generates 
asymptomatic heterozygotes and embryonic lethal homozygotes, suggesting that the 
milder phenotype seen in humans is associated with residual frataxin expression and that 
frataxin has an important role during development. Embryonic death occurs between ED 
6.75 and ED 7.5. Cell death is not the consequence of abnormal iron accumulation since 
there are no visible iron deposits in dead embryos (Cossee et al. 2000). 
The human frataxin gene rescues Frda knockout mice. Rescued mice display 
normal phenotypes, behavioral and biochemical (activity of mitochondrial respiratory 
chain complexes I-IV, aconitase, citrate synthase) parameters showing that human 
frataxin can substitute for endogenous murine frataxin (Pook et al. 2001). Human frataxin 
is properly processed, targeted to mitochondria and expressed in the appropriate tissues. 
However, its expression is higher in brain, heart, skeletal muscle and liver, and lower in 
blood when compared to mouse frataxin. This indicates the existence of tissue specific 
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mechanisms that regulate the Frda locus, that may not affect human FRDA expression 
equally well (Pook et al. 2001; Sarsero et al. 2004). 
Protein expression analyzed in transgenic mice, generated with a bacterial 
artificial chromosome (BAC) genomic reporter construct consisting of an inframe fusion 
between human FRDA gene and the gene coding for enhanced green fluorescent protein 
(EGFP), shows frataxin expression beginning with ED 3.5. All the major internal organs 
exhibit EGFP expression, and the FRDA-EGFP expression is two times higher in 
homozygous than hemizygous mice (Sarsero et al. 2005). This shows that frataxin 
expression is ubiquitous and proportional to the number of functional frataxin alleles. 
The first viable FRDA mouse model has been created using a conditional gene-
targeting approach. This technique yielded two mouse lines with complete frataxin 
deficiency in targeted tissues: MCK line (skeletal and cardiac muscles mutant) and NSE 
line (neuronal, heart and liver mutant). These mutants show progressive 
pathophysiological and biochemical features of the human disease: cardiac hypertrophy 
and accumulation of damaged mitochondria, large sensory neurons dysfunction, 
deficiency of complexes I-III of the respiratory chain and mitochondrial aconitase. The 
onset of the pathology and inactivation of ISC is followed by time-dependent 
intramitochondrial ferric iron accumulation in the heart of MCK mutants, demonstrating 
that iron deposits are rather the consequence, and not the causative mechanism (Puccio et 
al. 2001). Chelation therapy reduces iron in the heart of the MCK mutant and limits heart 
hypertrophy, but can not rescue the metabolic defects (Whitnall et al. 2008). 
 Neuron-specific deletion of frataxin has been generated in two mutants that 
develop progressive mixed cerebellar and sensory ataxia, the most prominent features of 
FRDA. The Cb (cerebellum) mutant has significant reduction in frataxin in the 
cerebellum, while the Br (brain) mutant shows frataxin reduction in cerebellum, brain, 
brain stem and spinal cord. Non-neuronal tissues are not affected. Despite the more 
restricted frataxin deficiency, the Cb mutant shows a more severe neurological deficit 
with loss of ambulation by 1 year of age. These mutants show some features that are very 
similar to the human disease: degeneration of the posterior columns of the spinal cord, of 
the neurons in Clarke’s columns and of the large sensory neurons in dorsal root ganglia, 
and absence of motor neuropathy. ISC deficiency has also been observed. 
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Neurodegeneration in dorsal root ganglia implies autophagy and lipofuscin accumulation. 
Autophagy leads to removal and degradation of damaged cytosolic proteins and 
organelles. Lipofuscin is a peroxidation product composed of proteins, lipids, 
carbohydrates, iron and other metals. Their accumulation is due to incomplete 
autophagocytosis and lysosomal degradation of mitochondria and could explain the lack 
of detectable iron deposits in dorsal root ganglia (Simon et al. 2004). 
 While cardiomyocytes seem to compensate for frataxin deficiency by 
mitochondrial proliferation and cellular hypertrophy, dorsal root ganglia use the 
autophagic process as a protective mechanism for the elimination of defective 
mitochondria that enables them to survive longer without frataxin. The progressive 
autophagic process reflects therefore the slowly progressive nature of the neurological 
phenotype (Puccio et al. 2001; Simon et al. 2004). Removal of exon 4 of the Frda gene 
targeted to pancreatic β-cells causes slowly progressive diabetes in mice. Increased 
formation of ROS, increased apoptosis and decreased proliferation of pancreatic β-cells 
leading to reduced islet mass, impaired insulin secretion and eventually to type II diabetes 
(relative deficiency of insulin producing β-cells) (Ristow et al. 2003). 
 A frataxin knockin mouse has been created in an effort to generate a more 
appropriate model for the human disease. After introduction of a (GAA)230 repeat in the 
first intron of the mouse Frda gene, frataxin expression is reduced to 75% of wild type 
(WT) expression. Since these levels are too high for the mouse to develop a FRDA-like 
phenotype, frataxin knockin mice (frda(GAA)230/(GAA)230) have been crossed with frda+/- 
generating frataxin knockin/knockout mice (frda―/(GAA)230) (Miranda et al. 2002). 
Although frataxin levels in these mice are 25-36% of normal levels (low enough to cause 
FRDA in humans), these mice are viable and do not develop any anomalies of motor 
coordination, iron metabolism or response to iron loading (Miranda et al. 2002). 
However, the frataxin knockin (frda(GAA)230/(GAA)230) mice recapitulate the genetics and 
epigenetics of FRDA: they show significant reduction in the levels of frataxin mRNA in 
brain, cerebellum and heart (Rai et al. 2008) and changes in H3 and H4 post-translational 
modifications in chromatin near the GAA repeat (Rai et al. 2008) that correspond to those 
found in FRDA cells (Herman et al. 2006). Treatment with HDACI increases acetylation 
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of H3 and H4 in chromatin near the GAA repeat and restores both frataxin mRNA and 
protein expression (Rai et al. 2008). 
 The mouse models, especially the MCK mutant (frataxin deficient in skeletal and 
cardiac muscle) provides new insights into the link between FRDA and oxidative stress. 
Lack of induction of SOD activity suggests that continuous oxidative damage to ISC 
results from inadequate SOD activity (Chantrel-Groussard et al. 2001). The stable or 
small increase in oxidative stress markers may be due to concomitant decrease of the 
respiratory chain activity (the major source of ROS production in the cell). It has been 
suggested that the excess iron mineralization is the consequence of ISC deficiency, and 
not the causative mechanism of ROS production and little redox-active iron, if any, is 
present in FRDA cells (Puccio et al. 2001; Seznec et al. 2004; Seznec et al. 2005).  
 Frataxin overexpressing mice show an increased induction of oxidative 
phosphorylation (Pomplun et al. 2007) and an altered response during hematopoietic 
differentiation (Miranda et al. 2004), with no other abnormal biochemical or clinical 
phenotypes (Miranda et al. 2004). Thus, it has been concluded that overexpression of 
frataxin in mice is innocuous and is not a concern when designing gene therapy 
treatments for FRDA (Miranda et al. 2004). Frataxin expression is decreased during 
erythropoietic response triggered by phenylhydrazine (PHZ; causes hemolytic anemia 
and triggers active erythropoiesis in the spleen) in both WT and frataxin overexpressing 
mice. However the response is delayed in frataxin overexpressing mice compared to WT 
(Miranda et al. 2004). Similar results have been obtained in mouse Friend 
erythroleukemia cells (Becker et al. 2002). Dimethyl sulfoxide (DMSO) induction of 
erythroid differentiation and hemoglobinization and protoporphyrin IX down-regulates 
frataxin expression, while TfR and β-globin mRNA levels are increased. Since 
downregulation of frataxin leads to mitochondrial iron loading, these data suggests that 
reduced frataxin during erythroid differentiation results in iron sequestration for heme 
biosynthesis (Becker et al. 2002), or that less frataxin is required for heme synthesis than 
for ISC synthesis because of frataxin's high affinity for ferrochelatase. The binding 
affinity between frataxin and ferrochelatase is 28 times greater than the affinity between 
frataxin and ISU, and thus reduced frataxin levels have a bigger impact on the ISC 
pathway, keeping the iron available for heme incorporation (Yoon and Cowan 2004). 
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1.7 Yeast Model  
 The frataxin gene (YFH1) encodes the yeast homologue of human frataxin 
(Yfh1p), a 174 amino acid protein. It is targeted to mitochondria and processed in two 
steps by yeast mitochondrial processing peptidase (Babcock et al. 1997; Foury and 
Cazzalini 1997; Koutnikova et al. 1997; Wilson and Roof 1997; Branda et al. 1999). 
 
1.7.1 FRDA Knockout Yeast 
 yfh1Δ cells exhibit respiratory deficiency due to loss of mtDNA, deficiency of 
aconitase and mitochondrial ISC containing proteins, unregulated and extensive 
mitochondrial iron accumulation and increased sensitivity to oxidative stress (hydrogen 
peroxide, ferrous iron) (Babcock et al. 1997; Foury and Cazzalini 1997; Koutnikova et al. 
1997; Rotig et al. 1997; Wilson and Roof 1997; Foury and Talibi 2001). Frataxin 
deficiency leads to increased expression of the iron regulon (Foury and Talibi 2001) and 
transcription of the latter seems to respond directly to ISC biosynthesis, and not to free 
iron (Chen et al. 2004).  
 Normal human frataxin is able to complement the deficiency of yfh1Δ yeast, while 
human frataxins carrying mutations found in FRDA patients are unable to do so (Wilson 
and Roof 1997; Branda et al. 1999; Cavadini et al. 2000). Also, excess zinc in the growth 
medium prevents iron accumulation and increases the growth rate of yfh1Δ cells and their 
resistance to oxidative stress, but cannot restore the deficiency of ISC and heme proteins 
or the mitochondrial respiration, suggesting a possible use of zinc against oxidative stress 
in frataxin deficiency (Santos et al. 2003). There is a lack of information on zinc in 
FRDA but it is possible that zinc can fill some of the roles of iron and/or block iron 
uptake. 
 Yeast cells have no ferritin gene, but over-expression of either human MtF 
(Campanella et al. 2004) or cytosolic L type ferritin (Desmyter et al. 2004) rescues the 
respiratory defect and lengthens the lifespan of yfh1Δ yeast. This indicates that iron 





1.7.2 Yeast with Chronically Reduced Levels of Frataxin 
Yeast with 15-20 fold reduction in frataxin show intramitochondrial iron 
accumulation and considerable oxidative damage in both mitochondrial and nuclear DNA 
(Karthikeyan et al. 2003). This yeast model was developed as a better model for human 
FRDA. 
  
1.7.3 Role of Frataxin in Mitochondrial Iron Export 
 Mitochondrial iron accumulation in yfh1Δ appears at the expense of cytosolic iron 
(Babcock et al. 1997). Reintroduction of YFH1 in yfh1Δ results in the export of 
accumulated mitochondrial iron into the cytosol, showing that excess iron deposits in 
yfh1Δ yeast are bioavailable (Radisky et al. 1999) and can be incorporated in ISC and 
exported (Chen et al. 2002). It has been suggested that part of the excess mitochondrial 
iron is ferric citrate acting either as an iron carrier, or as a promoter of oxidative stress 
(Chen et al. 2002) or insoluble ferric phosphate, explaining the unavailability of iron for 
yeast ferrochelatase and the synthesis of zinc protoporphyrin instead of iron 
protoporphyrin (Lesuisse et al. 2003). One of the questions still to address is whether 
pathological iron can be mobilized and exported in FRDA. 
 
1.7.4 Role of Frataxin as Iron Chaperone 
 While ISC can be inactivated by oxidative stress, this does not seem to be the case 
in FRDA. Low activities of aconitase and ferredoxin are accompanied by abundant 
expression of their apo-forms (lacking the ISC) and the small amounts of active protein 
synthesized are stable. This shows that deficiency of ISC containing proteins appears to 
be the result of decreased incorporation of ISC in the apo-proteins, and not the result of 
oxidative damage to the protein itself (Chen et al. 2002). This also suggests that, at least 
in yeast, frataxin is not essential for ISC synthesis, but renders the process more efficient 
(Duby et al. 2002). 
 Yfh1p has been reported to interact with several proteins but some of these 
interactions need to be confirmed. Yfh1p physically interacts with aconitase, Isu1/Nfs1 
(ISU scaffold protein/cysteine desulfurase), ferrochelatase, succinate dehydrogenase and 
subunits of the electron transfer flavoprotein complex (Gerber et al. 2003; Lesuisse et al. 
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2003; Park et al. 2003; Bulteau et al. 2004; He et al. 2004; Ramazzotti et al. 2004; 
Gonzalez-Cabo et al. 2005). Interactions with ISC containing proteins are stabilized by 
ferrous iron and result in iron loading onto the ISC (Gerber et al. 2003; Park et al. 2003). 
Thus, frataxin is able to bind iron and acts as an iron chaperone to ISC and heme 
pathways. 
 Protein crystallography of yeast frataxin has identified conserved acidic residues 
in the helix1 – strand 1 protein residue, that undergo amide chemical shift changes and 
could be iron-binding sites on frataxin. Even more, ferrochelatase appears to bind to 
frataxin’s helical plane in a manner that includes its iron-binding interface (He et al. 
2004). 
    
1.7.5 Role of Frataxin as Iron Storage Protein 
Like human frataxin, Yfh1p can assemble in vitro and in vivo forming large 
homopolymers (600kDa-1Mda) when exposed to excess iron (Adamec et al. 2000) and 
its assembly responds to increases in mitochondrial iron uptake (Gakh et al. 2008). In 
vitro, the polymers sequester 2400-3000 atoms of iron in a ferrihydrite core. Unlike 
human frataxin, assembly of Yfh1p requires the presence of iron for its subunit-subunit 
assembly. Yeast apofrataxin does not show any tendency to self-associate (Adamec et al. 
2000; Gakh et al. 2002; Nichol et al. 2003).  
Yfh1p assembly is driven by two sequential iron oxidation reactions. At a low 
Fe2+/frataxin subunit stoichiometry, a ferroxidase reaction induces the first assembly step 
and the formation of frataxin trimer (α3). Initially the Fe2+ is loosely bound and can be 
easily made bioavailable. As the iron/frataxin subunit ratio increases, autoxidation 
overrides ferroxidation and higher order polymers are produced (α6, α12, α24, α48). Fe3+ 
becomes less and less accessible with formation of a stable iron-protein complex that can 
store 50-75 atoms of iron per subunit (Park et al. 2002; Park et al. 2003). These data 
support the hypothesis that Yfh1p is an iron storage protein that can also function as an 
iron chaperone. 
Mutations that impair the ferroxidation or mineralization activity of Yfh1p 
increase the sensitivity of yeast cells to oxidative stress, shorten their life span and 
prevent survival in the absence of the anti-oxidant enzyme SOD (Gakh et al. 2006). 
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These mutations slow down frataxin assembly but do not alter its iron chaperone function 
(Gakh et al. 2006). Thus, iron detoxification is another function of frataxin relevant to 
anti-oxidant defense and cell longevity.  
  
1.8 Mitochondrial Ferritin 
Cells contain two kinds of ferritin: cytosolic and mitochondrial (Arosio et al. 
2008). 
 
1.8.1 Cytosolic Ferritin 
 Cytosolic ferritin is a heteropolymer composed of 24 subunits of 2 types (H or 
heavy chains and L or light chains) that can store up to 4500 atoms of iron. H chains are 
encoded on chromosome 11q13 and have ferroxidase activity. Each H chain has a 
binuclear center that binds 2 Fe(II) and catalyses their oxidation to Fe(III). L chains are 
encoded on chromosome 19q13 and assist in iron core formation. Besides molecular 
oxygen, ferritin is able to use hydrogen peroxide for the oxidation of Fe(II) and shows 
ROS detoxification abilities. Iron release from ferritin is realized through reduction, 
probably by a NAD(P)H-dependent ferrireductase. Cytosolic ferritin synthesis is 
regulated at the level of translation in response to iron. Its mRNA has an IRE in the 5’ 
UTR. In low iron conditions, IRP1 binds to IRE and repress ferritin translation. When 
cellular iron increases, an iron atom is inserted in the [3Fe-4S] cluster of IRP1. The new 
formed [4Fe-4S] cluster destabilizes the binding of IRP1 to IRE and increases the 
synthesis of ferritin in order to increase iron storage capacity of the cell. In conclusion, 
ferritin is an iron storage protein that keeps iron in a non-toxic, and yet bioavailable form 
(reviewed in (Harrison and Arosio 1996; Arosio et al. 2008)). 
  
1.8.2 Mitochondrial Ferritin 
Discovery of MtFt has led to new insights into iron metabolism and mitochondrial 
associated diseases. 
 MtFt gene is localized on chromosome 5q23. It is an intronless gene that encodes 
a 242 amino acid protein (30 kDa). MtFt precursor is targeted to mitochondria and 
processed to a 22 kDa subunit that assembles into typical ferritin shells and has 
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ferroxidase activity. So, MtFt is an unusual H-type ferritin targeted to mitochondria (Levi 
et al. 2001). 
 Unlike cytosolic ferritins, MtFt mRNA lacks an IRE in its 5’UTR and the factors 
regulating its synthesis remain poorly understood (Drysdale et al. 2002). While the 
sequence of MtFt is very similar to cytosolic H ferritin (Levi et al. 2001), Ser144 found in 
MtFt but absent in H ferritin is thought to reduce ferroxidase activity of MtFt. As a result, 
MtFt is thought to behave like cytosolic L ferritins that tightly sequester excess iron 
(Bou-Abdallah et al. 2005).  MtFt is expressed at high levels in erythroblasts from 
patients with sideroblastic anemia (impaired heme synthesis) and testis and at lower 
levels in pancreatic islets of Langerhans, brain, spinal cord and adipocytes (Drysdale et 
al. 2002; Levi and Arosio 2004), whereas frataxin is expressed in all tissues. Hydrogen 
peroxide catalyzed ferrihydrite mineralization is supported by frataxin and cytosolic 
ferritins, but not supported by MtFt (Bou-Abdallah et al. 2005). Therefore one of 
frataxin’s unique roles in the mitochondria may be to protect DNA from hydrogen 
peroxide (Karthikeyan et al. 2003) and MtF may serve different but complementary roles 
in iron detoxification. 
Overexpression of MtFt in normal mouse fibroblasts (Nie et al. 2005) and in 
HeLa cells (Corsi et al. 2002) results in a mitochondrial iron overload with preferential 
iron sequestration in MtFt as ferrihydrite, at the expense of cytosolic iron. 
Overexpression of MtFt in TA-H1299 cells (non-small cell lung carcinoma) increases the 
sensitivity of these cells to oxidative stress (Lu et al. 2009). 
 Yeast has no ferritin gene, but over-expression of either MtFt (Campanella et al. 
2004) or cytosolic L type ferritin (Desmyter et al. 2004) rescues the respiratory defect 
and lengthens the lifespan of yfh1Δ. This indicates that iron mineralization by whatever 
means, has a beneficial effect on iron overloaded mitochondria. MtFt seems to provide a 
redundant mechanism to store iron and control ROS formation primarily through 






1.9 General Hypothesis and Research Objectives 
1.9.1 Hypothesis 
 The chemical form of mitochondrial iron and the metal distribution within the 
nervous system are altered in FRDA. 
1.9.2 Research Objectives 
 a. Determine the chemical form of mitochondrial iron in FRDA fibroblasts and 
compare it to that of control fibroblasts. 
 b. Validate RS-XRF for brain metal mapping. 
 c. Map the distribution of iron, copper and zinc in the cerebellar cortex, cerebellar 
white matter and dentate nucleus. 
 d. Map the distribution of iron, copper and zinc in the brain and spinal cord from a 




























The Chemical Form of Mitochondrial 

















FRDA is a progressive neurodegenerative disease inherited as an autosomal 
recessive trait that affects 1:50,000 Caucasians (Campuzano et al. 1996; Durr et al. 1996). 
The molecular defect in FRDA results from a hyper-expansion of a GAA trinucleotide 
repeat in the first intron of the frataxin gene that interferes with transcription of frataxin 
(Campuzano et al. 1996). Patients with fewer GAA repeats on the smaller allele make 
more frataxin, and as a result their disease starts later in life and/or progresses more 
slowly (Durr et al. 1996). Most patients are homozygous for the expanded alleles 
(Campuzano et al. 1996; Durr et al. 1996) and their GAA repeats adopt a triple helical 
structure forming a novel stable DNA structure called “sticky DNA”. This inhibits the 
transcription of the FRDA gene by sequestration of the RNA polymerases (Bidichandani 
et al. 1998; Ohshima et al. 1998; Sakamoto et al. 1999; Sakamoto et al. 2001). Genomic 
instability is a feature of human FRDA (Durr et al. 1996) and tissue specific expansions 
of GAA repeats have been described in cerebellum and dorsal root ganglia in a mouse 
model expressing human frataxin in the context of elevated GAA repeats known to cause 
human disease (Clark et al. 2007).  
FRDA is the consequence of deficiency of frataxin, a nuclear encoded 
mitochondrial targeted protein (Gibson et al. 1996; Babcock et al. 1997; Campuzano et 
al. 1997; Koutnikova et al. 1997; Priller et al. 1997). FRDA patients have extremely low, 
sometimes undetectable frataxin mRNA levels (Campuzano et al. 1996; Cossee et al. 
1997) and show a severe reduction in frataxin expression ranging from 4 to 29% of 
normal levels (Campuzano et al. 1997). In mouse (Al-Mahdawi et al. 2006) as well as 
invertebrate models of FRDA (Anderson et al. 2005; Gakh et al. 2006; Vazquez-
Manrique et al. 2006; Llorens et al. 2007), reduced longevity and chronic oxidative stress 
is a common feature. 
Characteristic features of FRDA are degeneration of neurons especially in dorsal 
root ganglia, spinal cord and cerebellum (Hughes et al. 1968; Oppenheimer 1979; 
Lamarche et al. 1984), cardiomyocytes (Hewer 1968; Sanchez-Casis et al. 1976; 
Lamarche et al. 1984) and pancreatic beta cells (Hewer 1968; Hewer and Robinson 
1968). These cells are metabolically active, non-dividing and long-lived and express 
frataxin at high levels (Campuzano et al. 1996).  
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There is considerable evidence that frataxin is a bifunctional protein that acts as 
both a chaperone for ferrous iron and an iron storage protein that mineralizes iron as 
ferrihydrite, a biomineral composed of ferric oxide/hydroxide octahedra.  
Frataxin chaperones ferrous iron to the ISC pathway by forming a complex with 
scaffold proteins and cysteine desulfurase (Gerber et al. 2003; Muhlenhoff et al. 2003; 
Yoon and Cowan 2003; Ramazzotti et al. 2004), and to the heme biosynthetic pathway by 
interacting with ferrochelatase (Lesuisse et al. 2003; Park et al. 2003; Yoon and Cowan 
2004; Schoenfeld et al. 2005). It also stabilizes aconitase during oxidative stress (Bulteau 
et al. 2004; Bulteau et al. 2005). Frataxin is also expressed in the cytosol where it is 
involved in ISC synthesis (Acquaviva et al. 2005; Lu and Cortopassi 2007). When 
frataxin is knocked down in normal embryonic kidney cells, the earliest consequence is a 
defect in cytoplasmic iron sulfur proteins followed by increased oxidative damage. This 
leads to a decline in mitochondrial aconitase activity, deficiency of ISC and deficiency of 
heme, followed by an increase of mRNA levels of major enzymes involved in heme 
biosynthesis (i.e. mitochondrial monoamine oxidase A and mitochondrial δ-
aminolevulinate synthase 1) (Lu and Cortopassi 2007). 
The first step in human frataxin assembly is the formation of the trimer that binds 
a single atom of iron at its 3-fold channel (O'Neill et al. 2005; Karlberg et al. 2006). 
Changes in the channel conformation at the 3-fold axis of the trimer are proposed to 
regulate whether ferrous iron is oxidized for storage or made available for transfer to 
proteins that require iron (Karlberg et al. 2006). Frataxin binds iron in yeast (Adamec et 
al. 2000) and its assembly responds to increases in mitochondrial iron uptake (Gakh et al. 
2008). Like yeast frataxin (Adamec et al. 2000; Gakh et al. 2002; Park et al. 2002; Park et 
al. 2003), human frataxin mineralizes iron in vitro as ferrihydrite within a 48 subunit 
polymer (Cavadini et al. 2002; Nichol et al. 2003; O'Neill et al. 2005; O'Neill et al. 2005) 
but unlike yeast, human frataxin polymerizes in the absence of excess iron through 
subunit interactions mediated through residues in the N-terminus that are not conserved 
in yeast (O'Neill et al. 2005). A pool of high molecular weight frataxin protein has been 
identified in mouse and human heart suggesting that frataxin assembles in vivo (Cavadini 
et al. 2002; O'Neill et al. 2005) but it remains to be established if frataxin polymers 
mineralize iron in vivo in human FRDA. 
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Frataxin homopolymers consist of ordered rod-shape polymers of globular 
particles that have small electron dense cores (Cavadini et al. 2002; Gakh et al. 2002) 
resembling the iron cores of ferritin (Cavadini et al. 2002). XAS studies of human 
frataxin polymers assembled in vitro showed that the ferrihydrite crystallites in the 
frataxin core are similar to, but less ordered than iron cores of ferritin (Nichol et al. 
2003). 
The importance of oxidative stress in FRDA pathology has been a subject of 
debate. Studies using mouse FRDA models indicate that oxidative stress varies between 
tissues. Conditional knockouts in heart and neural tissues show little evidence of 
oxidative stress (Puccio et al. 2001; Seznec et al. 2004; Seznec et al. 2005), while 
pancreas (Ristow et al. 2003) and liver (Thierbach et al. 2005) knockouts are sensitive to 
oxidants. Mouse models expressing only low levels of human frataxin show decreased 
aconitase activity and mild oxidative stress with iron accumulation as a late event leading 
to progressive neurodegeneration and cardiac pathology (Al-Mahdawi et al. 2006). 
Cultured fibroblasts and lymphoblasts from FRDA patients display increased sensitivity 
to oxidative stress (Wong et al. 1999; Wong et al. 2000) and FRDA patients display signs 
of increased oxidative stress, including elevated markers of free radical damage to DNA, 
lipid peroxidation, reduced plasma levels of glutathione, reduced aconitase activity and 
elevated IRP1 (Rotig et al. 1997; Piemonte et al. 2001; Karthikeyan et al. 2003; Lobmayr 
et al. 2005). Iron deposits are seen in patients’ myocardial cells (Sanchez-Casis et al. 
1976; Lamarche et al. 1980; Bradley et al. 2000), hepatocytes and spleen (Bradley et al. 
2000) and FRDA fibroblast cultures (Delatycki et al. 1999). Magnetic Resonance in vivo 
studies show increased iron in the dentate nucleus of FRDA patients (Waldvogel et al. 
1999; Boddaert et al. 2007) but these findings have been challenged by biochemical 
studies of post-mortem tissues that failed to reveal an increase in iron (Koeppen et al. 
2007). Over-expression of frataxin in FRDA lymphoblasts changes the proportion of 
filterable and non-filterable iron, indicating that frataxin has a direct influence on the 
chemical form of iron (Tan et al. 2001). 
The chaperone function of frataxin has been dissected from its function in 
mineralizing iron in yeast. Frataxin with mutations that reduce the ferroxidase activity of 
frataxin and impair iron mineralization, leave its iron chaperone function unimpaired.  
 31
Yeast expressing frataxin with these mutations exhibits mild chronic oxidative damage 
that reduces cellular lifespan (Gakh et al. 2006). However unlike yeast, human cells have 
ferritin that can also mineralize iron with great efficiency and in some cells provide a 
redundant mechanism of iron detoxification (Arosio et al. 2008; Campanella et al. 2009).  
Cells have two kinds of ferritin. A heteropolymer formed from H and L subunits 
is found in the cytosol and other cellular compartments (Renaud et al. 1991; Arosio et al. 
2008) while a homopolymer formed from an H-type subunit is targeted to mitochondria 
(Levi et al. 2001). MtFt is expressed at high levels in erythroblasts from patients with 
sideroblastic anemia, in normal testis and at lower levels in pancreatic islets of 
Langerhans, brain, spinal cord and adipocytes (Levi et al. 2001; Drysdale et al. 2002; 
Levi and Arosio 2004; Santambrogio et al. 2007). Unlike cytosolic ferritins, MtFt mRNA 
lacks an IRE in its 5′ UTR, and the factors regulating its synthesis remain poorly 
understood. MtFt synthesis is induced when heme synthesis is disrupted in erythroid cells 
(Cazzola et al. 2003) but the generality of this control mechanism to other cell types has 
not been established. While the sequence of MtFt is very similar to cytosolic H ferritin, 
Ser144 found in MtFt but absent in H ferritin is thought to reduce ferroxidase activity of 
MtFt. As a result, MtFt is thought to behave like cytosolic L ferritins that tightly 
sequester excess iron (Bou-Abdallah et al. 2005). MtFt may have a ferrihydrite iron core 
that is similar to that of cytosolic ferritins, but the unique microenvironment in 
mitochondria could favor the mineralization of other iron oxides. The mineral form of 
MtFt iron cores assembled in vivo remains to be determined. 
MtFt and frataxin may serve complementary roles in iron detoxification. Since 
both human MtFt (Campanella et al. 2004) and L ferritin (Desmyter et al. 2004) have the 
ability to partially rescue frataxin knock-out yeast, MtFt seems to provide a redundant 
mechanism to store iron and control reactive oxygen species formation primarily through 
regulation of mitochondrial iron availability (Campanella et al. 2009). In yeast, frataxin 
assembly driven by increased mitochondrial iron uptake (Gakh et al. 2008) detoxifies 
redox-active iron by sequestering it in a non-toxic form in a protein-protected 
environment (O'Neill et al. 2005). Frataxin may also play a unique role in protecting the 
DNA from Fenton chemistry (Rotig et al. 1997; Isaya et al. 2004) since hydrogen 
peroxide catalyzed ferrihydrite mineralization is supported by frataxin but is not 
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supported by MtFt (Grant et al. 1998; Zhao et al. 2002; Bou-Abdallah et al. 2005; Ilari et 
al. 2005; Su et al. 2005). 
 
2.2 Hypothesis and Research Objectives 
2.2.1 Hypothesis 
 The chemical form of iron is altered in mitochondria of fibroblasts from FRDA 
patients and is different from that of mitochondrial iron from control fibroblasts. 
2.2.2 Research Objectives 
 a. Determine the chemical form of mitochondrial iron in FRDA fibroblasts and 
compare it to that of control fibroblasts. 
 b. Characterize the iron storage proteins and changes in their expression in FRDA 
versus control fibroblasts. 
 
2.3 Materials and Methods 
2.3.1 Cell culture 
2.3.1.1 Fibroblast Cell Lines 
Primary fibroblasts were obtained from the NIGMS Human Genetic Cell Repository 
(Coriell Institute for Medical Research) and Canadian Repository for Mutant Human Cell 
Strains (McGill University) (Table 1). Donor cell lines GM04078 and GM03816 were 
derived from a brother and sister with a diagnosis of FRDA at both the molecular and 
clinical levels with the sister being less severely affected. The McGill cell line MCH070 
and Coriell GM08400 were sex matched controls. Clinical summary and case histories 
provided by Coriell confirmed the absence of the disease in GM08400 and GAA triplet 
expansions of the frataxin gene were determined to be in the normal range for the McGill 








Table 1. Fibroblast primary cell lines. 
 
Sex (family) ID GAA repeats Diagnostic Provenience
M (1) GM04078 420/541 FRDA Coriell 
F (1) GM03816 330/380 FRDA Coriell 
M (2) MCH070 <66 Control McGill 
F (3) GM08400 Not determined Control Coriell 
 
 
Table 2. Iron enrichment of the growth medium. 
 
 MEM + 10% CCS Blood (Kratz et al. 2008) 
Iron 70.46 µg/dl 41 – 141 µg/dL 
TIBCa 97.41 µg/dl 251 – 406 µg/dL 
% Saturationb 72% 16 – 35% 
a Total Iron Binding Capacity 
















2.3.1.2 Growth Medium 
 Fibroblasts were cultured in Eagle’s Minimal Essential Medium (MEM) with 
Eagle’s salts (GIBCO) supplemented with 10% Cosmic Calf Serum (CCS) (Hyclone) 
(growth medium) so that the iron content of the culture medium was very close to that of 
human serum (Table 2). 
 
2.3.1.3 Fibroblast Cultures 
 Upon arrival, the 25 cm2 culture flasks (T25, Falcon) were wiped with 70% 
ethanol and incubated at 37ºC overnight in a humidified atmosphere of 5% CO2 in air as 
per Coriell’s instructions. On observation, the fibroblasts were nearly confluent, arranged 
in parallel arrays, displayed the normal spindle-shaped morphology and showed no signs 
of contamination.  
 The next day fibroblasts were fed by withdrawing the shipping medium and 
replacing it with 5 ml growth medium. The cultures were then incubated at 37º in a 
humidified atmosphere of 5% CO2 in air.  Cells were fed twice a week and split 1:5 when 
they reached confluence.  
 
2.3.1.4 Cell Harvesting 
 Confluent cell cultures were rinsed three times in Puck’s balanced salt solution 
(PBSS) to remove all traces of serum. The fibroblasts were then incubated in 0.025% 
trypsin/0.01% ethylenediaminetetraacetic acid (EDTA)/PBSS for 5-10 minutes at 37ºC. 
Using a phase contrast microscope, the cells were closely monitored. When most of the 
cells lifted off the surface, the trypsin solution was flushed over the surface to assist in 
dislodging the remaining attached fibroblasts. To inactivate the trypsin, 0.1 ml CCS/1 ml 
cell suspension was added. The resulting cell suspension was centrifuged at 800 RPM for 
10 minutes and then resuspended in growth medium.  
 To determine the number of viable cells, an aliquot of 0.4 ml cell suspension was 
stained with 0.1 ml of 0.3% Nigrosin dye. Viable cells remained unstained, whereas the 
Nigrosin dye stained the dead or dying cells in purple-black. Viable cells were counted in 
the four square compartments of each of the two sides of a hemacytometer (Improved 
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Neubauer Levy Hemacytometer, Hausser Scientific Partnership). The number of viable 
fibroblasts per ml was calculated using the following formulas: 
 
Average total count = (Total Count side1 + Total Count side2)/2       (2.1) 
Number of viable cells/ml = (Average total count/4) x 10 x 1000 x (5/4)      (2.2) 
 
2.3.1.5 Fibroblast Subculture 
 Using the cell count described above, the cell suspension was diluted to the 
desired cell concentration in growth medium (5.0-6.0 x 104 cells/ml) and each T25 vented 
cap flask was seeded with 5 ml of final cell suspension (1.0-1.2 x 104 cells/cm2). Flasks 
were placed in the 37ºC, 5% CO2 incubator and checked the next morning for cell 
attachment. 
 
2.3.1.6 Long-term Storage of Cells 
 Following cell harvesting and counting, the cell suspension was diluted to the 
desired cell concentration in growth medium (106 cells/ml) and 1 ml of the resulting cell 
suspension was placed into each of the several cryovials (Nalgene). To each vial, 53 µl 
DMSO was added. Cryovials were then sealed and placed into an isopropanol filled 
cryocontainer (Nalgene Cryo 1ºC Freezing Container, Nalgene Company) which was 
stored overnight in a -70ºC freezer. The following morning, the cryovials were 
transferred to a liquid nitrogen storage dewer.  
 
2.3.1.7 Cell Recovery from Cryogenic Storage 
 The desired number of cryovials were removed from liquid nitrogen and 
immediately placed in a water bath at 37ºC. When completely thawed, the content of 
each cryovial was diluted in 5 ml growth medium. To remove all traces of cryoprotectant, 
the cell suspension was centrifuged and re-diluted in 5 ml fresh growth medium. An 
aliquot was removed for cell counting. Based on the results of the cell count, the cell 




2.3.2 Isolation of Mitochondria 
Mitochondria were isolated from 20–40 million cells from pooled confluent 
cultures. The cell pellet was homogenized on ice using a 7 ml Dounce homogenizer with 
a Teflon pestle (Pyrex) by moving the pestle up and down 20 times. The amount of 
homogenization needed to rupture the cells was determined by microscopic examination 
during the homogenization process. The ‘heavy’ mitochondrial fraction (HMF) was 
obtained using a mitochondrial isolation kit (MITOISO1, Sigma) employing two 
differential centrifugation steps at 4ºC each using one low speed (1,000 x g) and one high 
speed (3,500 x g) centrifugation as per kit instructions. This yielded a mitochondrial 
fraction with low contamination from peroxisomes and lysosomes. The final 
mitochondrial pellet was suspended in 20 µl storage buffer (10 mM HEPES, pH 7.4, 0.25 
M sucrose, 1 mM ATP, 0.08 mM ADP, 5 mM sodium succinate, 2 mM K2HPO4, 1 mM 
DTT) provided by the kit and aliquots were prepared for transmission electron 
microscopy, XAS analysis and Western blotting. 
 
2.3.3 Transmission Electron Microscopy 
Aliquots of HMF were prepared for transmission electron microscopy (TEM) 
following standard protocols (Locke and Huie 1980) to confirm mitochondrial purity and 
membrane integrity.  
The mitochondria were fixed overnight in 2.5% Glutaraldehyde in 0.1 M 
Phosphate Buffer (PB), pH 7.4 at 4ºC. In order to keep the mitochondrial pellet together, 
the next morning the mitochondria were resuspended in a warm 2% Bactoagar in 0.1 M 
PB and immediately centrifuged in a Beckman microfuge so that the agar was not 
allowed to cool and solidify before the mitochondria were pelleted at the bottom of the 
microfuge tube. The tube was then placed in the refrigerator for 15 minutes to allow the 
agar to solidify. The mitochondrial pellet was removed by cutting the tube with a razor 
blade and removing the excess agar.  
The small piece of agar containing the mitochondrial pellet was then washed in 
0.1 M PB containing 0.22 M sucrose, postfixed with 0.8% osmium tetroxide in 0.1 M PB 
containing 0.22 M sucrose at 4ºC for 1 hour, washed in 0.1 M PB, dehydrated in 
increasing concentrations of ethanol and then acetone. This was followed by infiltration 
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with Epon 812 : acetone, pure Epon 812 overnight and polymerization of the samples in a 
60ºC oven for 48-72 hours.  
After polymerization, the blocks were rough trimmed with a double edge razor 
blade, smooth trimmed with a glass knife cut on a LKB Knife Maker Type 7801A and 
thin sections were cut using a diamond knife (Du Pont) on a Reichert-Jung Ultracut 
microtome. The gold and silver sections were flattened with toluene vapours and then 
lifted on the dull side of 300 mesh square copper grids (EM Sciences), stained on grid 
with 2% uranyl acetate and Reynold’s lead citrate and examined with a Philips 410LS 
transmission electron microscope.  For each sample approximately 4 grids and 4 
micrographs were examined. 
 
2.3.4 X-ray Absorption Spectroscopy 
2.3.4.1. Sample Preparation for XAS 
To reduce ice diffraction artefacts, mitochondria for XAS were suspended in a 
minimal amount of storage buffer in 20% glycerol prior to flash freezing. Samples (30 µl) 
were loaded into 1 mm path length Lucite sample cells and flash-frozen in isopentane 
chilled in liquid nitrogen. Samples were stored and transported to the synchrotron in 
liquid nitrogen. Human frataxin, iron loaded in vitro (a kind gift of Dr. G. Isaya) and iron 
loaded horse spleen holoferritin (Sigma) served as models of less ordered and highly 
ordered ferrihydrite respectively as previously described (Nichol et al. 2003). Dry human 
met-hemoglobin and bovine hemin (Sigma) were dissolved in 20% glycerol and used as 
saturated solutions. Metalloproteins were prepared in 20% glycerol. Other iron model 
compounds were prepared for transmittance measurements by intimately grinding each 
with a boron nitride diluent and pressing each into a 2 mm thick sample holder between 
layers of metal-free Mylar. 
 
2.3.4.2 X-ray Absorption Near Edge Structure 
Data from mitochondria was acquired on the SPEAR 3 storage ring (85-100 mA 
at 3.0 GeV) on beamlines 9-3 and 10-2 each equipped with a Silicon (220) double-crystal 
monochromator. Data from some model compounds were also collected on SPEAR 3 
beamline 2-3 and SPEAR 2 beamline 7-3. The incident and transmitted X-ray intensities 
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were monitored using N2-filled ionization chambers. The Fe K X-ray absorption near-
edge spectra of mitochondria were recorded as K fluorescence excitation spectra using a 
solid state array of 30 germanium detectors (Canberra) (Cramer et al. 1988). The X-ray 
energy was calibrated with reference to the lowest K-edge energy inflection point of a 
standard metallic iron foil (EXAFS Co), run concurrently, the energy of which was 
assumed to be 7111.3 eV. Harmonic rejection was accomplished on beamline 9-3 using 
an upstream vertically collimating Rh-coated mirror and downstream refocusing Rh-
coated mirror and on beamline 10-2, by detuning one monochromator crystal to 
approximately 50% off peak. Four sweeps were collected for each sample. 
Photoreduction was seen in two independent unaffected HMFs after warming to liquid 
nitrogen temperatures (Figure 1). Therefore each dataset was examined for 
photoreduction between sweeps and between datasets. In order to reduce X-ray damage, 
samples were maintained at between 5 and 10 K in a liquid helium flow cryostat (Oxford 











Figure 1. Photoreduction of unaffected HMF. Unaffected HMF shows photoreduction 
upon second run after warming to liquid nitrogen temperatures, seen as the translation of 















2.3.4.3 XAS Data Analysis 
Data analysis was performed using the EXAFSPAK suite of computer programs. 
Quantitative determination of the different chemical forms of iron present was carried out 
by least-squares fitting of the near-edge spectra to linear combinations of the spectra of 
standards, as previously described (Pickering et al. 1998). 
From a library of more than 30 model iron compounds, 22 were retained during 
several rounds of refinement and these were used to fit all the near edges (Table 3). An 
important distinction with this type of analysis is that incorporation of the spectrum of a 
particular compound in a fit is an indication of the presence of a class or species, rather 
than of the particular compound from which the spectrum in question was obtained. No 
smoothing or related data manipulations were performed. 
 
2.3.5 Polyacrylamide Gel Electrophoresis (PAGE) and Western Blotting 
2.3.5.1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 The HMF was diluted 1:2 with sample buffer (2% SDS, 5% β-mercaptoethanol, 
25% glycerol, 0.001% bromophenol blue, 0.0625 M Tris-HCl, pH 6.8) and homogenized. 
Samples were sonicated (10 pulses, Sonifer® Cell Disruptor Model W140, Heat Systems 
– Ultrasonic, Inc.) then boiled for 10 minutes and centrifuged for 10 minutes at 12,000 x 
g. The supernatant was transferred to fresh tubes. 
 Small aliquots (5 µl) were used for protein quantification. Protein concentration 
was measured using the BioRad Protein Assay (BioRad) based on the Bradford dye-
binding procedure (Bradford 1976) and the color change was quantified with a 
spectrophotometer (BioRad SmartSpecTM Plus) at an assay wavelength of 595 nm. 
SDS-PAGE was performed using the method originally described by Laemmli 
(Laemmli 1970) with the following modifications. Samples containing equal amounts of 
proteins (70 µg/lane) were loaded on 15% gels or on 4-15% precast gradient gels 
(BioRad). The precast gradient gels do not have SDS included in the separating gel or 
stacking gel. SDS is included in the running buffer (25 mM Tris, 192 mM glycine, 0.1% 




Table 3. Iron model compounds and metalloproteins used in fits. 
 
Model compounds and metalloproteinsa Chemical formula Coordination
Fe (III)  
  1.  Ferrihydrite (horse spleen ferritin) FeOOH 6O 
  2.  Human frataxin holopolymer FeOOH 6O 
  3.  Goethite FeOOH 6O 
  4.  Hematite α-Fe2O3 6O 
  5.  Magnetite Fe3+2Fe2+O4 6O 
  6.  Ferric sulfate Fe2(SO4)3 6O 
  7.  Ferric oxide Fe2O3 6O 
  8.  Ferric pyrophosphate Fe4(P2O7)3 4O 
  9.  Ferric phosphate FePO4 4O 
10.  Ferric citrate FeC6H5O7 3O 
11.  Heme (human met- hemoglobin) 5N 
12.  Hemin (bovine) 4N, 1Cl 
13.  Cytochrome c 4N 
Iron-sulfur cluster  
14. Ferredoxin - oxidized (Anabaena) [Fe2-S2(SR)2]2- 4S 
15. Rubredoxin - oxidized (P. furiosus) [Fe(SR)4]1- 4S 
16. Iron regulatory protein - oxidized [Fe3-S4]+ 4S 
17. Rubredoxin – reduced (P. furiosus) [Fe(SR)4]2- 4S 
18. Ferredoxin – reduced (Anabaena) [Fe2(SR)4]3- 4S 
Fe (II)  
19. Ferrous sulfide FeS 1S 
20. Ferrous ammonium sulphate [Fe(H2O)6](NH4)2(SO4) 6O 
21. Ferrous hexaimidazole dichloride [Fe(imidazole)6]Cl2 6N 
22. Ferrous sulfate FeSO4 6O 
a Spectra from the listed compounds are used in the fit to represent a general class or category of compound, 













2.3.5.2 Discontinuous Native PAGE 
 The HMF was diluted 1:2 with sample buffer (25% glycerol, 0.001% 
bromophenol blue, 0.0625 M Tris-HCl, pH 6.8). Protein quantification was performed 
using the Bio-Rad Protein Assay. Samples (13 µg/lane) were loaded on 4-15% precast 
gradient gels (Biorad) and polypeptides were separated for 7 hours at 120 V. To ensure 
polypeptide separation under non-denaturing conditions the sample buffer did not contain 
SDS and β-mercaptoethanol and the running buffer did not contain SDS (Ornstein 1964). 
 
2.3.5.3 Western Blotting 
 Immunoblotting was performed using the method of Towbin et al (1979) (Towbin 
et al. 1979) with the following modifications. Gels were equilibrated for 15 minutes in 
transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol) and transferred to 
nitrocellulose (Pall Life Sciences) membrane using the BioRad wet transfer apparatus. 
The SDS-PAGE transfer was performed for 90 minutes at 75 V on ice. The non-
denaturing PAGE transfer was done for 2 hours at 75V on ice using transfer buffer that 
contained 1% SDS. Complete transfer was monitored with Ponceau S stain (0.1% 
Ponceau S (Sigma) in 1% acetic acid) for detection of proteins on nitrocellulose 
membranes. Membranes were then washed with Tris-buffered saline (TBS) (20 mM Tris-
HCl, pH 7.5, 0.5 M NaCl), and blocked in blocking solution (5% skim milk (Carnation), 
0.1% Tween-20 (EM Science) in TBS) for 1 hour. Membranes were incubated with 
primary antibodies overnight at 4°C. Membranes were washed 3 times in blocking 
solution for 5, 15, and 5 minutes. Secondary antibodies incubation was done at room 
temperature for 2 hours with rocking. Membranes were washed 3 times in blocking 
solution for 5, 15, and 5 minutes, then washed in TBS containing 0.1% Tween for 15 
minutes followed by a 5 minute wash in TBS. Horseradish peroxidase (HRP)-bound 
proteins were detected using a chemiluminescence kit (PerkinElmer Life Sciences, Inc.) 
and X-ray film (Kodak Biomax XAR). 
 
2.3.5.4 Immunodetection of Proteins and Purity of Mitochondrial Fractions  
Detection of frataxin homopolymers, monomers and enrichment of progressive 
cellular fractions with mitochondria was estimated by Western blotting using a 
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polyclonal antibody against human frataxin raised in rabbit (1:3000) (gift from Dr. Grazia 
Isaya) and a secondary goat anti-rabbit antibody tagged with HRP (1:4000) (BioRad).  
Ferritin was detected on Western blots of both denaturing and non-denaturing gels 
with polyclonal antibodies against human heart ferritin, raised in sheep (1:1000) (Novus 
Biological) and a secondary HRP-tagged rabbit IgG anti-sheep antibody (1:4000) (Inter 
Medico). This human ferritin antibody cross-reacted with recombinant human MtFt (a 
kind gift of Dr. Paolo Arosio, University of Milan, Italy) as well as ferritin H and L 
subunits.  
The purity of mitochondrial fractions was measured in two ways. Contamination 
of the HMF by cytosol was determined using the monoclonal antibody (JLA20) against 
chicken actin raised in mouse (1:5000) (Lin 1981) and HRP-tagged goat anti-mouse 
antibodies (1:3000) (BioRad). Lysosomal content of progressive cellular fractions was 
determined using a polyclonal antibody against human lysosomal-associated membrane 
protein 1 (LAMP1) synthetic peptide raised in rabbit (1:220) (Sigma) and HRP-tagged 
goat anti-rabbit (1:4000) (BioRad).  
  
2.3.5.5 Iron Detection 
 Native blots were stained for iron with Ferene S (Chung 1985) (Sigma) overnight 
at 4ºC. The sensitivity of Ferene S stain on gels and blots was compared with the 
sensitivity of protein detection with HRP tagged antibodies. Serial dilution of ferritin and 
frataxin were separated under non-denaturing conditions. A gel was stained for iron with 
Ferene S. The duplicate gel was electroblotted on nitrocellulose and stained for iron with 











2.4.1 HMF are Highly Enriched in Mitochondria 
Mitochondria were isolated from fibroblasts from affected male and female 
siblings. Equal amounts of protein from successive pellets obtained during cell 
fractionation were examined using antibodies directed against marker proteins for the 
cytosol (actin), lysosomes (LAMP1) and frataxin to monitor enrichment and purity of the 
final HMF. Actin was not present in the HMF (Figure 2, lane 3) but was seen in whole 
cell lysates (Figure 2, lane 4), indicating little contamination of the HMF with cytosolic 
cytoskeletal elements. While some lysosomes were present in HMF (Figure 3C) they 
were not enriched during fractionation (Figure 3C, lane 4). The amount of the frataxin 
was highest in the HMF (Figure 3B, lane 4) indicating that the HMF was enriched in 
mitochondria. TEM confirmed that the HMF contained intact mitochondria with very few 
lysosomes and membrane fragments (Figure 4). 
 
2.4.2 Mitochondria from Affected and Unaffected Cells are Rich in Ferrihydrite 
Quantitative analysis using the near-edge region of the X-ray absorption spectrum 
was performed using a library of iron models (Table 3). Iron K near edge spectra of HMF 
are compared in Figure 5 and their respective fits are shown in Table 4. The spectra 
shown in Figure 5 are representative of 6 independent affected and 4 independent 
unaffected HMF samples (Table 4). All show that ferrihydrite is the predominant species 
and when all ferric oxides are summed they constitute most of total iron. Minor species 
such as hemin, some ferrous species and iron–sulfur clusters were fitted to both affected 
and unaffected HMF but not in any consistent way. The fit error or residual was low for 











Figure 2. Estimation of cytosolic contamination of the HMF. The cytosolic protein actin 
was detected on Western blots with a monoclonal anti-actin antibody. Lane 1: molecular 
weight marker; lane 2: actin; lane 3: HMF lysate; and lane 4: whole fibroblast lysate. 
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Figure 3. Estimation of mitochondrial enrichment and lysosomal contamination. Proteins 
in successive pellets from the mitochondrial isolation procedure were separated under 
denaturing conditions. Lane 1: whole cell lysate; lane 2: pellet from 1st 1,000 x g 
centrifugation; lane 3: pellet from 2nd 1,000 x g centrifugation; lane 4: HMF. (A) Ponceau 
stain shows equal protein loading, molecular weight markers on left; (B) anti-frataxin. 
Frataxin was present as a 38 kDa dimer; and (C) anti-LAMP1. A band was visible at 120 

















Affected        
1. GM04078A        
Best fit 55 (6)  27 (6)d 13 (3)  5 (1)b1 0.040 
Forced fit  40 (6) 40 (7)d 15 (4)  5 (1)b1 0.060 
2. GM04078        
Best fit 73 (8)  13 (8)d  5 (1)f 9 (2)b1 0.120 
Forced fit  70 (7) 16 (7)d  4 (1)f 10 (2)b1 0.149 
3. GM04078        
Best fit 70 (5)   13 (7) 10 (1)f 7 (1)b2 0.071 
Forced fit  50 (6)  40 (8) 6 (1) f 4 (2)b2 0.138 
4. GM04078        
Best fit 39 (5)  25 (5)d  11(1)g 25(1)b1 0.069 
Forced fit  26 (6) 38 (6)d  10 (1)g 26 (2)b1 0.108 
5. GM03816B        
Best fit 72 (5)  16 (2)e 8 (5) 4 (1)f  0.693 
Forced fit  57 (4) 22 (2)e 19 (7) 2 (1)f  1.027 
6. GM03816        
Best fit 64 (1)    19 (1)f 17 (2)b1 0.362 
Forced fit  64 (1)   18 (2)f 18 (2)b1 0.438 
        
Unaffected        
7. MCH070C        
Best fit  86 (2) 8 (2)e  6 (1)g  0.179 
Forced fit 90 (3)  4 (3)e  6 (1)g  0.243 
8. MCH070        
Best fit  26 (9) 29 (8)e 20 (12)  25 (5)b1 0.753 
Forced fit 34 (12)  25 (8)e 16 (12)  25 (5)b1 0.807 
9. GM08400D        
Best fit  63 (6) 16 (4)e   21 (2)b1 0.638 
Forced fit 67 (7)  12 (5)e   21 (2)b1 0.698 
10. GM08400        
Best fit  84 (2)    16 (3)b2 0.825 
Forced fit 84 (3)     16 (3)b2 1.115 
a Percentage contribution of iron species to total iron in whole mitochondria. Samples number 1, 5, 7 and 9 are plotted 
in Figure 5A, B, C and D, respectively. Precisions, shown in parenthesis, are calculated as three times the estimated 
standard deviation, as derived from the diagonal elements of the covariance matrix; best fit using all model spectra in 
Table 3; the form of ferritin or frataxin that remained in the best fit was removed from the fit and alternate ferrihydrite 
was forced to fit; b Rubredoxin from P. furiosus; b1 reduced rubredoxin; b2 oxidized rubredoxin; c Fit error (x10-3) or 
residual is the average of the sum of the squares of the differences between the observed and calculated signals for all 





Figure 4. Mitochondrial fraction obtained from FRDA fibroblasts. Isolation of 
mitochondria using the mitochondrial isolation kit yielded a fraction highly enriched in 
mitochondria. Some membrane fragments and few lysosomes were found but no other 








Figure 5. Quantitative analysis of Fe K-edge spectra. Each panel shows the normalized 
spectrum of isolated mitochondria (• • •) together with the best fit (——). The 
components of the fit are scaled by their relative contributions: components are category 
as in Table 3. Each category has a unique line type shown in brackets and each species 
has a unique letter. Category 1, ferrihydrite (– • • –) (a) horse spleen ferritin, (b) human 
frataxin; Category 2, Fe–S cluster ( - - -) (c) reduced rubredoxin; Category 3, other iron 
oxides (– – –) (d) goethite, (e) hematite; Category 4, other ferrous species (– • –) (f) 
ferrous ammonium sulfate hexahydrate, (g) ferrous hexaimidazole dichloride; Category 
5, hemin (– - –) (h) see Table 3 (samples number 1, 5, 7 and 9) for numerical results of 
the fits. (A) affected male (GM04078); (B) affected female (GM03816); (C) unaffected 
male (MCH070); (D) unaffected female (GM08400). (E) spectra of affected and 
unaffected females overlaid showing differences between them; (F) (i) affected female 
fitted with unaffected female; (ii) horse spleen ferritin fitted with frataxin; (iii) difference 
between affected and unaffected HMF overlaid with difference between ferritin and 


















The highly ordered ferrihydrite of ferritin best fitted the HMF from affected 
fibroblasts (Figure 5A, B, Table 4) while the less ordered ferrihydrite of frataxin best 
fitted the unaffected HMF (Figure 5C, D, Table 4). When ferrihydrite from ferritin was 
removed from the fit for affected HMF (Table 4, forced fit), fit errors increased, the 
proportion of ferrihydrite, as found in frataxin, was less and the proportion of other 
highly ordered ferric oxides (goethite/hematite) increased. When ferrihydrite from 
frataxin was removed from the fit for unaffected HMF, fit errors increased and the 
proportion of other highly ordered ferric oxides was reduced and precisions were poorer. 
When overlaid the iron K-edges of affected and unaffected HMF were slightly different 
(Figure 5E). When the K-edge from affected HMF was fitted with unaffected HMF the 
difference between the two had features that matched differences between horse spleen 
ferritin and frataxin (Figure 5F). The difference between affected and unaffected spectra 
was greater than that between ferritin and frataxin (Figure 5F) indicating differences in 
other iron species other than ferrihydrite. Given that the near edge of ferritin and frataxin 
iron cores are similar and ferrihydrite is the predominant form of iron (Figure 5E) (Nichol 
et al. 2003), I sought to confirm the presence of holoferritin using conventional 
immunoblots of native and denatured proteins from HMF lysates. 
 
2.4.3 Identification of Ferritin Subunits in HMF 
Ferritin subunits were identified by their respective mobility on gels and cross-
reaction with anti-ferritin antibody (Figure 6). Whole fibroblasts (Figure 6, lane 2) 
contained H and L subunits of cytosolic ferritin. In contrast, the predominant ferritin 
subunit in HMF (Figure 6, lanes 3 and 4) was larger than the L and H subunits (20.0 and 
20.9 kDa respectively) and slightly larger than the recombinant MtFt peptide (21.1 kDa) 
(Figure 6, lane 1). The processed MtFt subunit is the largest ferritin subunit at 21.6 kDa 






Figure 6. Identification of ferritin subunits in HMF.  HMF were denatured and separated 
by SDS-PAGE on 4–15% gradient gels. Ferritin was identified using a polyclonal 
antibody raised against human heart ferritin. Lane 1: recombinant MtFt with reported 
MW of 21.1 kDa; lane 2: whole fibroblast lysate, arrowheads show H and L subunits; 
lane 3: HMF FRDA affected; lane 4: HMF FRDA affected; lane 5: Ctr, unaffected. 
Molecular weights predicted from the primary structure of each ferritin subunit are listed 



















2.4.4 Mitochondrial Frataxin Polymers are Present in Unaffected Fibroblasts 
Once I established that the predominant ferritin in HMF was MtFt, I sought to 
determine if it contained iron. The sensitivity of iron staining versus Western blotting was 
determined using dilutions of horse spleen ferritin and human frataxin. Immunoblotting 
easily detected 0.76 µg of ferritin protein but iron was removed by blotting (compare 
Figure 7A, a and b), reducing sensitivity of the Ferene S assay. A similar loss of iron after 
blotting was seen for frataxin (Figure 7B). Ferritin and frataxin were detected in 
unaffected fibroblasts by immunoblotting but no iron was detected indicating that iron 
had been lost or that apoferritin and apofrataxin predominated. Antibody detection of 
protein was more sensitive than iron staining of the same amount of ferritin and 
electroblotting reduced the sensitivity of iron staining (Figure 7). 
 
2.4.5 MtFt is Elevated in FRDA Mitochondria 
After spectra were collected, HMF proteins were separated under non-denaturing 
conditions. A high molecular weight band that cross-reacted with human heart ferritin 
antibodies but that migrated more slowly than the L-rich horse spleen holoferritin 
(440 kDa) standard was detected in affected HMF with a smaller amount in unaffected 
HMF (Figure 8A and B, upper panel). Since the predominant ferritin subunit in the HMF 
is the size predicted for MtFt, the high molecular weight holoferritin in the HMF is most 
likely MtFt. This MtFt stained for iron with Ferene S in affected but not unaffected HMF 
(Figure 8A and B lower panel). It was three times more abundant in affected than in 
unaffected HMF indicating that affected cells have elevated levels of MtFt protein. Note 
the absence of stainable iron in 0.76 µg of horse spleen ferritin (Figure 7A). Taken 
together, these data show that MtFt is increased and stores significant iron in FRDA cells. 
High molecular weight frataxin polymers were also detected in the control fibroblast 








Figure 7. Sensitivity of Ferene S stain for iron and Western blotting for ferritin. Duplicate 
dilution series of (A) horse spleen holoferritin (38– 0.76 µg) and (B) human holofrataxin 
(2.7–0.027 µg) were separated under non-denaturing conditions. A gel was stained with 
Ferene S (A, panel a; B, panel a). The duplicate gel was electro-blotted to nitrocellulose 
and stained for iron with Ferene S (A, panel b; B, panel b). After iron staining, ferritin (A, 
panel c) and frataxin (B, panel c) were detected with their respective specific antibodies 
as described in experimental procedures. Exposure times were 1 minute for ferritin and 







Figure 8. Mitochondrial ferritin is upregulated in HMF from affected cells. HMF proteins 
were separated under non-denaturing conditions on 4–15% gradient gels. (A) upper panel 
anti-heart ferritin, lower panel Ferene S iron stain (equal protein per lane). (B) upper 
panel anti-heart ferritin, lower panel Ferene S iron stain (equal volume per lane). (C) 
same as (A) but reacted with polyclonal anti-human frataxin antibodies. Lanes: Ft – horse 
spleen ferritin; FRDA – affected mitochondria (GM04078 in A, GM03816 in B); Ctr – 


















XAS is a powerful tool to speciate metals in intact systems without damaging the 
sample. X-rays probe all of the iron and therefore in a non-homogenous sample, like 
whole mitochondria, it provides an average composition. Near edge analysis indicates 
that on average, ferrihydrite is the predominant chemical form of iron in both FRDA and 
control mitochondria and ferric oxides constitute most of the total iron. Since XAS 
provides an average composition, individual mitochondria may have more or less. 
The cell has multiple mechanisms to control the uptake and metabolism of iron in 
different forms. The relative importance of ferritin and frataxin in cytosolic and 
mitochondrial iron storage is poorly understood. I found that although ferrihydrite is 
present in both frataxin replete and frataxin deficient mitochondria, ferrihydrite seems to 
be associated with MtFt only in frataxin deficient mitochondria. In addition, only FRDA 
mitochondria have MtFt upregulated 3-fold and only MtFt from FRDA mitochondria 
stains for iron. An unanswered issue is what induces the apparent 3-fold increase in MtFt. 
Since MtFt mRNA lacks an IRE, “free” iron does not seem to be the trigger acting at the 
translational level (Levi et al. 2001; Drysdale et al. 2002). The only known stimulus for 
MtFt synthesis is the disruption of heme synthesis (Cazzola et al. 2003). In erythroid 
cells, heme synthesis is associated with a down regulation in frataxin expression and 
blockage of heme synthesis induces MtFt synthesis and iron uptake (Becker et al. 2002). 
When frataxin is limiting, iron is preferentially directed away from Fe–S cluster synthesis 
towards heme synthesis (Yoon and Cowan 2003) but since Fe–S cluster proteins are 
required in the final steps of heme synthesis (Yoon and Cowan 2004; Schoenfeld et al. 
2005; Wingert et al. 2005), heme synthesis is blocked. In sideroblastic anemia, iron not 
incorporated into heme is shunted to MtFt (Levi et al. 2001; Drysdale et al. 2002; 
Cazzola et al. 2003) and the same may happen in FRDA at least in those cells that have 
the capacity to synthesize mitochondrial ferritin. Expression of MtFt in HeLa cells results 
in decreased levels of cytosolic ferritins, up-regulation of TfR and iron retention in 
mitochondria as MtFt (Corsi et al. 2002).  Under stressful conditions (i.e. treatment with 
H2O2 and Antimycin A), MtFt expression also reduces the formation of ROS and 
increases the activity of mitochondrial ISC (Campanella et al. 2009). Overexpression of 
MtFt in frataxin deficient yeast (Campanella et al. 2004) and FRDA fibroblasts 
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(Campanella et al. 2009) rescues the respiratory function, prevents the mitochondrial iron 
accumulation and mitochondrial DNA damage and prevents the formation of ROS. Thus, 
cells with little or no apo-MtFt or those that cannot upregulate MtFt synthesis may be 
more vulnerable to frataxin deficiency than are fibroblasts. 
The strong iron staining of the MtFt after electroblotting is intriguing (Figure 8A, 
B). It may indicate that MtFt binds iron tightly or its iron core differs from that of horse 
spleen ferritin. Contributions of other iron oxides to the XAS spectra may also represent 
ferritin-bound iron that is mineralized in a different form in the unique environment of 
the mitochondrial matrix. Other iron oxides naturally constitute a small fraction of horse 
spleen ferritin iron cores (Cowley et al. 2000) and are elevated in hemochromatosis, 
Alzheimer’s disease (magnetite, wustite) and thalassemia (goethite) (Ward et al. 1994; 
Ward et al. 2000; Collingwood et al. 2005; Quintana et al. 2006). These studies propose 
that the presence of ‘abnormal’ iron oxides contributes to cellular pathology. 
I also observed differences in frataxin levels between FRDA and control 
mitochondria. I expected and saw reduced levels of frataxin in affected fibroblasts. 
Assembled frataxin has been reported in vivo (Cavadini et al. 2002; O'Neill et al. 2005) in 
heart cells that are a prime target of FRDA pathology. I show that frataxin also assembles 
in mitochondria of control fibroblasts, a cell type spared in FRDA. Stainable iron could 
not be detected in the small amount of frataxin present in HMF. This was expected since 
human frataxin in vitro, binds much less iron than does ferritin and this is likely lost 
during electroblotting (Figure 7). 
I focused on speciating mitochondrial iron because it may be possible to slow the 
progression of both the neurodegeneration and cardiomyopathy that characterize FRDA 
by devising treatment strategies that normalize mitochondrial iron chemistry. XAS 
provides a clinically relevant fingerprint of the iron chemistry of normal and abnormal 
mitochondria. Treatment strategies focus on removing iron from mitochondria by 
chelation or reducing the effects of iron-catalyzed Fenton chemistry with antioxidants 
(Wong et al. 1999; Wong et al. 2000). I found that much of the iron in FRDA 
mitochondria is already stored as relatively non-toxic, but also poorly bioavailable 
ferrihydrite of MtFt (Bou-Abdallah et al. 2005) and ferrous iron species constitute a small 
proportion of the total iron. The XAS analysis lacked the sensitivity to detect consistent 
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differences in non-ferrihydrite iron but ferrous species were detected and these may be 
sufficient to support the kind of mild chronic oxidative stress that is reported in mouse 
models (Al-Mahdawi et al. 2006). This data also supports recent work indicating that 
little redox-active iron is present in FRDA cells (Seznec et al. 2005; Sturm et al. 2005) 
and suggests that the lack of iron bioavailability is also a factor involved in FRDA 
pathogenesis. Therefore chelation strategies should take into account that at least in cells 
that can synthesize MtFt, non-ferrihydrite iron may represent a small fraction of total 
mitochondrial iron and chelating the small ferrous iron pool could prevent mitochondria 
from carrying out even minimal functions. 
Fibroblasts, like cardiomyocytes and neurons, synthesize both frataxin and ferritin 
but the relative importance of each protein in iron homeostasis is poorly understood. In 
FRDA fibroblasts, the apparent upregulation and iron content of MtFt indicate that it 
plays an active role in iron detoxification through regulation of mitochondrial iron 
availability (Campanella et al. 2009). MtFt is upregulated in erythroid cells when heme 
synthesis is blocked and dysregulation of this pathway may also trigger MtFt synthesis in 
FRDA fibroblasts. By understanding how fibroblasts regulate MtFt synthesis we may 
better understand how to upregulate this protective protein in cardiac and neuronal cells 
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FRDA is the most common inherited ataxia (Campuzano et al. 1996) and 
typically presents before 25 years of age with progressive ataxia of gait and limbs, 
dysarthria, loss of deep tendon reflexes, extensor plantar responses, muscle wasting and 
loss of sensation, especially of vibration and joint position sense (Greenfield 1954; 
Geoffroy et al. 1976; Harding 1981; Durr et al. 1996). As the disease progresses, there 
may be horizontal nystagmus, saccadic-pursuit eye movements, difficulty with 
swallowing and breathing as well as cardiomyopathy, diabetes mellitus and skeletal 
deformities (Greenfield 1954; Geoffroy et al. 1976; Harding 1981; Durr et al. 1996). 
Some patients can develop optic nerve atrophy and hearing loss (Greenfield 1954; 
Geoffroy et al. 1976; Harding 1981; Durr et al. 1996). In contrast to the typical early 
onset form, late onset FRDA progresses more slowly and tendon reflexes are often 
retained (De Michele et al. 1994; Durr et al. 1996; Coppola et al. 1999). Magnetic 
resonance imaging in patients with typical and late onset FRDA reveals spinal cord 
atrophy that is sometimes associated with atrophy of the brainstem and cerebellum 
(Wessel et al. 1989; Klockgether et al. 1991; Wullner et al. 1993; Mascalchi et al. 1994; 
De Michele et al. 1995; Bhidayasiri et al. 2005). 
The neurological features of FRDA are explained by the neuropathological 
findings characteristic to this disease. The peripheral sensory nerves are severely affected 
with loss of large myelinated axons and loss of neurons in the dorsal root ganglia 
(Greenfield 1954; Hughes et al. 1968; Oppenheimer 1979; Lamarche et al. 1984). The 
spinal cord shows neuronal loss in the nucleus dorsalis of Clarke and loss of myelinated 
fibers in the posterior columns with the gracile fasciculus almost always more affected 
than the cuneate fasciculus (Greenfield 1954; Oppenheimer 1979; Lamarche et al. 1984). 
There is also degeneration of the corticospinal lateral and spinocerebellar tracts and, less 
frequently, of the corticospinal anterior tracts (Greenfield 1954; Oppenheimer 1979; 
Lamarche et al. 1984). Neurodegenerative changes seen in the dorsal columns and 
pyramidal tracts of the spinal cord can be traced through the medulla: neuronal loss in the 
gracile and cuneate nuclei and axonal degeneration in the pyramids (Greenfield 1954; 
Oppenheimer 1979; Lamarche et al. 1984). The loss of large, myelinated axons in the 
spinocerebellar pathways can also be traced through the inferior and superior cerebellar 
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peduncles to the cerebellar Purkinje cells. In FRDA, these neurons degenerate, especially 
in the vermis of the cerebellum (Greenfield 1954; Oppenheimer 1979; Lamarche et al. 
1984). Neurons are also lost in the dentate nucleus (Oppenheimer 1979; Lamarche et al. 
1984; Koeppen et al. 2007). Some cases also present with neuronal loss in the optic 
nerves and tracts, subthalamic nuclei, thalamus and globus pallidus (Oppenheimer 1979; 
Lamarche et al. 1984). 
FRDA is caused by deficiency of the nuclear encoded mitochondrial protein, 
frataxin (Campuzano et al. 1996; Campuzano et al. 1997; Priller et al. 1997). Frataxin 
deficiency reduces heme and iron-sulfur cluster synthesis which can lead to iron 
accumulation in some cells and oxidative stress (Babcock et al. 1997; Foury and 
Cazzalini 1997; Koutnikova et al. 1997; Rotig et al. 1997; Wilson and Roof 1997; 
Bradley et al. 2000; Emond et al. 2000; Schulz et al. 2000).  
In humans, iron deposits have been demonstrated in patient cardiomyocytes 
(Sanchez-Casis et al. 1976; Lamarche et al. 1980; Bradley et al. 2000), hepatocytes and 
spleen cells (Bradley et al. 2000) and FRDA fibroblast cultures (Delatycki et al. 1999) 
using Perls’ stain and electron microscopy. Magnetic Resonance in vivo studies show 
increased iron in the dentate nucleus of FRDA patients (Waldvogel et al. 1999; Boddaert 
et al. 2007) but these findings have been challenged by biochemical studies of post-
mortem tissues that failed to reveal an increase in iron (Koeppen et al. 2007). However, 
there are no human studies linking the nervous system neurodegeneration in FRDA to 
iron accumulation. Moreover, even though early work suggested a possible dysregulation 
of copper and zinc metabolism in FRDA patients (Barbeau et al. 1984; Huxtable et al. 
1984; Shapcott et al. 1984), the possible involvement of copper and zinc in FRDA 
neurodegeneration has not been investigated. 
Metals accumulate in the brain as a function of age (Morris et al. 1992; Bartzokis 
et al. 1997; Martin et al. 1998; Ogg et al. 1999; Zecca et al. 2004; Bartzokis et al. 2007) 
and there is increasing evidence that brain metal accumulation is found in a variety of 
neurodegenerative and ageing-related disorders (Rossi et al. 2004; Zecca et al. 2004; 
Frazzini et al. 2006; Molina-Holgado et al. 2007). For many years there has been 
tremendous interest in human brain metal metabolism but complete metal maps have not 
been available (Zecca et al. 2004). Such baseline data are required to fully understand the 
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relationship between metals, aging and neurodegenerative disease. While destructive 
analytic techniques such as atomic absorption and inductively coupled mass spectrometry 
have been used to quantify metals in selected brain regions (Hock et al. 1975; Dexter et 
al. 1987; Dexter et al. 1989; Duflou et al. 1989; Dexter et al. 1991; Dexter et al. 1992; 
Dexter et al. 1993; Rajan et al. 1997; Becker et al. 2005) and some magnetic resonance 
imaging sequences are used to image iron in vivo (Haacke et al. 2005), histochemistry has 
long been the gold standard to localize metals in brain slices. However Perls’ and 
Turnbull’s methods detect only nonheme iron (Perls 1867; Zaleski 1887; Gomori 1936; 
Meguro et al. 2007), copper histochemistry lacks sensitivity and specificity (Pilloni et al. 
1998; Henwood 2003; Ferenci et al. 2005) and complex techniques are required to 
distinguish protein-bound from ionic zinc (Danscher et al. 1985; Lopez-Garcia et al. 
2002). Because each of these methods employs a different chemistry, they cannot be 
combined or used sequentially on the same tissue section. Therefore, easy and 
quantitative assessment of interrelationships between metals has been lacking.  
In contrast to histology, X-ray fluorescence (XRF) is element specific; hence each 
metal is detected irrespective of its chemical state. Traditional point-to-point XRF 
imaging has been successfully employed to map multiple metals in small areas of brain 
tissue sections at high resolution (Yoshida et al. 2001; Ishihara et al. 2002; Collingwood 
and Dobson 2006; Miller et al. 2006; Linkous et al. 2007), but the time required to map 
large areas of the brain in this way is prohibitive. This chapter shows the first results of 
rapid-scanning X-ray fluorescence mapping (RS-XRF) of brain. RS-XRF employs unique 
hardware and software to substantially increase scanning speed so as to be useful in 
mapping entire brain slices. Since FRDA human tissues are not readily available, the new 
method was initially validated by comparing the metal distribution in normal (N) and 
Parkinson’s disease (PD) brain. PD was chosen because there is an extensive literature 
showing abnormalities in brain metals and iron in particular. 
PD is the second most common neurodegenerative disease, affecting between 0.1 
and 0.3% of the population (MacDonald et al. 2000). The diagnostic characteristic of 
idiopathic PD is the loss of dopaminergic neurons from the substantia nigra pars 
compacta leading to a reduction of dopaminergic transmission within the basal ganglia 
(Javoy-Agid et al. 1984; Agid et al. 1989). PD has been linked to genetic propensity, 
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other neurodegenerative diseases, cerebrovascular diseases, head trauma, pesticide 
exposure and use of psychoactive medications (Dick et al. 2007). While no link has been 
found between iron, copper or manganese exposure and PD (Dick et al. 2007), 
endogenous zinc and copper can be altered and iron is known to accumulate in the 
substantia nigra (Dexter et al. 1987; Dexter et al. 1989; Dexter et al. 1991; Dexter et al. 
1992; Dexter et al. 1993). Iron also accumulates in the brain with age (Hallgren and 
Sourander 1958; Morris et al. 1992; Morris and Edwardson 1994; Zecca et al. 2004; 
Zecca et al. 2004; Bartzokis et al. 2007) and dysregulation of iron (Thomas and Jankovic 
2004), zinc (Frederickson and Cuajungco 2005) and copper (Madsen and Gitlin 2007) 
has been linked to a variety of neurodegenerative (Dexter et al. 1987; Dexter et al. 1989; 
Jellinger et al. 1990; Sofic et al. 1991; Kawas and Brookmeyer 2001; Dick et al. 2007) 
and ageing-related disorders (Zecca et al. 2004; Zecca et al. 2004; Molina-Holgado et al. 
2007). The motivation for this work was the prospect of doing systematic studies on 
metal pathology in neurodegenerative diseases in general with future direct application to 
FRDA. 
 
3.2 Hypothesis and Research Objectives 
3.2.1 Hypothesis 
 RS-XRF is a synchrotron technique capable of simultaneously colocalizing 
multiple metals in human brain slices on a practical time scale and identifying variations 
in metal distribution that may be linked to pathology of neurodegenerative disease. 
3.2.2 Research Objectives 
Compare the distribution of iron, copper and zinc in single slices from 
Parkinson’s disease and control brains. 
 
3.3 Materials and Methods 
3.3.1 Rapid-Scanning X-ray Fluorescence Mapping 
 XRF imaging was performed at wiggler beam lines 6-2 and 10-2 at the Stanford 
Synchrotron Radiation Laboratories (SSRL). The beam lines were operated in standard 
configuration with a collimating mirror upstream of a Si (1 1 1) monochromator and a 
pair of total reflection focusing mirrors downstream. The beam was focused onto a 50 μm 
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diameter tantalum pinhole placed close to the sample (Figure 9). Since the sample was 
mounted at a 45º angle to the incident beam, the 100 μm thick pinhole was tilted such 
that the horizontal beam size was reduced to 50/√2 = 35 µm, which in turn results in a 50 
µm footprint on the sample. The beam intensity I0 was monitored with a N2-filled ion 
chamber upstream of the pinhole. During scanning, small drifts of the beam with respect 
to the pinhole were corrected periodically. A photon counting 13-element germanium 
detector system (Canberra) with Gaussian shaping amplifiers employing 0.125 μs 
shaping times plus single channel analyzers was used to detect the XRF signal. For each 
element, the electronic (single channel analyzer) windows were set to capture the 
fluorescent photons from the Kα1 and Kα2 emission lines averaged at a mean Kα energy 
of (2 EKα1 + EKα2)/3. The signals of all 13 detector elements within the window of each 
chemical element were added with a fan-in unit and the sum signals were fed into the 
readout system. The detector was placed at a 90º angle to the beam in order to minimize 
the unwanted scattering signal. 
Conventional thick autopsy specimens are well suited to RS-XRF because the 
effective penetration/escape depth, defined as the thickness of sample needed to decrease 
the signal to 1/e, is 0.33, 0.56 and 0.65 mm for the iron, copper and zinc Kα fluorescence 
lines, respectively. Since the escape depth is constant, relative concentrations of a given 
metal in different brain samples can be compared. Comparing amounts of different 
metals is challanging because the escape depth and fluorescence yield of each metal is 
different. 
The samples were mounted on a computerized xy translational stage and rapid 
scans were performed by continuously translating the sample horizontally across the 
beam. At the end of each line, a vertical step (40 μm/step) was performed, and the 




Figure 9. Rapid-scanning X-ray fluorescence mapping experimental setup. Synchrotron 
X-rays at 11 keV passed through a 50 μm aperture (Ap). The beam intensity was 
monitored with a N2-filled ion chamber (I0). The brain slice was mounted vertically on a 
motorized stage (St) at 45º to the incident X-ray beam and raster scanned in the beam. A 












 Data were recorded at two different scanning speeds (see Figures 10 and 14). 
Using standard hardware, data were collected at a rate corresponding to a travel distance 
of 40 μm per readout. The readout system used custom-built real-time software coupled 
with standard beam line hardware to provide deterministic data acquisition. The system 
had adjustable count times in units of 10 ms plus ~2.8 ms overhead per readout. At an 
incident beam energy of 11 keV and a flux of ~3 × 1010 photons s−1, the scanning speed 
of ~1.75 mm s−1 was chosen. This corresponded to a total time of ~22.8 ms (20 ms 
readout time + 2.8 ms overhead) per 40 µm pixel. The X-ray dose under these conditions 
is 233 grays (every 22.8 ms). This is almost five orders of magnitude less than the 
common dose limit for crystallography studies which is 2 × 107 grays (Henderson and 
Schertler 1990) and about 13 times higher than the dose required to produce mild brain 
damage in duck embryos (Dilmanian et al. 2001). Synchronization of motor speed and 
readout time was critical in bidirectional scans in order to avoid misalignment of 
subsequent lines in the image. To avoid scanning times of more than 7 h, each half brain 
slice was mapped in segments that were later digitally reassembled. 
To further increase scanning speed, new hardware was developed by collaborators 
at the SSRL, to scan with essentially no dead time between readouts. Conceptually, an 
entire line of data was collected into a local memory area and transferred to the control 
computer at the end of each line. The hardware used a programmable timer to precisely 
set the data measurement time and internal data buffers to decouple the measurement 
timing from the data transfer process. Electronics were implemented in a Xilinx Virtex-4 
field programmable gate array featuring an embedded PowerPC microprocessor. The 
embedded system was built using Xilinx Embedded Development Kit software. The 
peripheral device contained a 32 bit timer with 10 ns resolution, sixteen 32 bit counters 
with a maximum count rate of 10 MHz, data point counter and trigger and interrupt logic. 
The peripheral device was implemented in very high speed integrated circuit hardware 
description language. At the end of each measurement, additional counter logic stored the 
measurement results in the buffer register and started the next measurement with no 
delay. An interrupt was generated after each measurement, and the microcontroller 
moved data from registers to large (8 MB) secondary buffers. A lower priority software 
process transferred the buffered data to the computer, so any delays at the communication 
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link or host computer did not affect the data acquisition timing. In addition to 
programmable measurement timing and input/output polarity, the electronics could 
convert data to 16 bit values and send measurement results only from specified counters 
to reduce the amount of transferred data. 
Using this system, scanning speed was increased from 1.75 mm s−1 to 7 mm s−1 
corresponding to a count time of 5.7 ms per 40 μm pixel. This enabled us to map the 
basal ganglia in 0.8 hours (Figure 14) as compared to the same sized area in 3.7 hours 
(Figure 11). At 3 × 1010 photons s−1, this was sufficient to detect the Kα signal of iron, 
copper and zinc and to produce a high-quality image. 
 
3.3.2 Image Analysis 
For each element, a two-dimensional matrix (width × height) of signal counts was 
obtained. Data were plotted as elemental maps using Interactive Data LanguageTM (ITT 
Visual Information Systems). Fluorescence was normalized to take into account 
fluctuations in the intensity of the incoming X-ray beam. The fluorescence signal from 
metal-rich contaminant particles was reduced to the mean value of all pixels plus three 
standard deviations. While the plastic sheet protector (400 μm total thickness) contributed 
significantly to scatter (~46%), it kept the heavy brain slices from sagging during 
imaging. Counts contributed by a single thickness (200 μm) of plastic overlayer were 
removed using IDL. 
 
3.3.3 Metal Quantification 
Normalized fluorescence for each metal in N and PD brains was calculated within 
a standard 30 × 30 pixels box using IDL software. Normalized fluorescence is the 
fluorescence detected from the illuminated tissue volume normalized by the combined 
elastic and Compton scatter from the same region. This would be proportional to the 
amount of the fluorescing element per mass of tissue. The Mann–Whitney test was 
employed to determine if differences in pixel intensity between N and PD metal 
measurements were statistically significant. The median pixel intensity and the standard 
deviations for each box were plotted (Figure 12). 
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3.3.4 Clinical Information 
Two brains were obtained from the Stanford University Medical Center, Stanford, 
CA, USA. The first was from an 80 year old Caucasian female who died of pneumonia. 
Examination by Dr. Hannes Vogel, a certified neuropathologist at Stanford University 
Medical Center, revealed no overt changes and the brain was assessed as normal. The 
second was obtained from a 70 year old Caucasian male, who died of respiratory failure 
secondary to neurological decline. The patient had been diagnosed with PD prior to death 
and pathologic examination was consistent with this diagnosis. Institutional review board 
approval was obtained and provided to SSRL prior to the commencement of the study. 
The experiment was compliant with the Health Insurance Portability and Accountability 
Act Privacy Rule and the patients’ identities were not known to any of the authors. 
Additional human tissue was obtained from the NICHD Brain and Tissue Bank 
for Developmental Disorders at the University of Maryland, Baltimore, Maryland, under 
contracts N01-HD-3-3368 and N01-HD-4-3383. Ethics approval (# Bio 07-75) was 
obtained from the University of Saskatchewan. A small coronal section of a control 
forebrain (N2) was from a 15 year old Caucasian female who died in a motor vehicle 
accident. 
 
3.3.5 Preparation of Brain Slices 
Brains were fixed and stored in buffered formalin. Brains were manually sliced 
with a knife and each slice was sealed in a metal-free plastic sheet protector (A-10CR, 
Itoya Ltd). The N brain slice was half of a coronal section of the forebrain through the 
genu of the internal capsule, rostral tip of dorsal thalamus and rostral third of the 
hypothalamus. The matching PD slice was slightly caudal to the N brain. The midbrain 
was sliced through the inferior colliculus, trochlear nucleus and superior cerebellar 
peduncle with the matching PD being slightly cranial. N2 was a coronal section of the 
forebrain through the basal ganglia at the level of the anterior commissure and rostral 






This method takes advantage of bright synchrotron X-rays and the rapid-scan 
technology described above. Brain slices were raster scanned across a small, collimated 
X-ray beam. The fluorescence signal of several metals was recorded simultaneously 
resulting in elemental maps of the brain slices. Maps showing the abundance and location 
of iron, zinc and copper were obtained in comparable brain slices from two subjects of 
advanced age, one normal (N) and one with PD (PD), and in a small section from a 
normal young brain (N2). 
In many parts of the brain, high iron generally corresponded to low zinc and vice 
versa (Figure 10), seen most clearly in the basal ganglia (Figures 10B, C and 11A–C). 
The relative amount of each metal in N and PD was quantified by region (Figure 12A, B). 
Levels of zinc were slightly lower in PD across all regions ranging from 8% lower than N 
in the caudate to 30% in the internal capsule and putamen (Figure 12B). In contrast, iron 
levels varied widely by region (Figure 12A). The greatest differences between N and PD 
were seen in the basal ganglia (Figure 11A, D) and midbrain (Figure 13A, E), the areas 
that are most affected in PD. For example, the caudate had 60% less iron whereas the 
substantia nigra had 40% more (Figure 12A). Overall, the iron maps were in agreement 
with high-resolution MR imaging (Fatterpekar et al. 2002). A copper map was collected 
along with iron and zinc for N2 basal ganglia, N and PD midbrain (Figures 14B, F and 
13). Consistent with previous studies, brain copper was less abundant than iron and zinc 




 Cortical iron and zinc localization was similar in PD and N with a prominent 
broad band, rich in both iron and zinc (Figure 10D arrows), corresponding to the heavily 
myelinated subcortical white matter (U fibers). 
 
3.4.2 Basal Ganglia 
In N, N2 and PD, the basal ganglia were very rich in iron (Figures 11A, D and 
14B), in keeping with the known iron content of this brain region (Drayer 1988; Morris et 
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al. 1992; Morris et al. 1992). Iron-rich structures resembling neurites and neuronal cell 
bodies were seen in the putamen, head of the caudate nucleus and the lateral and medial 
globus pallidus in all brains. The laminae that define the limits of the putamen and globi 
pallidi were particularly metal-rich in PD (Figure 11D–F). PD iron (Figure 11F, arrows 
and inset) showed a gradient surrounding large vessels adjacent to the putamen that was 
not seen around similar-sized vessels in the N brain (Figure 11A) or in the PD midbrain 
(Figure 13E). No gradient of perivascular zinc was observed in N or PD. 
 
3.4.3 Midbrain 
Iron levels in both N and PD were highest in the substantia nigra when compared 
to other parts of the midbrain (Figure 13A, E). Measured in the medial substantia nigra, 
the PD midbrain had 40% more iron than the similar region in the N midbrain (Figures 
13A, E and 12A). Zinc distribution was similar in N and PD (Figure 13C, G), but overall 
zinc was lower (Figure 12B). Since N and PD sections were at slightly different levels, 
this could affect the interpretation. 
In general, copper and iron co-localized in midbrain (Figure 13A, B, E, F, 
arrowhead shows debris). While not abundant in midbrain, copper was seen in the 
substantia nigra and inferior colliculus (Figure 13B, H). While copper levels across these 
areas were similar in N and PD, the midline of the substantia nigra showed irregular low 




Figure 10. Metal levels in the brain vary widely by region. Normal (N) human forebrain, 
coronal section: A. optical image; B. iron map; C. zinc map; D. overlay of iron (red) and 
zinc (blue); square, area magnified in figure 11(A–C); arrow heads, subcortical white 
matter; scan speed 22.8 ms per pixel; scale bar = 7.5 mm; color scales (B, C) represent 
the normalized total Kα fluorescence counts, proportional to total metal present, from 






































Figure 11. Metal content is abnormal in PD basal ganglia. Basal ganglia, coronal section 
normal (N) brain A–C (expanded view of Figure 10); PD brain D–F; A, D. Iron maps; B, 
E. Zinc map; C, F. Overlay of iron and zinc; cn – caudate nucleus; p – putamen; lgp – 
lateral globus pallidus; mgp – medial globus pallidus; lml – lateral medullary lamina; 
mml – medial medullary lamina; aml – accessory medullary lamina; ic – internal capsule; 
ins – insula; ot – optic tract; ac – anterior commissure; vaf – ventral amygdalofugal 
fibers; amg – amygdaloid nucleus; u – uncus; ent – enthorinal cortex; hip –hippocampus; 
* –blood vessel; arrows – perivascular iron (a magnified view of the three blood vessels 
in the putamen indicated by arrows is shown in inset); scale bar = 5 mm; color scales (A, 
B, D, E) represent the normalized total Kα fluorescence counts, proportional to total 











Figure 12. Metal levels are abnormal in selected regions of PD brain. Comparison of the 
normalized fluorescence (columns) in N (blue) and PD (magenta) by region. A. Iron 
fluorescence and B. zinc fluorescence. Note that the two plots do not compare Fe with 
Zn. The Mann–Whitney test was employed to determine if differences between N and PD 
metal measurements were statistically significant. Columns indicate median values of 
900 individual pixels (30 × 30 square). Error bars indicate standard deviations. *** 
signifies extremely significant differences (P < 0.0001) between measurements. More 
extensive studies are required to determine which differences are disease related. (Note: 
normalized fluorescence is the fluorescence detected from the illuminated tissue volume 
normalized by the combined elastic and Compton scatter from the same region. This 







Figure 13. Metal distribution is abnormal in PD midbrain. Transverse section, normal (N) 
midbrain (A–D) and PD midbrain (E–H); A, E. Iron map; B, F. Copper map; C, G. Zinc 
map; D, H. Overlay of iron, copper and zinc; sn – substantia nigra; cc – crus cerebri; scp 
– spinocerebellar peduncle; ic – inferior colliculus; scan speed 22.8 ms per pixel; color 
scales (A, B, C, E, F, G) represent the normalized total Kα fluorescence counts, 

















Figure 14. Increased scan speed still produces high-quality metal maps. Basal ganglia, 
coronal section, normal (N2) brain collected using a rapid readout system; scan speed 5.7 
ms per pixel; A. Optical image; B. Iron map; C. Copper map; D. Intensity scales 
represent the normalized total Kα fluorescence counts, proportional to total metal present, 
from black (lowest) to color (highest); E Zinc map; F. Overlay of iron, copper and zinc; 
cn – caudate nucleus; p – putamen; lgp – lateral globus pallidus; ic – internal capsule; ac 







This chapter describes results obtained using a new synchrotron approach that 
offers significant advantages over analytical or histological methods in localizing and 
quantifying brain metals. Both RS-XRF and traditional point-to-point XRF imaging can 
non-destructively, quantitatively and simultaneously map multiple metals with the added 
ability to speciate metals at points of interest. RS-XRF adds the capability of mapping 
large samples on a practical time scale (2005; Service 2006; Bergmann 2007). 
Unlike conventional histology sections, XRF samples are not dehydrated or 
embedded, and therefore the same sample can be subsequently processed for histology or 
immunohistochemistry if desired. Formalin fixation stops post-mortem degradation and 
enables collection of elemental maps at room temperature. The major metals iron, copper 
and zinc (Chua-anusorn et al. 1997; Bush 2000) as well as nickel and chromium (Gellein 
et al. 2008) are well retained in fixed tissues even after long periods of storage, but 
substantial leaching of arsenic, cadmium, magnesium, rubidium and antimony has been 
measured (Gellein et al. 2008). However, post-mortem degradation, fixation and leaching 
of some elements could change metal chemistry making the interpretation of X-ray 
Absorption Near Edge Structure spectra collected from human autopsy material 
problematic. Animal brain, flash-frozen at the time of death, would yield spectra that 
better reflect in vivo metal chemistry. The large size of these brain maps also makes them 
ideal for direct comparison with magnetic resonance images (McCrea et al. 2008). 
Testing hypotheses and discovering previously unrecognized metal-associated 
pathologies require a large sample size and/or multiple samples from different brain 
regions or different individuals. For example, I saw elevated perivascular iron in PD 
(Figure 11F and inset). To appreciate the extent and generality of this finding, large brain 
maps from multiple subjects would be needed and such studies are now feasible with RS-
XRF. 
Another advantage of RS-XRF over other methods is that multiple metals can be 
easily co-localized and linked to known brain structures, as exemplified by the 
localization of copper in the midbrain (Figure 13B, F). In a larger analytical study, Dexter 
(Dexter et al. 1989; Dexter et al. 1991) found that the substantia nigra copper content in 
PD was lower than normal. My data support Dexter’s analyses but also show that 
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copper’s spatial distribution in the midbrain is complex. Subtle changes in copper 
distribution would be extremely difficult if not impossible to detect by other means and 
could be important in PD pathogenesis. 
PD was chosen for the validation study because iron has been shown to 
accumulate in dopaminergic neurons in the substantia nigra pars compacta (Jellinger et 
al. 1990; Sofic et al. 1991). This excess iron promotes oxidative generation of free 
radicals through the interaction with α-synuclein (Hsu et al. 2000; Ostrerova-Golts et al. 
2000; Turnbull et al. 2001) and neuromelanin leading to neurodegeneration. RS-XRF 
mapping confirmed both the abnormal amount and location of excess iron in the midbrain 
that are characteristic of PD. 
Although the setup used here did not collect full MCA spectra, rapid scanning 
does not preclude collecting MCA spectra for the post-mapping detection of additional or 
unexpected elements. A possible way of collecting full spectra might include the use of a 
buffered memory option using digital electronics from XIA. 
RS-XRF is a new and powerful tool that makes systematic studies of brain metals 
practical. It can be applied to any human or animal tissue and I foresee important 
applications in testing whether a metal chelator designed to remove a particular metal 
disrupts the levels of others. Using animal models, RS-XRF also has great potential to 
improve our understanding of global metal metabolism and the inter-relationships 
between metals. With rapidly advancing beamline technology at third-generation 
synchrotrons, it should be possible to map very large sections in a matter of a few 
minutes, making systematic RS-XRF studies on serial slices of whole organs practical.  
RS-XRF is the ideal tool to interrogate the possible involvement of metals in 
FRDA pathology, not only in neurodegeneration but also in cardiac degeneration. 
However, since the disease is examined at a very advanced stage in the case of post-
mortem formalin-fixed human specimens RS-XRF will not be able to demonstrate 
whether the metals are the cause or the consequence of the degenerative process. Metal 
maps of brains and hearts from FRDA mouse models at various stages of the disease will 


























 Spinocerebellar ataxias (SCA) are a group of progressive ataxias in which 
degeneration of the spinal cord tracts is associated with cerebellar degeneration 
(Greenfield 1954). FRDA is the most common autosomal recessive ataxia accounting for 
up to half of the all hereditary ataxias (Pandolfo 1998). The neuropathological hallmark 
of FRDA is the degeneration of the posterior columns and loss of the large myelinated 
axons in the dorsal roots as a consequence of the degeneration of large neurons in the 
dorsal root ganglia (Greenfield 1954; Hughes et al. 1968; Oppenheimer 1979; Lamarche 
et al. 1984). Degeneration of the dorsal nuclei of Clarke, cuneate and gracile nuclei and 
spinocerebellar tracts completes the sensory neuropathy (Greenfield 1954; Oppenheimer 
1979; Lamarche et al. 1984). Ataxia in FRDA is the consequence not only of this sensory 
neuropathy but also of the cerebellar degeneration. Severe neuronal loss in the dentate 
nuclei, marked atrophy of the superior cerebellar peduncles and moderate Purkinje cell 
loss in the cerebellar cortex (Greenfield 1954; Oppenheimer 1979; Lamarche et al. 1984) 
show that the cerebellum is a major site involved in the FRDA neuropathology. Although 
Magnetic Resonance in vivo studies have shown increased iron in the dentate nucleus of 
FRDA patients (Waldvogel et al. 1999; Boddaert et al. 2007), biochemical studies of 
post-mortem tissues have failed to reveal an increase in iron (Koeppen et al. 2007). Thus 
the involvement of iron and oxidative stress in FRDA cerebellar neurodegeneration 
remains controversial. 
 The cerebellum serves as a major integrative center for the coordination of 
muscular activity, facilitation of movement, and motor planning. Cerebellar lesions result 
in ataxia, dysmetria, dysarthria, and oculomotor impairment (Klockgether 2000). 
Complex connections between the dentate nucleus, thalamus, basal ganglia, and 
prefrontal cortex support the hypothesis that the cerebellum is also involved in cognitive 
functions (Middleton and Strick 1994; Dum and Strick 2003), and indeed, cognitive 
impairment is associated with cerebellar pathology (Corben et al. 2006). Many disorders 
presenting with cerebellar degeneration are members of the continually growing family 
of neurodegenerative diseases involving excess central nervous system accumulation of 
metals. These include not only Friedreich’s ataxia, but also Wilson’s disease, 
Huntington’s disease and aceruloplasminemia (Byers et al. 1973; Starosta-Rubinstein et 
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al. 1987; Okamoto et al. 1996; Bartzokis et al. 1999; Koeppen et al. 2007). Metal 
deficiency can also lead to neurodegeneration involving the cerebellum, as exemplified 
by Menkes’ disease (Williams et al. 1978). 
Although an active area of research, many questions remain about how metal 
imbalance contributes to neurodegeneration (Cuajungco and Lees 1997; Zecca et al. 
2004; Madsen and Gitlin 2007). Knowing the macroscopic metal distribution of the 
normal cerebellum is an important step towards better understanding the role metals play 
in the pathogenesis of cerebellar degeneration and how neurodegenerative diseases 
change cerebellar metal distribution and metabolism. 
Histochemistry has long been the gold standard for localizing metals in brain 
slices. However, Perls’ and Turnbull’s methods are not able to detect heme iron (Gomori 
1936; Meguro et al. 2007), copper histochemistry lacks sensitivity and specificity (Pilloni 
et al. 1998; Henwood 2003), and zinc histochemistry detects only part of the tissue zinc 
pool (Danscher et al. 1985; Lopez-Garcia et al. 2002). 
In contrast, RS-XRF has been successfully employed to non-destructively and 
simultaneously map multiple metals in all chemical forms and oxidation states, whether 
protein-bound or free, or intracellular or extracellular in large samples on a practical time 
scale (McCrea et al. 2008; Gh Popescu et al. 2009). 
In this chapter RS-XRF is used to study the macroscopic distribution of iron, 
copper, and zinc in sagittal and axial views of the normal cerebellum in both a young 
subject with no neurodegenerative disease and an older subject with PD but without 
identifiable cerebellar pathology. 
 
4.2 Hypothesis and Research Objectives 
4.2.1 Hypothesis 
 Simultaneously-collected metal XRF maps of the cerebellum allow anatomical 
structures to be observed due to the different distribution and regional variation in the 
iron, copper and zinc content.  
4.2.2 Research Objectives 
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Map the distribution of iron, copper and zinc in the cerebellar cortex, cerebellar 
white matter and dentate nucleus in fixed slices of cerebellum with no identifiable 
pathology using RS-XRF. 
 
4.3 Materials and Methods 
4.3.1 Tissue Samples, Clinical and Neuropathological Information 
Frozen sagittal slices of normal cerebellum at the level of the dentate nucleus 
from a Caucasian woman were obtained from National Institute of Child Health and 
Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders at 
the University of Maryland, Baltimore, Maryland, under contracts N01-HD-3-3368 and 
N01-HD-4-3383 with ethics approval from the University of Saskatchewan (#BioReb 07-
75). Prior to mapping, they were fixed in buffered formalin. The patient died of 
oxycodone intoxication at the age of 23. Formalin-fixed axial slices through the 
cerebellum at the level of the dentate nucleus from a Caucasian man were obtained from 
the Saskatoon Health Region Movement Disorders Clinic (ethics approval # BioReb 06-
250). The patient died from renal failure at age 70. Clinical and pathological 
examinations confirmed a diagnosis of PD. The post-mortem interval collection times 
(PMI) were 19 and 10 hours, respectively.  
Gross examination of the cerebella of both patients was unremarkable. 
Microscopic examination of hematoxylin and eosin (HE) (Thompson and Hunt 1966), 
luxol fast blue/HE (Thompson and Hunt 1966) and modified Bielschowsky (Yamamoto 
and Hirano 1986) stained 5 μm thick paraffin sections of the dentate nucleus, cerebellar 
deep white matter and cerebellar cortex revealed no pathological abnormalities in either 
case. 
 
4.3.2 Rapid-Scanning X-ray Fluorescence Mapping 
RS-XRF imaging was performed at wiggler beam line 10-2 at the Stanford 
Synchrotron Radiation Lightsource (SSRL). The incident X-ray beam was set to an 
energy of 13 keV using a Si(111) double crystal monochromator in order to excite the K-
shell of the first transition row and lighter elements. Formalin-fixed brain slices 2 mm 
thick were cut with a commercial meat slicer (Hobart, circular, non-serrated blade with a 
 84
diameter of 30 cm), sealed in metal-free plastic sheet protectors (Itoya) and mounted 
vertically at 45° to the incident X-ray beam and 45° to the detector. The sample was 
translated rapidly in the beam in a raster pattern with continuous motor motion. Data was 
collected on the fly in both horizontal directions at a rate corresponding to a travel 
distance of 40 μm per readout, with count times of ~6 ms per 40 μm horizontal raster. A 
single-element Vortex-EX® silicon drift X-ray detector (SII NanoTechnology USA) was 
placed at a 90° angle to the beam to minimize signal due to scatter. Energy windows were 
set so as to resolve the Kα from the Kβ fluorescence lines of adjacent elements. Details of 
the imaging setup have been previously described (Gh Popescu et al. 2009). 
Image analysis was performed using Interactive Data Language™ (ITT Visual 
Information Systems) as previously described (Gh Popescu et al. 2009). Fluorescence 




4.4.1 Metal Maps of the Dentate Nucleus and Surrounding White Matter 
Although iron and zinc are more abundant than copper overall, they are 
distributed in a similar way in the central and subcortical white matter of the cerebellum 
in both the young and older brains. While copper is evenly distributed (Figures 15B and 
16B), iron and zinc levels increase towards the subcortical white matter (Figures 15A, C 
and 16A, C). 
Within the cerebellum, the metal maps (Figures 15 and 16) show the 
characteristic convoluted shape of the dentate nucleus, seen most clearly in the sagittal 
slice (Figure 16). The dentate nucleus is rich in iron and copper (Figures 15A–C and 
16A–C). Some copper colocalizes with iron (Figure 15D) and with iron and zinc (Figure 
16D). However, the tricolor maps (Figures 15D and 16D) show that copper is distributed 
in the periphery of the dentate nucleus, while iron and zinc are situated at its interior. The 
dentate nucleus is not as easily resolved in the zinc map of the axial slice because it has a 







Figure 15. Iron and copper are most abundant in the dentate nucleus, while zinc is the 
richest in the cortical white matter of the cerebellum; cerebellum, axial section, 
Parkinson’s disease without identifiable cerebellar pathology; A. Iron map; B. Copper 
map; C. Zinc map; D. Overlay of iron (red), copper (green), and zinc (blue); E. Gross 
axial section of the cerebellum; F. Color scales representing the normalized total Kα 
fluorescence, proportional to total metal present, from black (lowest) to color (highest); 
dn – dentate nucleus, gm – gray matter, wm – white matter, arrows blood vessels; scale 











Figure 16. Metal maps show a complex distribution of iron, copper, and zinc in the 
cerebellum; cerebellum, sagittal section, oxycodone intoxication; A. Iron map; B. Copper 
map; C. Zinc map; D. Overlay of iron (red), copper (green), and zinc (blue); E. Gross 
sagittal section of the cerebellum; F. Color scales representing the normalized total Kα 
fluorescence, proportional to total metal present, from black (lowest) to color (highest); 












4.4.2 Metal Maps of the Cerebellar Cortex 
In the cerebellar cortex, the high iron and zinc levels of the white matter are in 
sharp contrast with the low metal content of the gray matter (Figures 15A, C and 16A, 
C). The striking branching pattern of the cerebellar white matter (arbor vitae) is clearly 
resolved on the basis of metal content in the sagittal slice (Figure 16A, C). In contrast, 
copper is more evenly distributed (Figures 15B and 16B), with the subcortical white 
matter slightly richer than the central white matter (Figure 15B). The gray matter of the 
cerebellar cortex cannot be readily distinguished from the white matter on the basis of 
copper content (Figures 15B and 16B). 
Blood vessels filled with iron and zinc-rich material are clearly seen traversing the 
white and gray matter of the cerebellum (Figure 15A, C, E, arrows). 
 
4.5 Discussion 
 RS-XRF is uniquely suited for mapping brain metals. It is the only technique that 
permits quantitative simultaneous mapping of multiple metals in the same tissue slice, 
and it detects all chemical forms of each metal (Gh Popescu et al. 2009). Used as a tool 
for elemental analysis, RS-XRF provides spatial resolution that is far superior to 
conventional methods in which excised cubes of tissue are dissolved for bulk analytical 
analysis. Used as an imaging method, RS-XRF shows all metals simultaneously without 
damaging the sample, thus surpassing all conventional “single-metal” staining methods. 
This capability to see how the dysregulation of one metal affects others in adjacent 
tissues may prove to be the key to understanding global metal regulatory pathways in the 
brain. RS-XRF is a powerful tool that makes systematic studies of metals in whole 
cerebellum and/or multiple samples or different individuals practical and sets the stage 
for further investigations of neurodegenerative diseases. 
This study focuses upon the normal cerebellum from a young patient and an older 
individual to provide a baseline for future studies. Despite the different age, sex, and PMI 
of the two patients and different planes of section, the metal distribution of the two 
cerebella is very similar. RS-XRF metal maps provide new information about the relative 
amount and location of iron, copper, and zinc in the cerebellum which is known as one of 
the brain structures richest in iron (Hock et al. 1975; Morris et al. 1992), copper (Warren 
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et al. 1960; Dexter et al. 1989; Duflou et al. 1989; Rajan et al. 1997), and zinc (Dexter et 
al. 1989; Rajan et al. 1997). 
Our results agree with previously published quantitative (Warren et al. 1960; 
Hock et al. 1975; Duflou et al. 1989) and histochemical (Morris et al. 1992) analyses 
showing that dentate nucleus has the highest iron (Figures 15A and 16A) and copper 
(Figures 15B and 16B) content in the cerebellum and is also very rich in zinc (Figure 
15C). Unlike histochemical iron stains, RS-XRF maps all chemical forms and oxidation 
states of iron. While the iron map of the sagittal slice (Figure 16A) closely reflects the 
previously described distribution of non-heme iron (Morris et al. 1992), the cerebellar 
cortex has a higher iron content, and iron in the normal convoluted shape of the dentate 
nucleus is more intense than histochemistry reveals. This may indicate that heme iron 
forms a larger proportion of total iron in these regions or that the processing procedures 
required for conventional histology leach or redistribute some iron from the dentate 
nucleus and cortex. 
XRF maps also provide additional information about the relative location of 
copper and iron within the dentate nucleus (Figures 15D and 16D). The copper is situated 
towards the periphery of the nucleus, the iron is located towards its interior, and only part 
of the copper colocalizes with iron. Studies of the primate dentate nucleus reveal different 
size neurons arranged into zones containing different neurotransmitters (Chan-Palay 
1977). This could explain metal segmentation of the dentate, but high resolution studies 
with X-ray microprobe are required to localize copper to specific neurons. 
The dentate nucleus can be localized in the sagittal but not the axial section based 
on zinc content (Figure 15C). This difference may represent real differences between 
neuronal subpopulations that differ between the sections or could be related to PD or to 
age-related differences between the two. The dentate nucleus in humans has an older 
dorsomedial portion (paleodentate) and a newer ventrolateral portion (neodentate). 
Neurons in the two subdivisions of the dentate nucleus have different connections and 
sizes (Chan-Palay 1977; Middleton and Strick 1994; Parent 1996) and could have 
different zinc contents. Of the metals, free zinc is relatively abundant in some classes of 
neurons, especially in the presynaptic terminals (Mocchegiani et al. 2005). While it is 
hard to correlate the sagittal orientation of the dentate with the available unfolded 
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functional maps because of different planes of section, the part of dentate nucleus present 
in the axial section (Figure 15) corresponds to the nonmotor domain concerned with 
cognition and visuospatial function (Dum and Strick 2003). Thus, the different zinc 
content may also reflect neuronal populations belonging to different dentate output 
channels. 
The metal segmentation of the dentate with the copper located towards the 
periphery and iron and zinc towards its interior (Figures 15D and 16D) is a new and very 
interesting observation. It is known that the dentate nucleus is affected in a wide range of 
neurodegenerative diseases. The presence of two neuronal populations with different 
metal contents in the dentate could prove to be very important since these neurons might 
possess different susceptibilities to neurodegeneration similar to neurons in pars 
compacta and pars reticulata of substantia nigra and their different susceptibility to 
neurodegeneration in PD. The dentate nucleus is a major site of neurodegeneration in 
FRDA (Greenfield 1954; Oppenheimer 1979; Lamarche et al. 1984) and involvement of 
iron in FRDA cerebellar degeneration is controversial. However, this might be explained 
by the different metal content of lesions at different stages of disease (Popescu et al. 
2009a). By interrogating a potentially active site of degeneration, in vivo Magnetic 
Resonance studies show increased iron in the dentate nucleus of FRDA patients 
(Waldvogel et al. 1999; Boddaert et al. 2007) while biochemical studies of postmortem 
tissues fail to reveal an increase in iron (Koeppen et al. 2007) possibly because of 
addressing lesions in very advanced stages of neurodegeneration. 
Compared to other areas of the brain, elemental analyses of cerebellar metals are 
few, and direct comparison between different methodologies is difficult (Haacke et al. 
2005). However, when the increased water content of gray matter is taken into account, 
my results roughly agree with published elemental analyses (Duflou et al. 1989). In 
contrast, RS-XRF has little sampling error because all elements within a 50-μm spot are 
measured continuously across the entire sample to a depth of 0.55, 0.63, and 0.74 mm for 
iron, copper, and zinc, respectively. 
I show that the iron content varies within different regions of the white matter 
with the subcortical white matter having more iron than the white matter surrounding the 
dentate nucleus. Subcortical white matter also has more iron than the cortical gray matter. 
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Cerebellar gray and white matter are very rich in zinc (Hock et al. 1975; Duflou et al. 
1989), with the subcortical white matter containing the highest zinc levels (Figures 15C 
and 17C). The normal zinc status of the brain and the delicate zinc/copper balance have 
to be maintained since zinc toxicity has been linked to cerebellar demyelinating lesions 
(Prodan and Holland 2000) and even multiple sclerosis (Schiffer et al. 2001). In contrast, 
copper is more evenly distributed between central white matter, subcortical white matter, 
and cortical gray matter (Figures 15B and 16B) of the cerebellum. This could accurately 
reflect in vivo copper, but some post-mortem diffusion could occur. Of the metals, copper 
is entirely protein bound with little or no free copper present in cells (O'Halloran and 
Culotta 2000) and only trace amounts of copper leach from formalin fixed tissues even 
over 18 months of storage (Gellein et al. 2008). Thus, I propose that the distribution of 
copper in these maps reflects the distribution in vivo. The abundant metal presence in the 
white matter is not totally unexpected since iron (Ortiz et al. 2004; Todorich et al. 2008), 
copper (Madsen and Gitlin 2007), and zinc (Tsang et al. 1997; Kursula et al. 1999) are 
essential for myelin synthesis, structure, and maintenance with oligodendrocytes being 
the main iron repository cells in the brain (Connor and Menzies 1996). 
It has been established that the major metals, iron, copper, and zinc (Bush et al. 
1995; Chua-anusorn et al. 1997), as well as nickel and chromium (Gellein et al. 2008) are 
well retained in fixed tissues even after long periods of storage, but substantial leaching 
of arsenic, cadmium, magnesium, rubidium and antimony has been measured (Gellein et 
al. 2008). However, it is not known if distribution is affected. The sharp delineation of 
cerebellar structures based upon iron and zinc content indicates that there is little 
migration of these metals. 
Abundant iron and zinc, but not copper, are associated with cerebellar blood 
vessels (Figure 15A, C, E, arrows). Some of this appears to be in the vessel wall and 
some in blood. The ability to see intravascular and perivascular metals is one of the major 
advantages of RS-XRF (Gh Popescu et al. 2009), since vascular changes are linked to 
neurodegenerative diseases (Brun and Englund 1986; Faucheux et al. 1999).  
The brain is a specialized organ that metabolizes and accumulates metals as part 
of its normal functioning (Zecca et al. 2004; Bartzokis et al. 2007). Iron, copper, and zinc 
function as cofactors in essential metalloproteins and are required for oxidative 
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phosphorylation, neurotransmitter biosynthesis, modulation of neurotransmission, 
antioxidant defense, nitric oxide metabolism, oxygen transport, and synthesis of proteins, 
DNA, and RNA (Cuajungco and Lees 1997; Ponka 1999; Madsen and Gitlin 2007). The 
cerebellum is a major metal repository (Hock et al. 1975; Dexter et al. 1989; Duflou et al. 
1989; Morris et al. 1992; Rajan et al. 1997) where large amounts of iron, copper, and zinc 
coexist and colocalize. The high metal content of the dentate nucleus and cerebellar white 
matter makes them particularly susceptible to metal-catalyzed oxidative damage, protein 
aggregation, neurotoxicity, and neurodegeneration (Cuajungco and Lees 1997; Zecca et 
al. 2004; Madsen and Gitlin 2007). In a rich metal environment, loss of function of 
metalloproteins and loss of defense against oxidative stress caused by deficiency of one 
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 Degenerative disorders of the cerebellum, its afferent and/or efferent connections 
result in a characteristic type of irregular, uncoordinated movement called ataxia, which 
represents the core clinical feature of these conditions. SCA are a group of progressive 
cerebellar ataxias in which cerebellar degeneration is associated with clearly identifiable 
involvement of the spinal cord, with degeneration of the spinal tracts leading to sensory 
loss, diminished / absent tendon reflexes or hyperreflexia and Babinski sign. FRDA 
(Lamarche et al. 1980; Babcock et al. 1997; Adamec et al. 2000), ataxia with isolated 
vitamin E deficiency (AVED) (Kaplan 2002), X-linked sideroblastic anemia with ataxia 
(XLSA/A) (Allikmets et al. 1999; Napier et al. 2005), ataxia-telangiectasia (A-T) 
(Shackelford et al. 2003; Shackelford et al. 2004) and infantile-onset spinocerebellar 
ataxia (IOSCA) (Bottomley and Muller-Eberhard 1988; Lönnqvist et al. 2000) are 
examples of SCA which are caused by or lead to disturbances in iron homeostasis with 
oxidative damage as a common biochemical feature. Moreover, even though early work 
suggested a possible dysregulation of copper and zinc metabolism in some SCA, 
especially FRDA (Barbeau et al. 1984; Huxtable et al. 1984; Shapcott et al. 1984), the 
involvement of other metals in SCA neurodegeneration has not yet been investigated. 
In this chapter, RS-XRF is used to compare the relative amounts and distribution 
of metals in the brain and spinal cord from a patient with a long history of SCA (type 
undefined) with a sex and age matched control. My data indicate that not only iron, but 
also copper and zinc may play a role in SCA physiopathology. 
 
5.2 Hypothesis and Research Objectives 
5.2.1 Hypothesis 
Metal distribution is abnormal in brain and spinal cord in SCA. 
5.2.2 Research Objectives 
a. Map the distribution of iron, copper and zinc in fixed slices of brain and spinal cord in 
SCA and compare it to that of control tissues. 




5.3 Materials and Methods 
5.3.1 Tissue Samples, Clinical and Neuropathology Information 
Formalin fixed SCA and control human tissue, clinical information and 
neuropathology reports were obtained from the NICHD Brain and Tissue Bank for 
Developmental Disorders at the University of Maryland, Baltimore, Maryland, under 
contracts N01-HD-3-3368 and N01-HD-4-3383. Ethics approval (# Bio 07-75) was 
obtained from the University of Saskatchewan. 
The SCA patient was a 44 year old Caucasian female whose cause of death was 
cardiopulmonary arrest. The control patient was a 42 year old Caucasian female who died 
of hypertensive atherosclerotic cardiovascular disease. The post-mortem interval 
collection times were 3 and 4 hours, respectively. 
The SCA and control spinal cord slices were axial sections at the cervical level. 
The SCA medulla was an axial section through the sensory decussation, hypoglossal, 
principal olivary and medial accessory olivary nuclei, while the control section was taken 
slightly rostral at the level of the reticular formation, solitary, principal olivary and 
posterior accessory olivary nuclei. Both the SCA and control cerebellum slices were axial 
sections at the level of the dentate nucleus. Both forebrain slices were coronal sections at 
the level of the caudate head, ventral pallidum, putamen, globus pallidus pars externa, 
genu of the internal capsule and anterior commissure, with the SCA section being at a 
slightly rostral level. 
Following RS-XRF mapping, spinal cord and medulla slices and representative 
cerebellar and forebrain structures (dentate nucleus, caudate, putamen, globus pallidus, 
internal capsule, cerebellar and cerebral cortex) were embedded in paraffin using a 
Tissue-Tek ® VIP tissue processor (Miles Scientific). Sections, 5 µm thick, were cut on a 
water bath using a Spencer microtome (American Optical Co.), air dried and then baked 
in a 37ºC oven overnight. Since the escape depth for iron, copper and zinc fluorescence is 
550, 630 and 740 µm respectively, I collected sections only from the top 100 µm of the 
face of the tissue slice from which fluorescence counts were collected. Sections were 
collected on Superfrost Plus micro slides (VWR), dried, deparaffinized and rehydrated by 
sequential immersion in xylene, xylene:ethanol (1:1), ethanol (absolute, 95%, and 70%) 
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and distilled water. For Luxol fast blue (LFB) staining the rehydration was stopped at 
95% ethanol and for Sudan black at 70% ethanol. Sections were stained with: 
a. hematoxylin (BDH Ltd.)/eosin (Aldrich) (HE) (Mallory 1938; Ibanez et al. 1960; 
McManus and Mowry 1960; Pathology 1960; Thompson and Hunt 1966) for 
demonstration of morphological components of tissues and cells 
b. Luxol fast blue (JT Baker Chemical Co.) (LFB) and Luxol fast blue /cresyl violet 
(Fisher) (LFB/CV), Klüver and Barrera modified, for demonstration of myelin (Kluver 
and Barrera 1953; Thompson and Hunt 1966) and Nissl substance (Thompson and Hunt 
1966). 
c. Sudan black (Sudan B black, MCB Reagents) (Chiffelle and Putt 1951; Pathology 
1957; Thompson and Hunt 1966) and periodic acid-Schiff (periodic acid, GFS Chemical 
Co.; basic fuchsin, Fisher) counterstained with Luxol fast blue (PAS/LFB) (Margolis and 
Pickett 1956; Margolis 1959) for demonstration of lipofuscin (Gray and Woulfe 2005). 
d. phosphotungstic acid (Ted Pella Inc.)/hematoxylin/nuclear fast red (Sigma) 
(PTA/H/NFR) for demonstration of glial fibres (Linder 1949; Thompson and Hunt 1966). 
 Staining was followed by standard dehydration through distilled water, ethanol 
(70%, 95%, absolute), xylene:ethanol (1:1) and xylene. Coverslips (VWR) were applied 
to the sections with Cytoseal mounting medium (Richard-Allen Scientific).  
Sudan black stained sections were not dehydrated after staining. They were 
washed in distilled water and immediately mounted using Kaiser’s glycerol jelly aqueous 
mordant (Hemason 1967).  
Slides were viewed under a Leitz DMRB light microscope (Carl Zeiss) and 
pictures were taken with a Sony Cybershot DSC-V3 digital camera. 
 
5.3.2 Alpha-synuclein Immunohistochemistry 
 Alpha-synuclein immunohistochemistry was performed by the Department of 
Pathology and Laboratory Medicine, University of Saskatchewan. Sections cut on a 
distilled water bath were air dried and then baked in a 50º oven overnight. Sections were 
dewaxed and hydrated through xylene and decreasing concentrations of alcohol and then 
to distilled water. Antigen retrieval was performed in a microwave using EDTA pH 9.0 
and allowed to cool again at room temperature. Sections were then loaded on Dako 
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Autostainer Plus for staining. Novocastra anti α-synuclein mouse monoclonal antibodies 
(Leica Microsytems) were used at a dilution of 1/25. Staining was completed using 
EnVision™ G/2 System/Alkaline Phosphatase, Rabbit/Mouse Permanent Red (Dako). A 
light hematoxylin counterstain was applied and then sections were dehydrated and 
mounted. Sections from a patient with a pathologically confirmed α-synucleopathy were 
used as a positive control. 
 
5.3.3 Rapid-scanning X-ray Fluorescence Mapping 
RS-XRF imaging was performed at wiggler beam line 10-2 at the Stanford 
Synchrotron Radiation Lightsource (SSRL). The incident X-ray beam was set to an 
energy of 13 keV using a Si(111) double crystal monochromator in order to excite the K-
shell of the first transition row and lighter elements. The imaging setup and methodology 
is described in section 3.3.1 and has been published (Gh Popescu et al. 2009; Popescu et 
al. 2009b). In brief, 2 mm thick tissue slices were sealed in metal-free plastic sheet 
protectors and mounted vertically at 45º to the incident X-ray beam and 45º to the 
detector. The sample was translated rapidly in the beam in a raster pattern with 
continuous motor motion. Data was collected on the fly in both horizontal directions at a 
rate corresponding to a travel distance of 40 µm per readout, with count times of ~6 ms 
per 40 µm horizontal raster. A single element Vortex-EX® silicon drift X-ray detector 
(SII NanoTechnology USA Inc.) was placed at a 90º angle to the beam to minimize 
signal due to scatter.  Energy windows were set so as to resolve the Kα from the Kβ 
fluorescence lines of adjacent elements. 
Fluorescence was normalized to take into account fluctuations in the intensity of 
the incoming X-ray beam. Image analysis and relative quantification of each metal was 
performed using Interactive Data Language ™ (ITT Visual Information Systems) as 
previously described in section 3.3.2 (Gh Popescu et al. 2009). Since the escape depth 
and the fluorescence yield differ for each element, different metals were not compared.  
Rather the amount of the same element, as determined by pixel intensity was compared 
between similar regions in the SCA and control. Normalized fluorescence for each metal 
was calculated within a standard 30 x 30 pixels box (n=900). The Mann-Whitney test was 
employed to determine if differences in pixel intensity between control and SCA were 
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statistically significant (Gh Popescu et al. 2009). Since only one SCA and one control 
were used I cannot generalize this statistical analysis to all SCA. 
 
5.4 Control Clinical History 
 The control patient was a 42 year old obese Caucasian patient who lived in the 
state of Maryland, USA. She was a smoker, had a history of high blood pressure and 
diabetes. Prior to her death, she complained of tingling and pain in her left arm and she 
was found unresponsive in bed. The pathology report found severe coronary 
atherosclerosis with acute plaque rupture and thrombotic occlusion of the right coronary 
artery and established hypertensive atherosclerotic cardiovascular disease as the cause of 
death. There was no evidence of trauma and blood tests showed that the patient did not 
consume alcohol or drugs prior to death. 
 
5.5 Case Report 
5.5.1 Clinical History 
 The patient was a 44 year old Caucasian woman whose cause of death was a 
cardiopulmonary arrest. The patient was an obese woman who worked as a secretary and 
lived at home in the state of Maryland, USA together with her husband and son. She did 
not smoke and consumed alcohol only occasionally. She had a long history of progressive 
bilateral SCA, diagnosed as FRDA when she was 25 years old based on clinical findings 
and electrophysiological testing. However, genetic tests for FRDA and other SCA failed 
to reveal any specific defect. Early development was normal but during her high school 
years she was thought to be “clumsy”, as she had trouble walking and sometimes needed 
to walk along the walls for support. This progressed to the point where she lost her 
balance with eye closure (i.e. a positive Romberg sign), followed by development of gait 
ataxia, confinement to a wheelchair, and development of appendicular ataxia and 
scanning dysarthria. She had no family history of a similar disorder and her 14 year old 
son appeared neurologically normal. Neurological examination also revealed absent deep 
tendon reflexes, bilaterally mute plantar responses, absent proprioception at ankles and 
barely perceptible at knees, barely perceptible vibration at knees and elbows and absent 
pinprick sensation in the legs and distal to mid forearms. The rest of the neurological 
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examination was normal, including full extraocular movements, normal pupillary 
function and optic discs, intact visual fields and no nystagmus. She had a history of 
depression, panic attacks, insomnia and stress urinary incontinence. Late in the disease 
she started to have visual hallucinations unrelated to her medication. She had no 
cardiomyopathy, other cardiac abnormalities, diabetes mellitus or skeletal deformities.   
 On the night of her death, she was admitted to the hospital for visual 
hallucinations and sleep deprivation. During the night, she was found unresponsive in 
bed. She had no blood pressure and was asystolic. A code was called but the resuscitation 
was unsuccessful. Although the physical examination of the cardiovascular system, 
electrocardiogram and echocardiography were normal and she did not have a history of 
cardiac problems, the pathology revealed that the cardiopulmonary arrest was due to an 
acute congestive heart failure, presumably secondary to an arrhythmia. 
 
5.5.2 Neuropathology (a neuropathology report was provided by NICHD Brain and 
Tissue Bank for Developmental Disorders and further analysis on available tissues was 
performed in the Department of Anatomy and Cell Biology, University of Saskatchewan) 
 The gross examination of the brain and spinal cord was unremarkable, except for 
a slight decrease in the pigmentation of the substantia nigra (unavailable for my 
examination and metal mapping) and flattening of the dorsal aspects of the spinal cord at 
cervical levels. 
 Microscopic examination of spinal cord sections revealed a profound loss of 
myelinated axons in the dorsal columns, especially in the graciles fasciculi and the 
adjacent dorsal nerve roots (Figure 17B; Figure 18B). White matter vacuolation (Figure 
17Q-asterisks) and gliosis were also present (Figure 17Q-arrow heads). Lower levels of 
the spinal cord (not available for my examination and metal mapping) also showed loss 
of myelinated axons in the spinocerebellar tracts and neuronal loss and gliosis in the 
dorsal nuclei of Clarke. LFB staining showed moderate myelin pallor in the ventral 



















Figure 17. Neuropathological changes seen in a case of SCA type undefined. A. Normal 
appearance of myelinated axons in the control dorsal columns (LFB/CV); B. 
Degeneration of the SCA dorsal columns, with a dramatic decrease in the number of 
myelinated axons (LFB/CV); C. Normal appearance of the inferior olivary nucleus and 
olivocerebellar fibres in the control medulla (LFB/CV); D. Degeneration of the 
olivocerebellar fibres in the SCA medulla (LFB/CV); E. Normal appearance of neurons 
and glial cells in the control inferior olivary nucleus (H/E); F. Increased number of 
enlarged cells (indicated by arrows) exhibiting a homogeneous, eosinophilic cytoplasm 
and eccentric, normal-looking nuclei consistent with reactive astrocytosis in SCA inferior 
olivary nucleus (H/E); G. Normal appearance of the control cerebellar cortex (LFB/CV); 
H. Disappearance of Purkinje cells and mild gliosis in the SCA cerebellar cortex 
(LFB/CV); I. Normal appearance of the subcortical white matter of the control 
cerebellum (LFB/CV); J. Degeneration of the subcortical white matter of the SCA 
cerebellum (LFB/CV); K. Normal appearance of the control cerebellar white matter in 
the dentate hilum and around the dentate nucleus (LFB/CV); L. Severe loss of myelinated 
axons in the dentate hilum and in the white matter surrounding the dentate nucleus of the 
SCA patient (LFB/CV); M. Normal appearance of neurons in the control dentate nucleus 
(LFB/PAS); N. SCA dentate nucleus neurons containing abundant PAS positive 
lipofuscin inclusions (arrows) (LFB/PAS); O. Normal appearance of neurons in the 
control dentate nucleus (Sudan black); P. SCA dentate nucleus neurons containing 
abundant Sudan black positive lipofuscin inclusions (Sudan black); Q. Presence of 
vacuoles (asterisks) and increased glial fibres (arrows) in the SCA degenerated dorsal 
columns (PTA/H/NFR); R. Reactive astrocytosis in the SCA inferior olivary nucleus 
(PTA/H/NFR); S. Purkinje cells axonal swellings in the SCA cerebellar cortex; T. 
Normal appearance of the globus pallidus pars externa in the SCA patient; scale bar = 50 







 Examination of the brainstem showed moderate neuronal loss and reactive 
astrocytosis in the inferior olivary nuclei (Figure 17D, F-arrow heads, R-arrow head) and 
loss of myelinated axons in the olivocerebellar fibres and amiculum olivae (Figure 17D; 
Figure 19B). Other microscopic findings in the brainstem included neuronal loss and 
gliosis in the accessory cuneate nuclei and substantia nigra bilaterally, pallor of the 
medullary pyramids and atrophy of the superior cerebellar peduncles. 
 Sections of the cerebellum revealed areas of Purkinje cell loss with mild 
Bergmann gliosis and occasional axonal swellings (Figure 17H, S-arrow heads), while 
other cerebellar cortical regions, including the vermis were spared. There was moderate 
neuronal loss and gliosis in the dentate nucleus (Figure 17L) with the remaining neurons 
containing heavy PAS positive (Figure 17N) and Sudan black positive (Figure 17P) 
inclusions consistent with lipofuscin. There was severe loss of myelinated axons in the 
dentate hilum (Figure 17L), in the white matter surrounding the dentate nucleus (Figure 
17L) and in the subcortical white matter (Figure 17J). 
 Sections of the cerebral cortex, white matter and deep gray structures were 
unremarkable (globus pallidus pars externa shown in Figure 17T). 
 
5.5.3 Differential Diagnosis 
Many of the clinical features and neuropathological findings in this case are 
consistent with the diagnosis of FRDA. The majority of FRDA patients are homozygotes 
for two GAA repeats in the first intron of the frataxin gene (Campuzano et al. 1996; Durr 
et al. 1996; Pandolfo 1998), while a small percentage are compound heterozygotes for 
one GAA repeat and one point mutation (Durr et al. 1996; Pandolfo 1998). Since no 
instance of a FRDA patient carrying two frataxin point mutations has yet been described 
and homozygous deletions in the FRDA gene cause embryonic lethality in mice (Cossee 
et al. 2000), the failure of the genetic test to identify the presence of the GAA repeats on 
either of the two alleles of the FRDA gene makes this diagnosis unlikely. 
There was no evidence of occupational exposure to excess metals since the 
woman worked as a secretary. While domestic exposure to metals cannot be ruled out, 
her husband and son with whom she shared a domicile appeared neurologically normal. 
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The woman was obese and apparently well nourished and so there was no evidence of 
metal deficiency. 
Although the absence of a family history of a similar disorder suggests an 
autosomal recessive inheritance, a de novo mutation or false parenthood can not be 
excluded. I cannot rule out an autosomal dominant SCA or AVED because available data 
on this patient did not include vitamin E levels or the specific SCA for which genetic 
tests were negative. SCA autosomal dominant types 1 (Genis et al. 1995), 2 (Durr et al. 
1995; Estrada et al. 1999) and 7 (Gouw et al. 1994; Martin et al. 1994) also present with 
posterior column and olivopontocerebellar degeneration and a neurological phenotype 
similar to FRDA. Patients with AVED present with a neurological phenotype sometimes 
indistinguishable from FRDA (Hammans and Kennedy 1998) and neuropathological 
changes similar to FRDA (Larnaout et al. 1997; Yokota et al. 2000). However, the patient 
presented here did not show any of the oculomotor abnormalities seen in SCA1 (Orr and 
Klockgether 2000) and SCA2 (Bürk and Dichgans 2000), the macular degeneration 
characteristic to SCA7 (Stevanin et al. 2000) or the retinal abnormalities encountered in 
AVED (Koenig 2000).  
The absence of immunoreactivity to anti-α-synuclein antibodies (Dickson et al. 
1999) (Figure 20) rules out multiple system atrophy, an idiopathic neurodegenerative 
disorder that can present with olivopontocerebellar atrophy and cerebellar ataxia (Papp et 
al. 1989). 
Clioquinol-induced subacute myelo-optic-neuropathy presents with a panel of 
neuropathological changes almost identical to the SCA case I present, but the exact 
mechanism of clioquinol intoxication in not yet known (Koga et al. 1997). Clioquinol is 
known for its ability to chelate iron, copper and zinc (Schaumburg and Herskovitz 2008) 
and it is currently used in clinical trials for chelation therapy of Alzheimer’s disease 
(Finefrock et al. 2003).  
This case does not perfectly match the clinical and neuropathological features of a 
single clearly identifiable SCA, although a rare or aberrant presentation or more 





5.6.1 Areas of Degeneration Have Low Metal Content 
 The dorsal columns, especially the graciles fasciculi, show the most striking loss 
of myelinated fibres in the SCA spinal cord (Figure 17B; Figure 18B). The degenerated 
dorsal columns of the SCA cervical cord have a lower metal content than the other white 
matter columns (Figure 18E, G, I, K) and also lower (35% less iron, 32% less copper, 
19% less zinc, p<0.0001, Table 5) than the corresponding regions of the control spinal 
cord (Figure 18D, F, H, J).  
A very interesting copper distribution was found in the region of the inferior 
olivary nucleus (Figure 19F). The inferior olivary nucleus of the control medulla is poor 
in copper but its convoluted shape is visible due to the contrast with the high copper 
content of the olivocerebellar fibres and afferent fibres that surround it (amiculum olivae) 
(Figure 19F). I believe that this is the first description of high copper content in this 
region of the normal medulla.  Similar high copper content was also found in the olives 
of other disease controls (Figure 21). The neuropathological examination shows the 
degeneration of the SCA olivocerebellar fibres and amiculum olivae (Figure 17D, F; 
Figure 19B) and the copper XRF map shows loss of copper (57% less than the control, 
p<0.0001, Table 5) in these structures (Figure 19G). Iron (20% less, p<0.0001, Table 5) 
and zinc (34% less, p<0.0001, Table 5) are also lost in the olivary region (Figure 19E, I).  
 Neuronal loss in the dentate nucleus and loss of myelinated fibres in the dentate 
hilum, around the dentate nucleus and in the subcortical white matter are seen in the SCA 
cerebellum (Figure 17J, L, N, P).  The metal content of the normal dentate nucleus has 
been described previously (Popescu et al. 2009b). Iron XRF maps of the cerebellum show 
the iron rich control dentate region (Figure 22D) and almost complete loss of iron in the 
SCA dentate nucleus and the adjacent white matter (51% less, p<0.0001, Table 5) (Figure 
22E). The branching pattern of the cerebellar white matter (arbor vitae) is clearly 
resolved on the basis of metal content (Figure 22D, E, F, G, J, K) as previously described 
(Popescu et al. 2009b). However, the contrast between the metal rich white matter and 
metal poor grey matter decreases in the case of the SCA cerebellum, especially for iron 
(Figure 22E) and zinc (Figure 22I) because of the lower metal content of the SCA white 
matter (23% less iron, 11% less copper, 21% less zinc, p<0.0001, Table 5). 
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Table 5. SCA metal quantification relative to control. 
 










Fe 0.0044 0.0068 35  
 Cu 0.0058 0.0085 32  
 Zn 0.0095 0.018 19  
Olive Fe 0.0044 0.0055 20  
 Cu 0.0074 0.0172 57  
 Zn 0.0076 0.0116 34  
Dentate 
nucleus 




Fe 0.0049 0.0064 23  
 Cu 0.0032 0.0036 11  
 Zn 0.0027 0.0034 21  
Ventral 
columns 
Fe 0.103 0.0052  98 
 Cu 0.0103 0.0063  63 





Fe 0.0903 0.0515  80 
 Zn 0.0258 0.0188  37 
a Normalized fluorescence (fluorescence counts/scatter counts). Normalized fluorescence is the 
fluorescence detected from the illuminated tissue volume normalized by the combined elastic and Compton 
scatter from the same region. This normalized value is proportional to the amount of the fluorescing 













Figure 18. Metals are decreased in the degenerated posterior columns and increased in the 
least affected ventral columns of the SCA patient. Spinal cord, axial section, control 
(A,D,F,H,J) and SCA (B,E,G,I,K). A. Normal appearance of the control spinal cord 
(LFB/CV); B. Degenerated posterior columns and myelin pallor of the SCA spinal cord 
(LFB/CV); C. Color scales represent the normalized total Kα fluorescence counts, 
proportional to total metal present, from black (lowest) to color (highest); D,E. Iron 
maps; F,G. Copper maps; H,I. Zinc maps; J,K. Overlay of iron, copper and zinc; dc-

















Figure 19. Metals are decreased in the degenerated olivocerebellar fibres and amiculum 
olivae of the SCA patient. Medulla, axial section, control (A,D,F,H,J) and SCA 
(B,E,G,I,K). A. Normal appearance of the control medulla (LFB/CV); B. Degenerated 
olivocerebellar fibres and amiculum olivae in the SCA spinal cord (LFB/CV); C. Color 
scales represent the normalized total Kα fluorescence counts, proportional to total metal 
present, from black (lowest) to color (highest); D,E. Iron maps; F,G. Copper maps; H,I. 
Zinc maps; J,K. Overlay of iron, copper and zinc; ion-inferior olivary nucleus; ocf-














Figure 20. SCA tissue shows a negative immunohistochemistry staining reaction to α-
synuclein. A. SCA tissue; B. Positive control tissue from a patient with a 
neuropathologically diagnosed α-synucleopathy; arrows-immunohistochemistry positive 























Figure 21. Olivocerebellar fibres have a high copper content in medullae (indicated by 
rectangles) from control patients and patients diagnosed with neurodegenerative diseases 
but without olivary involvement. A. Medulla from a patient with a pathologically 
diagnosed progressive supranuclear palsy; B. Medulla from a patient with a 
pathologically diagnosed progressive muscular atrophy; C. Medulla from a control 
patient who died as a result of multiple traumatic craniocerebral injuries; Green color 
scales represent the normalized total Cu Kα fluorescence counts, proportional to total 


















Figure 22. Iron is decreased in the degenerated dentate nucleus and metals are decreased 
in the cerebellar white matter of the SCA patient. Cerebellum, axial section, control 
(A,D,F,H,J) and SCA (B,E,G,I,K). A. Gross section of the control cerebellum; B. Gross 
section of the SCA cerebellum; C. Color scales represent the normalized total Kα 
fluorescence counts, proportional to total metal present, from black (lowest) to color 
(highest); D,E. Iron maps; F,G. Copper maps; H,I. Zinc maps; J,K. Overlay of iron, 
copper and zinc; dn-dentate nucleus; wm-white matter; gm-cortical gray matter; scale bar 










5.6.2 Ventral Columns of the Spinal Cord and Globus Pallidus Pars Externa of the SCA 
Patient Have Abnormally High Metals 
 The ventral columns show only moderate myelin pallor (Figure 18B). Iron, 
copper and zinc content are higher in the ventral columns of the SCA (98% more iron, 
63% more copper, 75% more zinc, p<0.0001, Table 5) than the control spinal cord 
(Figure 18E, G, I, K). Within the SCA, the ventral columns have higher iron content than 
the rest of the spinal cord. 
 The metal distribution of the forebrain is complex (Figure 23). I have previously 
shown large variations in metal content between white and gray matter and between brain 
regions such as basal ganglia (Gh Popescu et al. 2009; Popescu et al. 2009a) that are 
consistent between brains and that arise from differential cellular deposition of metals. 
Although the microscopic examination of the cerebral hemispheres and basal ganglia is 
unremarkable, the metal maps show an increase in the iron (80% more iron, p<0.0001, 
Table 5; Figure 23E) and zinc (37% more zinc, p<0.0001, Table 5; Figure 23I) content of 
the SCA globus pallidus pars externa. 
 
5.6.3 Metals are High in the Cerebral Blood Vessels of the SCA Patient 
 Upon gross inspection of both the SCA and control forebrain coronal sections 
blood vessels can be seen (Figure 23A, B-arrows). However, while the control blood 
vessels are barely visible in the iron and zinc maps (Figure 23A-arrows and 
corresponding regions in Figure 23D, H), the SCA blood vessels are very rich in iron, 
copper and zinc whether caught in longitudinal or cross-section (Figure 23B-arrows  and 
corresponding regions in Figure 23E, G, I).  
 The SCA metal maps also show small white matter regions that are very rich in 
all three metals but do not correspond to any structures identifiable on gross examination 













Figure 23. Metals are increased in the globus pallidus pars externa and cerebral blood 
vessels of the SCA patient. Forebrain, coronal section, control (A,D,F,H,J) and SCA 
(B,E,G,I,K). A. Gross section of the control forebrain; B. Gross section of the SCA 
forebrain; C. Color scales represent the normalized total Kα fluorescence counts, 
proportional to total metal present, from black (lowest) to color (highest); D,E. Iron 
maps; F,G. Copper maps; H,I. Zinc maps; J,K. Overlay of iron, copper and zinc; c-
caudate; p-putamen; gpe-globus pallidus pars externa; ic-internal capsule; ac-anterior 
commissure; arrows-blood vessels; arrowheads-metal rich white matter regions; scale bar 

























Iron, copper and zinc function as cofactors in essential metalloproteins and are 
required for oxidative phosphorylation, neurotransmitter biosynthesis and modulation of 
neurotransmission, antioxidant defence, nitric oxide metabolism, oxygen transport and 
synthesis of proteins, DNA and RNA (Cuajungco and Lees 1997; Ponka 1999; Madsen 
and Gitlin 2007). Iron (Ortiz et al. 2004; Todorich et al. 2008), copper (Madsen and 
Gitlin 2007) and zinc (Tsang et al. 1997; Kursula et al. 1999) are also essential for myelin 
synthesis, structure and maintenance. Thus, myelin degradation and replacement of dying 
axons by the gliotic scar in chronic lesions of patients with long-standing disease may 
explain why the degenerated white matter of the posterior columns (Figure 17B), 
olivocerebellar fibres (Figure 17D) and cerebellum (Figure 17J) of the SCA patient have 
lower metal content  (Figure 18, Figure 19, Figure 22). Furthermore, degradation of the 
myelin sheath is followed by the “dying back” of oligodendrocytes (Ludwin and Johnson 
1981; Rodriguez et al. 1993), the main iron repository cells in the brain (Connor and 
Menzies 1996), which would decrease the iron content even more in the degenerated 
areas. 
A new and very interesting observation was the high copper content of the control 
olivocerebellar fibres. A similar copper distribution was found in other control medullae, 
as well as in medullae from patients with neurodegenerative diseases that do not involve 
the olivocerebellar fibres (Figure 21). At this moment, I can only speculate why the only 
source of cerebellar climbing fibres has a unique copper distribution but further XAS and 
immunohistochemistry studies are needed to identify the chemical form and role of this 
copper. 
The dentate nucleus (Figure 22D) is one of the most iron-rich structures of the 
brain (Hock et al. 1975; Morris et al. 1992). Iron loss in the SCA dentate region (Figure 
22E) can be explained by the mild neuronal loss and by degeneration of myelinated fibres 
in the dentate hilum and around the dentate nucleus (Figure 17D). The neuropathological 
examination also revealed SCA neurons containing heavy PAS positive (Figure 17N) and 
Sudan black positive (Figure 17P) inclusions consistent with lipofuscin. Lipofuscin is a 
“wear and tear” pigment that increases with age (Brody 1960). The heavy lipofuscin 
accumulations seen in the SCA (compared to the lipofuscin present in the control dentate 
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neurons – Figure 17M, O) are abnormal for the patient's age and, thus, they may 
represent a sign of premature ageing. Although lipofuscin has been reported to bind iron 
and copper (Terman and Brunk 2004), in this SCA case the elevated lipofuscin is not 
associated with similarly elevated metals. 
The brain is a major metal repository that not only accumulates, but also 
metabolizes metals as part of its normal functioning (Zecca et al. 2004; Bartzokis et al. 
2007). This makes it particularly susceptible to metal-catalyzed oxidative damage, 
protein aggregation and neurotoxicity (Cuajungco and Lees 1997; Zecca et al. 2004; 
Madsen and Gitlin 2007). Metals have been also involved in the induction and 
subsequent aggregation of defective protein structures such as ataxin-3, the protein that 
causes spinocerebellar ataxia type 3 (Ricchelli et al. 2007). I found increased metal levels 
in the SCA ventral columns of the spinal cord (Figure 18) and globus pallidus pars 
externa (Figure 23), despite the lack of overt pathological changes other than a decrease 
in myelin stain (Figure 18B). In cerebellar ataxia associated with heteroallelic 
ceruloplasmin gene mutation (Miyajima et al. 2001), iron deposition has been previously 
reported in the globus pallidus associated with minimal or no pathological changes. Iron 
accumulation and myelin breakdown are known to begin before the first appearance of 
pathological changes in many neurodegenerative diseases (Bartzokis 2004; Bartzokis et 
al. 2007). While I can hypothesize that increased metals, not associated with pathological 
changes, represent an incipient stage of neurodegeneration, my results do not clarify if 
the excess metals are the cause or the result of this process. Indeed, the ability of iron 
(Zecca et al. 2004; Madsen and Gitlin 2007), copper (Madsen and Gitlin 2007) and zinc 
(Cuajungco and Lees 1997) to promote ROS formation and neurotoxicity is well known. 
Alternatively, the iron increase could be the result of an upregulation of iron intake 
necessary for axonal repair and remyelination (Graeber et al. 1989; Raivich et al. 1991). 
The same could be true for copper and zinc that are also essential for proper cellular 
functioning and myelin regeneration. Increased oxidative stress leading to demyelination 
and axonal damage can also lead to upregulation of metallothionein (Penkowa et al. 
2003; Penkowa and Hidalgo 2003) and copper-zinc SOD (Bowling et al. 1993; Maier and 
Chan 2002), protective proteins that employ copper and zinc as essential cofactors. 
However the lack of these metals in areas of degeneration indicates that these 
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metalloproteins are no longer abundant or present but not metallated once the pathology 
is severe. 
Iron, copper and zinc are abundant within the walls and perivascular spaces of 
SCA cerebral blood vessels (Figure 23B-arrows and corresponding regions in Figure 
23E, G, I, K), but not within the control blood vessels (Figure 23A-arrows and 
corresponding regions in Figure 23D, F, H, J). The ability to see intravascular and 
perivascular metals is one of the major advantages of RS-XRF (Gh Popescu et al. 2009; 
Popescu et al. 2009a), since vascular changes are linked to neurodegenerative diseases 
(Brun and Englund 1986; Faucheux et al. 1999). The metal-rich white matter regions 
seen in the forebrain (Figure 23K-arrow heads and corresponding regions in Figure 23E, 
G, I) might also represent deep blood vessels or small haemorrhages. 
In conclusion, iron, copper and zinc are low in areas where degeneration is very 
advanced and more abundant in areas where degeneration is potentially at an early stage. 
The different metal content of lesions at different stages of disease might explain for 
example, the contradictory results regarding the iron content of the dentate nucleus in 
FRDA. By interrogating a potentially active site of degeneration, in vivo Magnetic 
Resonance studies show increased iron in the dentate nucleus of FRDA patients 
(Waldvogel et al. 1999; Boddaert et al. 2007) while  biochemical studies of post-mortem 
tissues fail to reveal an increase in iron (Koeppen et al. 2007). My results suggest that 
iron levels might be correlated with disease progression. 
Using RS-XRF mapping, I have shown that not only iron, but also copper and 
zinc may play a role in the physiopathology of the SCA case I present. Thus, my study 
suggests that abnormalities of all three metals should be investigated in SCA of both 








































Frataxin is an essential mitochondrial protein involved in iron metabolism. Its 
deficiency causes FRDA characterized by a wide range of metabolic disturbances 
including deficiency of ISC and heme synthesis, mitochondrial iron accumulation and 
increased oxidative stress.  
Iron’s toxicity, reactivity and bioavailability are linked to its chemical form 
(Ponka 1999; Halliwell 2001; Arosio et al. 2008). The cell has multiple mechanisms to 
control the uptake and metabolism of iron in different forms. The body uses ferrous iron 
in many molecules but only stores iron as ferric oxide/hydroxides, like ferrihydrite 
(Ponka 1999).  
One of the “unknowns” of FRDA has been the chemical form of mitochondrial 
iron. It has been hypothesized that it should be possible to slow the progression of both 
the neurodegeneration and cardiomyopathy that characterize FRDA by reducing the iron 
damage. Treatment strategies have focused on either reducing the amount of iron in 
mitochondria through iron chelation or reducing the effects of iron-catalyzed Fenton 
chemistry with antioxidants reviewed in (Marmolino and Acquaviva 2009).  
Using XAS I have shown that most of the mitochondrial iron in both the FRDA 
and control fibroblasts is stored as ferrihydrite (Popescu et al. 2007a). I have also shown 
that in FRDA fibroblasts most of the mitochondrial iron is stored as the non-toxic, but 
also poorly bioavailable ferrihydrite of MtFt and little ferrous redox-active iron is present 
(Popescu et al. 2007a). My data supports the new concept that once MtFt is upregulated 
in FRDA (by whatever means) it competes for and sequesters the available mitochondrial 
iron. Since MtFt mineralizes this iron but does not readily release it, my work suggests 
that lack of iron available for heme and ISC synthesis contributes to FRDA 
pathophisiology. 
 Yeast has no ferritin gene, but expression of either MtFt (Campanella et al. 2004) 
or cytosolic L type ferritin (Desmyter et al. 2004) rescues the respiratory defect, prevents 
the mitochondrial iron accumulation, mitochondrial DNA damage and the formation of 
ROS and lengthens the lifespan of frataxin knock-out yeast. Similar findings were 
reported when MtFt is over-expressed in FRDA fibroblasts (Campanella et al. 2009). 
This indicates that iron mineralization by whatever means, has some beneficial effect on 
iron overloaded mitochondria.  
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 While only frataxin is able to chaperone iron to both ISC and heme proteins, both 
frataxin (Cavadini et al. 2002) and MtFt (Levi et al. 2001; Bou-Abdallah et al. 2005) can 
polymerize and detoxify redox-active iron by sequestering it in a non-toxic but 
bioavailable form in a protein-protected compartment at the expense of the cytosolic iron 
(Corsi et al. 2002; Li et al. 2008; Campanella et al. 2009). Human heart contains frataxin 
species of increasing molecular mass, ranging from monomers to polymers >1MDa 
(Cavadini et al. 2002; O'Neill et al. 2005) and I have also observed that high molecular 
mass frataxin polymers are present in unaffected human fibroblasts (Popescu et al. 
2007a). However, in frataxin deficient fibroblasts, mitochondria might attempt to 
compensate for the imbalance between iron uptake and egress by storing iron as 
ferrihydrite in MtFt (Popescu et al. 2007a).  
 Since most of the iron in FRDA mitochondria is already stored as relatively non-
toxic, but poorly bioavailable ferrihydrite in MtFt, chelation strategies should take into 
account that at least in cells that are able to synthesize MtFt, chelating the small non-
ferrihydrite iron pool could prevent mitochondria from carrying out even minimal 
functions. Moreover, the cytosolic iron depletion that already exists in FRDA could be 
worsened by non-specific chelators (Li et al. 2008). 
Fibroblasts, like cardiomyocytes and neurons, synthesize both frataxin and 
ferritins but the relative importance of each protein in iron homeostasis is poorly 
understood. They could serve different, but complementary roles in iron detoxification. 
One of frataxin’s unique roles in the mitochondria may be to protect DNA from hydrogen 
peroxide (Karthikeyan et al. 2003), while MtFt seems to provide a redundant mechanism 
to store iron and control ROS formation primarily through regulation of mitochondrial 
iron availability (Campanella et al. 2009). Since MtFt has been detected in heart tissue 
from FRDA patients (Michael et al. 2006), it is possible that the lack of iron availability 
is also involved in the cardiodegeneration associated with FRDA. By understanding how 
fibroblasts regulate MtFt synthesis we may better understand how to upregulate this 
protective protein in cardiac and neuronal cells of FRDA patients. 
In humans, iron deposits have been demonstrated in cardiomyocytes (Sanchez-
Casis et al. 1976; Lamarche et al. 1980; Bradley et al. 2000; Michael et al. 2006), 
hepatocytes and spleen cells (Bradley et al. 2000) from FRDA patients and in FRDA 
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fibroblast cultures (Delatycki et al. 1999) using Perls’ stain and electron microscopy. 
Magnetic Resonance in vivo studies show increased iron in the dentate nucleus of FRDA 
patients (Waldvogel et al. 1999; Boddaert et al. 2007) but these findings have been 
challenged by biochemical studies of post-mortem tissues that failed to reveal an increase 
in iron (Koeppen et al. 2007). However, there are no human studies linking the nervous 
system neurodegeneration in FRDA to iron accumulation. Moreover, even though early 
work suggested a possible dysregulation of copper and zinc metabolism in FRDA 
patients (Barbeau et al. 1984; Huxtable et al. 1984; Shapcott et al. 1984), the possible 
involvement of copper and zinc in FRDA neurodegeneration has not been investigated. 
Lack of such data could be partially explained by the absence of an appropriate 
tool necessary to map the global distribution of metals in the brain and spinal cord. 
Although there is tremendous interest in human brain metal metabolism, complete maps 
from individuals have not been available (Zecca et al. 2004). Such baseline data is 
required if we are to fully understand how FRDA and other neurodegenerative disease 
change global metal distribution and metabolism. 
While destructive analytic techniques such as atomic absorption and inductively 
coupled mass spectrometry have been used to quantify metals in selected brain regions 
(Hock et al. 1975; Dexter et al. 1987; Dexter et al. 1989; Duflou et al. 1989; Dexter et al. 
1991; Dexter et al. 1992; Dexter et al. 1993; Rajan et al. 1997; Becker et al. 2005) and 
some magnetic resonance imaging sequences are used to image iron in vivo (Haacke et al. 
2005), histochemistry has long been the gold standard to localize metals in brain slices. 
However Perls’ and Turnbull’s methods detect only nonheme iron (Perls 1867; Zaleski 
1887; Gomori 1936; Meguro et al. 2007), copper histochemistry lacks sensitivity and 
specificity (Pilloni et al. 1998; Henwood 2003; Ferenci et al. 2005) and complex 
techniques are required to distinguish protein-bound from ionic zinc (Danscher et al. 
1985; Lopez-Garcia et al. 2002). Because each of these methods employs a different 
chemistry, they cannot be combined or used sequentially on the same tissue section. 
Therefore, easy and quantitative assessment of interrelationships between metals has 
been lacking. 
Since XRF is element specific and can simultaneously map multiple metals in all 
chemical forms, I have applied RS-XRF to map the global metal distribution of both 
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normal and diseased brain and spinal cord (Gh Popescu et al. 2009; Popescu et al. 2009a; 
Popescu et al. 2009b). Traditional point-to-point X-ray microprobe has previously been 
successfully employed to map multiple metals in small areas of brain tissue sections at 
high resolution (Yoshida et al. 2001; Ishihara et al. 2002; Collingwood and Dobson 2006; 
Miller et al. 2006; Linkous et al. 2007) but the time required to map large areas of the 
brain in this way is prohibitive. Unlike X-ray microprobe which achieves cellular or 
subcellular resolution, RS-XRF gives a global anatomic view of metals in whole organ 
slices. As with electron microscopy, very high resolution limits what can be imaged 
within a reasonable time and this reduces the sample size. Cell biologists recognize the 
futility of moving to transmission electron microscopy until precise areas of interest have 
been identified at the anatomic and light microscopic level. This is why I have proposed 
RS-XRF could be used for examining the global metal distribution of the brain and 
finding pathological accumulations of metals (Gh Popescu et al. 2009). 
Since FRDA human tissues are not readily available, the new method has initially 
been validated by comparing the metal distribution in normal and PD brain (Gh Popescu 
et al. 2009). Then, it has been applied to study the macroscopic distribution of iron, 
copper, and zinc in normal cerebellum (Popescu et al. 2009b) and to compare the relative 
amounts and distribution of metals in the brain and spinal cord from a patient with a long 
history of SCA (type undefined) with a sex and age matched control (Popescu et al. 
2009a). The motivation for this work was the prospect of doing future systematic studies 
on metal pathology in neurodegenerative diseases in general with future direct 
application to FRDA. 
The cerebellum is an active site of neurodegeneration in FRDA (Greenfield 1954; 
Oppenheimer 1979; Lamarche et al. 1984) with the dentate nucleus showing the most 
severe neuronal loss (Oppenheimer 1979; Lamarche et al. 1984; Koeppen et al. 2007). I 
have shown that the dentate nucleus is extremely rich in iron, copper and zinc and that 
the cerebellar white matter has a high iron and zinc content (Popescu et al. 2009b) in the 
normal brain. There are other areas of brain that are also very rich in metals. The basal 
ganglia are rich in iron (Gh Popescu et al. 2009; Popescu et al. 2009a), the subcortical 
white matter is rich in zinc (Gh Popescu et al. 2009; Popescu et al. 2009a) and the 
substantia nigra is rich in both iron and copper (Gh Popescu et al. 2009).  
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Moreover, RS-XRF has provided us with new and very interesting findings. The 
dentate nucleus shows a characteristic metal segmentation with the copper located 
towards the periphery and iron and zinc towards its interior (Popescu et al. 2009b). The 
presence of two neuronal populations with different metal contents in the dentate could 
prove to be very important since these neurons might possess different susceptibilities to 
neurodegeneration. Another new observation is the high copper content of the olivary 
region of the normal brain (Popescu et al. 2009a). At this moment, I can only speculate 
why the only source of cerebellar climbing fibers has a unique copper distribution but 
further study is needed to identify the chemical form and role of this copper. Also, the 
ability to see intravascular and perivascular metals is one of the major advantages of RS-
XRF (Gh Popescu et al. 2009; Popescu et al. 2009a; Popescu et al. 2009b), since vascular 
changes are linked to neurodegenerative diseases (Brun and Englund 1986; Faucheux et 
al. 1999). 
The brain is a major metal repository (Hock et al. 1975; Dexter et al. 1989; 
Duflou et al. 1989; Morris et al. 1992; Rajan et al. 1997) where large amounts of iron, 
copper, and zinc coexist and colocalize. The high metal content of certain brain structures 
makes them particularly susceptible to metal-catalyzed oxidative damage, protein 
aggregation, neurotoxicity, and neurodegeneration (Cuajungco and Lees 1997; Zecca et 
al. 2004; Madsen and Gitlin 2007). In a rich metal environment, loss of function of 
metalloproteins and loss of defense against oxidative stress caused by deficiency of one 
or more metals (Madsen and Gitlin 2007) could also be responsible for 
neurodegeneration. 
The very interesting SCA case I have studied has provided us with clues about 
how metal distribution is affected in neurodegeneration (Popescu et al. 2009a), although 
my findings can not be generalized. Regions with neuronal loss and gliosis in the 
cerebellar cortex, inferior olivary, and dentate nuclei and areas showing loss of 
myelinated fibers in the posterior columns, cerebellar white matter and olivocerebellar 
fibers were all low in all metals in SCA compared to control. In contrast, the ventral 
columns of the spinal cord that exhibited only moderate myelin pallor had increased 
metal levels. Iron and zinc were also elevated in the globus pallidus pars externa in SCA 
relative to control (Popescu et al. 2009a). In conclusion, iron, copper and zinc are low in 
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areas where degeneration is very advanced and more abundant in areas where 
degeneration is potentially at an early stage. The different metal content of lesions at 
different stages of disease might explain for example, the contradictory results regarding 
the iron content of the dentate nucleus in FRDA. By interrogating a potentially active site 
of degeneration, in vivo Magnetic Resonance studies show increased iron in the dentate 
nucleus of FRDA patients (Waldvogel et al. 1999; Boddaert et al. 2007) while  
biochemical studies of post-mortem tissues fail to reveal an increase in iron (Koeppen et 
al. 2007). My results suggest that iron levels might be correlated with disease 
progression. 
Using XAS and RS-XRF, I have been able to identify the chemical form of iron in 
FRDA mitochondria and to show that not only iron, but also copper and zinc may play a 
role in the physiopathology of at least some SCA cases. Thus, this study suggests that 
abnormalities of all three metals should be investigated in FRDA and other SCA of both 















































7.1 FRDA Mitochondria Store the Majority of Iron as Ferrihydrite in MtFt 
Since iron’s toxicity, reactivity and bioavailability are linked to its chemical form 
(Ponka 1999; Halliwell 2001; Arosio et al. 2008), it has been hypothesized that it should 
be possible to slow the progression of both the FRDA associated neurodegeneration and 
cardiac degeneration by reducing the iron damage. However, the chemical form of 
mitochondrial iron in FRDA has remained an unanswered question. While previous 
studies performed by our laboratory have used XAS to determine the structure of 
frataxin’s iron core in vitro (Nichol et al. 2003), this is the first study that applies 
synchrotron technology to FRDA and uses XAS to characterize the chemical form of 
mitochondrial iron in FRDA in vivo (chapter II and (Popescu et al. 2007a). I have found 
that, while both FRDA and control mitochondria store most of the iron as ferrihydrite, the 
mitochondrial iron is associated with MtFt only in FRDA. This suggests that little redox-
active iron is present and that the lack of iron availability is more important than the ROS 
production in the pathogenesis of FRDA. Since most of the iron in FRDA mitochondria 
is already stored as relatively non-toxic ferrihydrite, chelation strategies should take into 
account that at least in cells that are able to synthesize MtF, chelating the small non-
ferrihydrite iron pool could prevent mitochondria from carrying out even minimal 
functions. Moreover, the cytosolic iron depletion that already exists in FRDA could be 
worsened by non-specific chelators (Li et al. 2008).  
I have performed this study using fibroblast cell cultures and further work is 
needed to see if my findings can be extended to those cells most affected in FRDA: 
neurons and cardiomyocytes. Since mature neurons and cardiomyocytes do not multiply 
in culture, this would be done by applying the same techniques I have used to tissues 
from FRDA patients collected immediately after death and flash frozen for storage. 
Possible difficulties would be represented by the poor availability of FRDA tissues, 
inevitable post-mortem changes and advanced stage of the disease at the time of the 
patients’ death. 
An alternative is the use of the mouse models, especially of the knockin/knockout 
mice (Miranda et al. 2002) that mimic the genetic and biochemical features of the human 
disease. The ease of sample collection and increased sample size represent definite 
advantages over human tissues. However, the main benefit that the use of mouse models 
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brings, is the ability to sample tissues at every stage of FRDA, not only in terminal states 
and to examine MtFt mRNA levels. 
 
7.2 RS-XRF is an Ideal Synchrotron Technique to Localize Metals in Tissue Slices 
and Characterize Disease Induced Disturbances in Metal Distribution and Quantity 
Not only iron, but also copper and zinc can cause metal-catalyzed oxidative 
damage, protein aggregation, neurotoxicity, and neurodegeneration (Cuajungco and Lees 
1997; Zecca et al. 2004; Madsen and Gitlin 2007). This study is the first one to apply RS-
XRF to mapping the global distribution of metals in brain and spinal cord slices. RS-XRF 
is a novel synchrotron technique developed and exclusively available at SSRL that can 
non-destructively, quantitatively and simultaneously map multiple metals in large 
samples on a practical time scale. I validated the use of RS-XRF to large pathology slices 
and demonstrated its significant advantages over analytical or histological methods in 
localizing and quantifying brain metals (chapter III and (Gh Popescu et al. 2009)). Unlike 
conventional histology sections, XRF samples do not have to be dehydrated or 
embedded, and therefore the same sample can be subsequently processed for histology or 
immunohistochemistry if desired.  
I have used this technique to localize metals in the human cerebellum (chapter IV 
and (Popescu et al. 2009b)), a major site of neurodegeneration in FRDA and to localize 
and quantify metals in a case of SCA of unknown aetiology (chapter V and (Popescu et 
al. 2009a)). Some new and very interesting findings are the metal segmentation of the 
dentate nucleus, the high copper content of the olivary region and the different metal 
content of lesions at different stages of disease that might explain some of the 
contradictory results regarding the iron content of areas of FRDA neurodegeneration. 
Regarding the high copper content of the olivocerebellar fibres and amiculum olivae of 
the normal medullae, a study that employs RS-XRF, EXAFS and immunohistochemistry 
is underway trying to elucidate the role, the chemical form and cellular location of this 
copper.  
Our results suggest that not only iron, but also copper and zinc may play a role in 
the physiopathology of neurodegeneration. In future work abnormalities of all three 
metals should be investigated in FRDA and other SCA of both known and unknown 
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aetiologies to identify possible new therapeutic targets. I have been able to map metals in 
a coronal section of the forebrain from a FRDA patient. This also is an ongoing study that 
will need more than one sample in order to obtain useful data. 
RS-XRF is a new and powerful tool that makes systematic studies of brain metals 
practical. It can be applied to any human or animal tissue and I foresee important 
applications in testing whether a metal chelator designed to remove a particular metal 
disrupts the levels of others. Using animal models, RS-XRF also has great potential to 
improve our understanding of global metal metabolism and the inter-relationships 
between metals.  
Some additional features have been or will be implemented in RS-XRF at SSRL’s 
beamline 10-2. The ability to collect full MCA spectra, the ability to image frozen tissue 
slices and collect XANES spectra will promote RS-XRF as the tool of choice in mapping 
and speciating brain metals in situ. With rapidly advancing beamline technology at third-
generation synchrotrons, it should be possible to map very large sections in a matter of a 
few minutes, making systematic RS-XRF studies on serial slices of whole organs 
practical.  
RS-XRF is the ideal tool to interrogate the possible involvement of metals in 
FRDA pathology, not only in neurodegeneration but also in cardiac degeneration. 
However, since the disease is examined at a very advanced stage in the case of post-
mortem formalin-fixed human specimens RS-XRF will not be able to demonstrate 
whether the metals are the cause or the consequence of the degenerative process. Metal 
maps of brains and hearts from FRDA mouse models at various stages of the disease will 
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 Several side projects I have been involved in during my Ph.D. are listed below. 
Some of them resulted in publications that are not included in my Ph.D. thesis. 
   The first main side project has been the mapping of metals in oocytes from 
Xenopus laevis using X-ray microprobe correlated with histology. This resulted in the 
publication of an article regarding the assymetrical distribution of metals in stage VI 
Xenopus laevis oocytes showing that synchrotron X-ray fluorescence microprobe would 
be a useful tool to examine how metals accumulate and redistribute during fertilization 
and embryonic development (Popescu et al. 2007b). This article has been featured on the 
cover of Biochemistry and Cell Biology journal. Since the publication of this paper more 
data has been collected to publish a more ample study regarding the metal distribution in 
stage III to stage VI Xenopus laevis oocytes. 
  The second main side project has been my involvement with Gene Expression 
Mapping using Synchrotron light (GEMS). I developed the animal model used to test the 
filed flattener prototype developed by Dr. Chapman’s team for K-edge subtraction 
imaging of small animals (Zhu et al. 2008). I have also been involved in culturing the C6 
glioma cells and their implantation in rats, and assisting with animal handling during 
GEMS experiments that took place at the Canadian Light Source. 
  Other main side projects that I started towards the latter period of my Ph.D. 
degree are the mapping of metals in brains from patients with multiple sclerosis and 
Huntington disease, and enough data is collected to publish these findings. 
  Other projects that I have been involved are the determination of the chemical 
form of mitochondrial zinc, the chemical form of extraterrestrial iron and the chemical 
form of metals in various Drosophila models of human neurodegenerative diseases, 
Magnetic Resonance/XRF correlation, and metal mapping in stroke and peripheral and 
central demyelination. 
 
 
 
 
 
 
